Johnson & Johnson (JNJ) 10-K 20 Feb 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 30, 2018	Feb. 15, 2019	Jul. 01, 2018
Document Information [Line Items]
Entity Registrant Name	JOHNSON & JOHNSON
Entity Central Index Key	200,406
Current Fiscal Year End Date	--12-30
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		2,663,138,579
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 325,000,000,000

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents (Notes 1 and 2)	$ 18,107	$ 17,824
Marketable securities (Notes 1 and 2)	1,580	472
Accounts receivable trade, less allowances for doubtful accounts $248 (2017, $291)	14,098	13,490
Inventories (Notes 1 and 3)	8,599	8,765
Prepaid expenses and other receivables	2,699	2,537
Assets held for sale (Note 20)	950	0
Total current assets	46,033	43,088
Property, plant and equipment, net (Notes 1 and 4)	17,035	17,005
Intangible assets, net (Notes 1 and 5)	47,611	53,228
Goodwill (Notes 1 and 5)	30,453	31,906
Deferred taxes on income (Note 8)	7,640	7,105
Other assets	4,182	4,971
Total assets	152,954	157,303
Current liabilities:
Loans and notes payable (Note 7)	2,796	3,906
Accounts payable	7,537	7,310
Accrued liabilities	7,601	7,304
Accrued rebates, returns and promotions	9,380	7,210
Accrued compensation and employee related obligations	3,098	2,953
Accrued taxes on income (Note 8)	818	1,854
Total current liabilities	31,230	30,537
Long-term debt (Note 7)	27,684	30,675
Deferred taxes on income (Note 8)	7,506	8,368
Employee related obligations (Notes 9 and 10)	9,951	10,074
Long-term taxes payable (Note 8)	8,242	8,472
Other liabilities	8,589	9,017
Total liabilities	93,202	97,143
Shareholders' equity:
Preferred stock — without par value (authorized and unissued 2,000,000 shares)	0	0
Common stock — par value $1.00 per share (Note 12) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)	3,120	3,120
Accumulated other comprehensive income (loss) (Note 13)	(15,222)	(13,199)
Retained earnings	106,216	101,793
Stockholders' Equity before Treasury Stock	94,114	91,714
Less: common stock held in treasury, at cost (Note 12) (457,519,000 shares and 437,318,000 shares)	34,362	31,554
Total shareholders’ equity	59,752	60,160
Total liabilities and shareholders’ equity	$ 152,954	$ 157,303

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Dec. 30, 2018	Dec. 31, 2017
Current assets:
Allowances for doubtful accounts	$ 248	$ 291
Shareholders' equity:
Preferred par value	$ 0	$ 0
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value per share (in dollars per share)	$ 1	$ 1
Common stock, shares authorized (in shares)	4,320,000,000	4,320,000,000
Common stock, shares issued (in shares)	3,119,843,000	3,119,843,000
Treasury stock, shares	457,519,000	437,318,000

Consolidated Statements of Earn

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Income Statement [Abstract]
Sales to customers	$ 81,581	$ 76,450	$ 71,890
Cost of products sold	27,091	25,439	21,789
Gross profit	54,490	51,011	50,101
Selling, marketing and administrative expenses	22,540	21,520	20,067
Research and development expense	10,775	10,594	9,143
In-process research and development	1,126	408	29
Interest income	(611)	(385)	(368)
Interest expense, net of portion capitalized (Note 4)	1,005	934	726
Other (income) expense, net	1,405	(42)	210
Restructuring (Note 22)	251	309	491
Earnings before provision for taxes on income	17,999	17,673	19,803
Provision for taxes on income (Note 8)	2,702	16,373	3,263
Net earnings	$ 15,297	$ 1,300	$ 16,540
Net earnings per share (Notes 1 and 15)
Basic (in dollars per share)	$ 5.70	$ 0.48	$ 6.04
Diluted (in dollars per share)	$ 5.61	$ 0.47	$ 5.93
Average shares outstanding (Notes 1 and 15)
Basic (in shares)	2,681.5	2,692	2,737.3
Diluted (in shares)	2,728.7	2,745.3	2,788.9

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Statement of Comprehensive Income [Abstract]
Net earnings	$ 15,297	$ 1,300	$ 16,540
Other Comprehensive Income (Loss), net of tax
Foreign currency translation	(1,518)	1,696	(612)
Securities
Unrealized holding gain (loss) arising during period	(1)	159	(52)
Reclassifications to earnings	1	(338)	(141)
Net change	0	(179)	(193)
Employee benefit plans
Prior service credit (cost), net of amortization	(44)	2	21
Gain (loss), net of amortization	(56)	29	(862)
Effect of exchange rates	92	(201)	159
Net change	(8)	(170)	(682)
Derivatives & hedges
Unrealized gain (loss) arising during period	(73)	(4)	(359)
Reclassifications to earnings	(192)	359	110
Net change	(265)	355	(249)
Other comprehensive income (loss)	(1,791)	1,702	(1,736)
Comprehensive income	$ 13,506	$ 3,002	$ 14,804

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Statement of Comprehensive Income [Abstract]
Foreign currency translation	$ 236
Securities	0	$ (96)	$ (104)
Employee benefits	4	(83)	346
Derivatives & hedges	$ (70)	$ 191	$ (134)

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Millions		Total	Retained Earnings	Accumulated Other Comprehensive Income	Common Stock Issued Amount	Treasury Stock Amount
Beginning Balance at Jan. 03, 2016		$ 71,150	$ 103,879	$ (13,165)	$ 3,120	$ (22,684)
Net earnings		16,540	16,540
Cash dividends paid		(8,621)	(8,621)
Employee compensation and stock option plans		2,130	(1,181)			3,311
Repurchase of common stock		(8,979)				(8,979)
Other		(66)	(66)
Other comprehensive income (loss), net of tax		(1,736)		(1,736)
Ending Balance at Jan. 01, 2017		70,418	110,551	(14,901)	3,120	(28,352)
Net earnings		1,300	1,300
Cash dividends paid		(8,943)	(8,943)
Employee compensation and stock option plans		2,077	(1,079)			3,156
Repurchase of common stock		(6,358)				(6,358)
Other		(36)	(36)
Other comprehensive income (loss), net of tax		1,702		1,702
Ending Balance at Dec. 31, 2017		60,160	101,793	(13,199)	3,120	(31,554)
Cumulative adjustment	[1]	(486)	(254)	(232)
Net earnings		15,297	15,297
Cash dividends paid		(9,494)	(9,494)
Employee compensation and stock option plans		1,949	(1,111)			3,060
Repurchase of common stock		(5,868)				(5,868)
Other		(15)	(15)
Other comprehensive income (loss), net of tax		(1,791)		(1,791)
Ending Balance at Dec. 30, 2018		$ 59,752	$ 106,216	$ (15,222)	$ 3,120	$ (34,362)
[1]	(1) See Note 1 to Consolidated Financial Statements for additional details on the effect of cumulative adjustments to retained earnings.

Consolidated Statements of Eq_2

Consolidated Statements of Equity (Parenthetical) - $ / shares	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Statement of Stockholders' Equity [Abstract]
Cash dividends paid (in dollars per share)	$ 3.54	$ 3.32	$ 3.15

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Cash flows from operating activities
Net earnings	$ 15,297	$ 1,300	$ 16,540
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles	6,929	5,642	3,754
Stock based compensation	978	962	878
Asset write-downs	1,258	795	283
Gain on sale of assets/businesses	(1,217)	(1,307)	(563)
Deferred tax provision	(1,016)	2,406	(341)
Accounts receivable allowances	(31)	17	(11)
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
Increase in accounts receivable	(1,185)	(633)	(1,065)
(Increase)/Decrease in inventories	(644)	581	(249)
Increase in accounts payable and accrued liabilities	3,951	2,725	656
Increase in other current and non-current assets	(275)	(411)	(529)
(Decrease)/Increase in other current and non-current liabilities	(1,844)	8,979	(586)
Net cash flows from operating activities	22,201	21,056	18,767
Cash flows from investing activities
Additions to property, plant and equipment	(3,670)	(3,279)	(3,226)
Proceeds from the disposal of assets/businesses, net	3,203	1,832	1,267
Acquisitions, net of cash acquired (Note 20)	(899)	(35,151)	(4,509)
Purchases of investments	(5,626)	(6,153)	(33,950)
Sales of investments	4,289	28,117	35,780
Other (primarily intangibles)	(464)	(234)	(123)
Net cash used by investing activities	(3,167)	(14,868)	(4,761)
Cash flows from financing activities
Dividends to shareholders	(9,494)	(8,943)	(8,621)
Repurchase of common stock	(5,868)	(6,358)	(8,979)
Proceeds from short-term debt	80	869	111
Retirement of short-term debt	(2,479)	(1,330)	(2,017)
Proceeds from long-term debt, net of issuance costs	5	8,992	12,004
Retirement of long-term debt	(1,555)	(1,777)	(2,223)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net	949	1,062	1,189
Other	(148)	(188)	(15)
Net cash used by financing activities	(18,510)	(7,673)	(8,551)
Effect of exchange rate changes on cash and cash equivalents	(241)	337	(215)
Increase/(Decrease) in cash and cash equivalents	283	(1,148)	5,240
Cash and cash equivalents, beginning of year (Note 1)	17,824	18,972	13,732
Cash and cash equivalents, end of year (Note 1)	18,107	17,824	18,972
Cash paid during the year for:
Interest	1,049	960	730
Interest, net of amount capitalized	963	866	628
Income taxes	4,570	3,312	2,843
Supplemental schedule of non-cash investing and financing activities
Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards	2,095	2,062	2,043
Conversion of debt	6	16	35
Acquisitions
Fair value of assets acquired	1,047	36,937	4,586
Fair value of liabilities assumed and noncontrolling interests	(148)	(1,786)	(77)
Net cash paid for acquisitions	$ 899	$ 35,151	$ 4,509

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Johnson & Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Description of the Company and Business Segments The Company has approximately 135,100 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a broad range of products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health and wound care markets. These products are marketed to the general public and sold both to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on six therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use. The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, interventional solutions (cardiovascular and neurovascular), diabetes care (divested in the fiscal fourth quarter of 2018) and vision fields, which are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. New Accounting Standards Recently Adopted Accounting Standards ASU 2014-09 : Revenue from Contracts with Customers On January 1, 2018, the Company adopted the new accounting standard, ASC 606, Revenue from Contracts with Customers and all the related amendments (new revenue standard) to all contracts using the modified retrospective method. The cumulative effect of initially applying the new revenue standard was recognized as an adjustment to the opening balance of retained earnings. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. The adoption of the new revenue standard has not had a material impact to either reported Sales to customers or Net earnings. Additionally, the Company will continue to recognize revenue from product sales as goods are shipped or delivered to the customer, as control of goods transfers at the same time. In accordance with the new revenue standard requirements, the disclosure of the impact of adoption on the Company's Consolidated Statement of Earnings and Balance Sheet was as follows: Statement of Earnings - For the fiscal year ended December 30, 2018 (Dollars in millions) As Reported Effect of change Balance without adoption of ASC 606 Sales to customers $ 81,581 (35 ) 81,546 Net earnings 15,297 (28 ) 15,269 Balance Sheet - As of December 30, 2018 As Reported Effect of change Balance without adoption of ASC 606 Assets 152,954 23 152,977 Liabilities 93,202 4 93,206 Equity $ 59,752 19 59,771 The Company made a cumulative effect adjustment to the 2018 opening balance of retained earnings upon adoption of ASU 2014-09, which decreased beginning retained earnings by $47 million . As part of the adoption of ASC 606 see Note 18 to the Consolidated Financial Statements for further disaggregation of revenue. ASU 2016-01 : Financial Instruments: Recognition and Measurement of Financial Assets and Financial Liabilities The Company adopted this standard as of the beginning of the fiscal year 2018 on a modified retrospective basis. The amendments in this update supersede the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and require equity securities to be measured at fair value with changes in the fair value recognized through net earnings. The standard amends financial reporting by providing relevant information about an entity’s equity investments and reducing the number of items that are recognized in other comprehensive income. The Company made a cumulative effect adjustment to the opening balance of retained earnings upon adoption of ASU 2016-01 that increased retained earnings by $232 million net of tax and decreased accumulated other comprehensive income for previously unrealized gains from equity investments. For additional details see Note 6 to the Consolidated Financial Statements. ASU 2016-16 : Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory The Company adopted this standard as of the beginning of the fiscal year 2018. This update removes the current exception in U.S. GAAP prohibiting entities from recognizing current and deferred income tax expenses or benefits related to transfer of assets, other than inventory, within the consolidated entity. The current exception to defer the recognition of any tax impact on the transfer of inventory within the consolidated entity until it is sold to a third party remains unaffected. As discussed further in Note 8 to the Consolidated Financial Statements, in the fourth fiscal quarter of 2018 the Company elected an accounting policy to treat the tax on global intangible low-taxed income (GILTI) under the deferred tax accounting model. As a result, the Company is required to record an additional deferred tax liability related to the basis difference of these intra-entity asset transfers. The Company recorded net adjustments including an increase to deferred tax assets of approximately $2.0 billion , an increase to deferred tax liabilities of approximately $1.7 billion , related to the GILTI accounting policy election in the fourth fiscal quarter of 2018, a decrease to Other Assets of approximately $0.7 billion and a decrease to retained earnings of approximately $0.4 billion . The adoption of this standard did not have a material impact on the Company's consolidated financial statements. ASU 2017-01 : Clarifying the Definition of a Business The Company adopted this standard as of the beginning of the fiscal year 2018. This update narrows the definition of a business by providing a screen to determine when an integrated set of assets and activities is not a business. The screen specifies that an integrated set of assets and activities is not a business if substantially all of the fair value of the gross assets acquired or disposed of is concentrated in a single or a group of similar identifiable assets. This update was applied prospectively. The adoption of this standard did not have a material impact on the Company's consolidated financial statements. ASU 2017-07 : Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost The Company adopted this standard as of the beginning of the fiscal year 2018. This update requires that an employer disaggregate the service cost component from the other components of net periodic benefit cost (NPBC). In addition, only the service cost component will be eligible for capitalization. The amendments in this update are required to be applied retrospectively for the presentation of the service cost component and the other components of NPBC in the Consolidated Statement of Earnings and prospectively, on and after the adoption date, for the capitalization of the service cost component of NPBC in assets. As required by the transition provisions of this update, the following table shows the impact of the adoption on the respective line items in the Consolidated Statement of Earnings for 2018 and the reclassifications to the 2017 and 2016 fiscal year Consolidated Statement of Earnings to retroactively apply classification of the service cost component and the other components of NPBC: (Dollars In millions) Increase (Decrease) to Net Expense 2018 2017 2016 Cost of products sold $ 51 85 104 Selling, marketing and administrative expenses 55 100 122 Research and development expense 21 40 48 Other (income) expense, net (127 ) (225 ) (274 ) Earnings before provision for taxes on income $ — — — The following table summarizes the cumulative effect adjustments made to the 2018 opening balance of retained earnings upon adoption of the new accounting standards mentioned above: (Dollars in Millions) Cumulative Effect Adjustment Increase (Decrease) to Retained Earnings ASU 2014-09 - Revenue from Contracts with Customers $ (47 ) ASU 2016-01 - Financial Instruments 232 ASU 2016-16 - Income Taxes: Intra-Entity Transfers (439 ) Total $ (254 ) ASU 2017-12 : Targeted Improvements to Accounting for Hedging Activities The Company elected to early adopt this standard as of the beginning of the fiscal second quarter of 2018. This update makes more financial and nonfinancial hedging strategies eligible for hedge accounting. It also amends the presentation and disclosure requirements and changes how companies assess effectiveness. The adoption of this standard did not have a material impact on the Company's consolidated financial statements. For additional required disclosures see Note 6 to the Consolidated Financial Statements. Recently Issued Accounting Standards Not Adopted as of December 30, 2018 ASU 2018-18 : Collaborative Arrangements This update clarifies the interaction between ASC 808, Collaborative Arrangements and ASC 606, Revenue from Contracts with Customers. The update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue if the counterparty is not a customer for that transaction. This update will be effective for the Company for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. ASU 2018-18 should be applied retrospectively to the date of initial application of ASC 606 and early adoption is permitted. The Company is currently assessing the impact of this update on the Company’s consolidated financial statements and related disclosures. ASU 2018-16: Derivatives and Hedging (Topic ASC 815) This update adds the Overnight Index Swap (OIS) rate based on the Secured Overnight Financing Rate (SOFR) as an eligible benchmark interest rate permitted in the application of hedge accounting. This update will be effective for the Company for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early adoption is permitted if an entity has adopted ASU 2017-12. The Company is currently assessing the impact of this update on the Company’s consolidated financial statements and related disclosures. ASU 2018-02 : Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income This update allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Job Act enacted in December 2017. This update will be effective for the Company for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. The Company does not expect this standard to have a material impact on the Company's consolidated financial statements. ASU 2016-13 : Financial Instruments - Credit Losses This update introduces the current expected credit loss (CECL) model, which will require an entity to measure credit losses for certain financial instruments and financial assets, including trade receivables. Under this update, on initial recognition and at each reporting period, an entity will be required to recognize an allowance that reflects the entity’s current estimate of credit losses expected to be incurred over the life of the financial instrument. This update will be effective for the Company for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. Early adoption is permitted. The Company is currently assessing the impact of this update on the Company’s consolidated financial statements and related disclosures. ASU 2016-02 : Leases This update requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. This update requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under current generally accepted accounting principles. This update will be effective for the Company for all annual periods beginning after December 15, 2018, including interim periods within those fiscal years. The Company will apply the new standard at its adoption date rather than at the earliest comparative period presented in the financial statements. The Company’s operating leases will result in the recognition of additional assets and the corresponding liabilities on its Consolidated Balance Sheets. The adoption of this standard will not have a material impact on the Company's consolidated financial statements. Cash Equivalents The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating. The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs). RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value. The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities. Investments Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments in equity securities for impairment and adjusts these investments to fair value through earnings, as required. Property, Plant and Equipment and Depreciation Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets: Building and building equipment 20 - 30 years Land and leasehold improvements 10 - 20 years Machinery and equipment 2 - 13 years The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8 years. The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows. Revenue Recognition The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales. Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information. Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals. Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company’s accounting policies, the Company generally issues credit to customers for returned goods. The Company’s sales returns reserves are accounted for in accordance with the U.S. GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the Medical Devices segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during the fiscal reporting years 2018, 2017 and 2016. Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. For all years presented, profit-share payments were less than 2.0% of the total revenues and are included in sales to customers. Shipping and Handling Shipping and handling costs incurred were $1,090 million , $1,042 million and $974 million in 2018 , 2017 and 2016 , respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 0.5% of sales to customers for all periods presented. Inventories Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method. Intangible Assets and Goodwill The authoritative literature on U.S. GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed the annual impairment test for 2018 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions. See Note 5 for further details on Intangible Assets and Goodwill. Financial Instruments As required by U.S. GAAP, all derivative instruments are recorded on the balance sheet at fair value. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level 1 having the highest priority and Level 3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1) minimize foreign currency exposure’s impact on the Company’s financial performance; (2) protect the Company’s cash flow from adverse movements in foreign exchange rates; (3) ensure the appropriateness of financial instruments; and (4) manage the enterprise risk associated with financial institutions. See Note 6 for additional information on Financial Instruments. Product Liability Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. As a result of cost and availability factors, effective November 1, 2005, the Company ceased purchasing third-party product liability insurance. The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated. Research and Development Research and development expenses are expensed as incurred in accordance with ASC 730, Research and Development. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization. The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company’s operations. In general, the income statement presentation for these collaborations is as follows: Nature/Type of Collaboration Statement of Earnings Presentation Third-party sale of product & profit share payments received Sales to customers Royalties/milestones paid to collaborative partner (post-regulatory approval)* Cost of products sold Royalties received from collaborative partner Other income (expense), net Upfront payments & milestones paid to collaborative partner (pre-regulatory approval) Research and development expense Research and development payments to collaborative partner Research and development expense Research and development payments received from collaborative partner Reduction of Research and development expense * Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life. For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense. The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO ® , co-developed with Bayer HealthCare AG and IMBRUVICA ® , developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company. The Company has a number of licensing arrangements for products and compounds including DARZALEX ® , licensed from Genmab A/S. Advertising Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $2.6 billion , $2.5 billion and $2.4 billion in 2018 , 2017 and 2016 , respectively. Income Taxes Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position. In the fourth fiscal quarter of 2018, the Company has elected to account for the GILTI tax under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred. The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the total tax effect of this repatriation would be approximately $0.7 billion under current enacted tax laws and regulations and at current currency exchange rates. See Note 8 for further information regarding income taxes. Net Earnings Per Share Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. The Company follows the provisions of U.S. GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued. Annual Closing Date The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52 weeks, but every five or six years the fiscal year consists of 53 weeks , and therefore includes additional shipping days, as was the case in 2015, and will be the case again in 2020. Reclassification Certain prior period amounts have been reclassified to conform to current year presentation.

Cash, Cash Equivalents and Curr

Cash, Cash Equivalents and Current Marketable Securities	12 Months Ended
	Dec. 30, 2018
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents and Current Marketable Securities	Cash, Cash Equivalents and Current Marketable Securities At the end of 2018 and 2017 , cash, cash equivalents and current marketable securities were comprised of: (Dollars in Millions) 2018 Carrying Amount Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,619 2,619 2,619 — U.S. Reverse repurchase agreements 3,009 3,009 3,009 — Other Reverse repurchase agreements 443 443 443 — Money market funds 3,397 3,397 3,397 — Time deposits (1) 485 485 485 — Subtotal $ 9,953 9,953 9,953 — Gov't Securities $ 9,474 9,474 8,144 1,330 Corporate debt securities 260 260 10 250 Subtotal available for sale (2) $ 9,734 9,734 8,154 1,580 Total cash, cash equivalents and current marketable securities $ 18,107 1,580 In 2018, the carrying amount was the same as the estimated fair value. In 2017, the carrying amount was the same as the estimated fair value. (Dollars in Millions) 2017 Carrying Amount Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,929 2,929 2,929 — Other Sovereign Securities (1) 279 279 219 60 U.S. Reverse repurchase agreements 4,025 4,025 4,025 — Corporate debt securities (1) 289 289 244 45 Money market funds 4,288 4,288 4,288 — Time deposits (1) 1,176 1,176 1,175 1 Subtotal $ 12,986 12,986 12,880 106 Gov't Securities $ 4,864 4,864 4,833 31 Other Sovereign Securities 186 186 80 106 Corporate debt securities 260 260 31 229 Subtotal available for sale (2) $ 5,310 5,310 4,944 366 Total cash, cash equivalents and current marketable securities $ 17,824 472 (1) Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income. Fair value of government securities and obligations and corporate debt securities were estimated using quoted broker prices and significant other observable inputs. The contractual maturities of the available for sale debt securities at December 30, 2018 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 9,670 9,670 Due after one year through five years 64 64 Due after five years through ten years — — Total debt securities $ 9,734 9,734 The Company invests its excess cash in both deposits with major banks throughout the world and other high-quality money market instruments. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.

Inventories

Inventories	12 Months Ended
	Dec. 30, 2018
Inventory Disclosure [Abstract]
Inventories	Inventories At the end of 2018 and 2017 , inventories were comprised of: (Dollars in Millions) 2018 2017 Raw materials and supplies $ 1,114 1,140 Goods in process 2,109 2,317 Finished goods 5,376 5,308 Total inventories $ 8,599 (1) 8,765 (1) Net of assets held for sale on the Consolidated Balance Sheet for approximately $0.2 billion related to the divestiture of the Advanced Sterilization Products business and $0.3 billion related to the strategic collaboration with Jabil Inc., both of which were pending as of December 30, 2018.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 30, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment At the end of 2018 and 2017 , property, plant and equipment at cost and accumulated depreciation were: (Dollars in Millions) 2018 2017 Land and land improvements $ 807 829 Buildings and building equipment 11,176 11,240 Machinery and equipment 25,992 25,949 Construction in progress 3,876 3,448 Total property, plant and equipment, gross $ 41,851 41,466 Less accumulated depreciation 24,816 24,461 Total property, plant and equipment, net $ 17,035 (1) 17,005 (1) Net of assets held for sale on the Consolidated Balance Sheet for approximately $0.1 billion related to the divestiture of the Advanced Sterilization Products business and $0.1 billion related to the strategic collaboration with Jabil Inc., both of which were pending as of December 30, 2018. The Company capitalizes interest expense as part of the cost of construction of facilities and equipment. Interest expense capitalized in 2018 , 2017 and 2016 was $86 million , $94 million and $102 million , respectively. Depreciation expense, including the amortization of capitalized interest in 2018 , 2017 and 2016 was $2.6 billion , $2.6 billion and $2.5 billion , respectively. Upon retirement or other disposal of property, plant and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds are recorded in earnings.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	12 Months Ended
	Dec. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	Intangible Assets and Goodwill At the end of 2018 and 2017 , the gross and net amounts of intangible assets were: (Dollars in Millions) 2018 2017 Intangible assets with definite lives: Patents and trademarks — gross $ 35,194 36,427 Less accumulated amortization 9,784 7,223 Patents and trademarks — net $ 25,410 29,204 Customer relationships and other intangibles — gross $ 21,334 20,204 Less accumulated amortization 8,323 7,463 Customer relationships and other intangibles — net $ 13,011 12,741 Intangible assets with indefinite lives: Trademarks $ 6,937 7,082 Purchased in-process research and development (1) 2,253 4,201 Total intangible assets with indefinite lives $ 9,190 11,283 Total intangible assets — net $ 47,611 53,228 (1) The decrease was primarily attributable to the write-down of $1.1 billion related to the assets acquired in the acquisitions of Alios Biopharma Inc. (Alios) and XO1 Limited (XO1). Of the $1.1 billion , the Company recorded a partial impairment charge of $0.8 billion related to the development program of AL-8176, an investigational drug for the treatment of Respiratory Syncytial Virus (RSV) and human metapneumovirus (hMPV) acquired with the 2014 acquisition of Alios. The impairment charge was calculated based on updated cash flow projections discounted for the inherent risk in the asset development and reflects the impact of the phase 2b clinical trial suspension, a decrease in the probability of success factors and the ongoing analysis of asset development activities. In addition, an impairment charge of $0.3 billion was recorded for the discontinuation of the development project for an anti-thrombin antibody associated with the 2015 acquisition of XO1. Additionally, $0.8 billion of IPR&D related to ERLEADA ™ was reclassified to definite lived intangible assets upon commercialization. Goodwill as of December 30, 2018 and December 31, 2017 , as allocated by segment of business, was as follows: (Dollars in Millions) Consumer Pharmaceutical Medical Devices Total Goodwill at January 1, 2017 $ 8,263 2,840 11,702 22,805 Goodwill, related to acquisitions (1) 102 6,161 2,200 8,463 Goodwill, related to divestitures (74 ) (1 ) (102 ) (177 ) Currency translation/other 584 109 122 815 Goodwill at December 31, 2017 $ 8,875 9,109 13,922 31,906 Goodwill, related to acquisitions 168 51 184 403 Goodwill, related to divestitures — — (1,348 ) (2) (1,348 ) Currency translation/other (373 ) (97 ) (38 ) (508 ) Goodwill at December 30, 2018 $ 8,670 9,063 12,720 30,453 (1) Goodwill of $6.2 billion related to the Actelion acquisition acquired in the fiscal second quarter of 2017, within the Pharmaceutical segment and $1.7 billion related to the AMO acquisition acquired in the fiscal first quarter of 2017, within the Medical Devices segment. (2) Goodwill of $1.0 billion is related to the divestiture of the LifeScan business. Goodwill of $0.3 billion is related to the divestiture of the Advanced Sterilization Products business, which was pending and classified as assets held for sale on the Consolidated Balance Sheet as of December 30, 2018. The weighted average amortization periods for patents and trademarks and customer relationships and other intangible assets are 11 years and 22 years , respectively. The amortization expense of amortizable assets included in cost of products sold was $4.4 billion , $3.0 billion and $1.2 billion before tax, for the fiscal years ended December 30, 2018 , December 31, 2017 and January 1, 2017 , respectively. The estimated amortization expense for the five succeeding years approximates $4.3 billion before tax, per year. Intangible asset write-downs are included in Other (income) expense, net. See Note 20 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany products and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The Company early adopted ASU 2017-12: Targeted Improvements to Accounting for Hedge Activities effective as of the beginning of fiscal second quarter of 2018. The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. During the fiscal second quarter of 2017, the Company entered into credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of December 30, 2018 , the total amount of collateral paid under the credit support agreements (CSA) amounted to $182 million net. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of December 30, 2018 , the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $41.1 billion , $7.3 billion , and $0.5 billion respectively. As of December 31, 2017 , the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $34.5 billion , $2.3 billion , and $1.1 billion respectively. All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction. Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedge are accounted through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. During the fiscal second quarter of 2016, the Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. As of December 30, 2018 , the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $195 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 13. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months , excluding interest rate contracts, net investment hedges and equity collar contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative. The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended December 30, 2018 and December 31, 2017 : December 30, 2018 December 31, 2017 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $ — — — 5 — — — — 5 — Derivatives designated as hedging instruments — — — (5 ) — — — — (5 ) — Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 56 — — — — — — Amount of gain or (loss) recognized in AOCI — — — 56 — — — — — — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income (1) 47 200 (220 ) — (24 ) (31 ) (159 ) (165 ) — (87 ) Amount of gain or (loss) recognized in AOCI (1) (32 ) (17 ) (193 ) — (4 ) 49 96 (199 ) — (60 ) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 133 — — — — 83 — Amount of gain or (loss) recognized in AOCI $ — — — 117 — — — — 110 — (1) Includes equity collar contracts. The equity collar contracts expired in December of 2017. For the fiscal years ended December 30, 2018 and December 31, 2017 , the following amounts were recorded on the Consolidated Balance Sheet Line item in the Consolidated Balance Sheet in which the hedged item is included Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability (Dollars in Millions) December 30, 2018 December 31, 2017 December 30, 2018 December 31, 2017 Current Portion of Long-term Debt $ 494 597 5 2 Long-term Debt — 496 — 3 The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended December 30, 2018 and December 31, 2017: (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Gain/(Loss) Recognized In Income on Derivative Derivatives Not Designated as Hedging Instruments December 30, 2018 December 31, 2017 Foreign Exchange Contracts Other (income) expense (68 ) (5 ) The following table is the effect of net investment hedges for the fiscal years ended December 30, 2018 and December 31, 2017: Gain/(Loss) Recognized In Accumulated OCI Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From Accumulated OCI Into Income (Dollars in Millions) Fiscal Nine Months Ended December 30, 2018 December 31, 2017 December 30, 2018 December 31, 2017 Debt $ 218 (597 ) Other (income) expense — — Cross Currency interest rate swaps $ 150 — Other (income) expense — — The Company adopted ASU 2016-01: Financial Instruments: Recognition and Measurement of Financial Assets and Financial Liabilities as of the beginning of the fiscal year 2018. This ASU amends prior guidance to classify equity investments with readily determinable market values into different categories (that is, trading or available-for-sale) and require equity investments to be measured at fair value with changes in fair value recognized through net earnings. The Company made a cumulative effect adjustment to the opening balance of retained earnings upon adoption of ASU 2016-01 which increased retained earnings by $232 million , net of tax, and decreased accumulated other comprehensive income for previously net unrealized gains from equity investments. The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The following table is a summary of the activity related to equity investments as of December 30, 2018 : (Dollars in Millions) December 31, 2017 December 30, 2018 Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 751 (247 ) 7 511 511 Equity Investments without readily determinable value $ 510 13 158 681 681 (1) Recorded in Other Income/Expense (2) Other includes impact of currency For equity investments without readily determinable market values, $54 million of the changes in fair value reflected in net income were the result of impairments. There were $67 million of changes in fair value reflected in net income due to changes in observable prices. For the fiscal years ended December 31, 2017 , changes in fair value reflected within other comprehensive income due to previously unrealized gains on equity investments with readily determinable fair values net of tax was a net gain of $232 million . Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 having the highest priority and Level 3 having the lowest. The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company did not have any other significant financial assets or liabilities which would require revised valuations under this standard that are recognized at fair value. The following three levels of inputs are used to measure fair value: Level 1 — Quoted prices in active markets for identical assets and liabilities. Level 2 — Significant other observable inputs. Level 3 — Significant unobservable inputs. The Company’s significant financial assets and liabilities measured at fair value as of December 30, 2018 and December 31, 2017 were as follows: 2018 2017 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 501 — 501 418 Interest rate contracts (2)(4) — 161 — 161 7 Total — 662 — 662 425 Liabilities: Forward foreign exchange contracts — 548 — 548 402 Interest rate contracts (3)(4) — 292 — 292 165 Total — 840 — 840 567 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts — 32 — 32 38 Liabilities: Forward foreign exchange contracts — 32 — 32 38 Available For Sale Other Investments: Equity investments (5) 511 — — 511 751 Debt securities (6) $ — 9,734 — 9,734 5,310 Gross to Net Derivative Reconciliation 2018 2017 (Dollars in Millions) Total Gross Assets $ 694 463 Credit Support Agreement (CSA) (423 ) (76 ) Total Net Asset 271 387 Total Gross Liabilities 872 605 Credit Support Agreement (CSA) (605 ) (238 ) Total Net Liabilities $ 267 367 (1) 2017 assets and liabilities are all classified as Level 2 with the exception of equity investments of $751 million , which are classified as Level 1. (2) Includes $6 million and $7 million of non-current assets for the fiscal years ending December 30, 2018 and December 31, 2017 , respectively. (3) Includes $3 million and $9 million of non-current liabilities for the fiscal years ending December 30, 2018 and December 31, 2017 , respectively. (4) Includes cross currency interest rate swaps and interest rate swaps. (5) Classified as non-current other assets. The carrying amount of the equity investments were $511 million and $751 million as of December 30, 2018 and December 31, 2017 , respectively. (6) Classified as cash equivalents and current marketable securities. See Notes 2 and 7 for financial assets and liabilities held at carrying amount on the Consolidated Balance Sheet.

Borrowings

Borrowings	12 Months Ended
	Dec. 30, 2018
Debt Disclosure [Abstract]
Borrowings	Borrowings The components of long-term debt are as follows: (Dollars in Millions) 2018 Effective Rate % 2017 Effective Rate % 5.15% Debentures due 2018 $ — 900 5.18 1.65% Notes due 2018 — 597 1.70 4.75% Notes due 2019 (1B Euro 1.14) (2) /(1B Euro 1.1947) (3) 1,139 (2) 5.83 1,192 (3) 5.83 1.875% Notes due 2019 494 1.93 496 1.93 0.89% Notes due 2019 300 1.32 300 1.75 1.125% Notes due 2019 699 1.13 699 1.13 3% Zero Coupon Convertible Subordinated Debentures due 2020 51 3.00 60 3.00 2.95% Debentures due 2020 548 3.15 547 3.15 1.950% Notes due 2020 499 1.99 499 1.99 3.55% Notes due 2021 449 3.67 448 3.67 2.45% Notes due 2021 349 2.48 349 2.48 1.65% Notes due 2021 998 1.65 998 1.65 0.250% Notes due 2022 (1B Euro 1.14) (2) /(1B Euro 1.1947) (3) 1,137 (2) 0.26 1,191 (3) 0.26 2.25% Notes due 2022 996 2.31 995 2.31 6.73% Debentures due 2023 250 6.73 250 6.73 3.375% Notes due 2023 805 3.17 806 3.17 2.05% Notes due 2023 498 2.09 498 2.09 0.650% Notes due 2024 (750MM Euro 1.14) (2) /(750MM Euro 1.1947) (3) 851 (2) 0.68 891 (3) 0.68 5.50% Notes due 2024 (500MM GBP 1.2636) (2) /(500MM GBP 1.3444) (3) 627 (2) 6.75 666 (3) 6.75 2.625% Notes due 2025 748 2.63 747 2.63 2.45% Notes due 2026 1,992 2.47 1,990 2.47 2.95% Notes due 2027 996 2.96 995 2.96 1.150% Notes due 2028 (750MM Euro 1.14) (2) /(750MM Euro 1.1947) (3) 847 (2) 1.21 887 (3) 1.21 2.900% Notes due 2028 1,493 2.91 1,492 2.91 6.95% Notes due 2029 297 7.14 296 7.14 4.95% Debentures due 2033 498 4.95 498 4.95 4.375% Notes due 2033 856 4.24 856 4.24 1.650% Notes due 2035 (1.5B Euro 1.14) (2) /(1.5B Euro 1.1947) (3) 1,693 (2) 1.68 1,774 (3) 1.68 3.55% Notes due 2036 988 3.59 987 3.59 5.95% Notes due 2037 991 5.99 991 5.99 3.625% Notes due 2037 1,486 3.64 1,486 3.64 5.85% Debentures due 2038 696 5.85 696 5.85 3.400% Notes due 2038 990 3.42 990 3.42 4.50% Debentures due 2040 538 4.63 538 4.63 4.85% Notes due 2041 297 4.89 296 4.89 4.50% Notes due 2043 495 4.52 495 4.52 3.70% Notes due 2046 1,972 3.74 1,971 3.74 3.75% Notes due 2047 991 3.76 990 3.76 3.500% Notes due 2048 742 3.52 742 3.52 Other 24 — 75 — Subtotal 30,320 (4) 3.19 % (1) 32,174 (4) 3.19 (1 ) Less current portion 2,636 1,499 Total long-term debt $ 27,684 30,675 (1) Weighted average effective rate. (2) Translation rate at December 30, 2018 . (3) Translation rate at December 31, 2017 . (4) The excess of the fair value over the carrying value of debt was $0.3 billion in 2018 and $2.0 billion in 2017 . Fair value of the long-term debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.(Level 2) The Company has access to substantial sources of funds at numerous banks worldwide. In September 2018 , the Company secured a new 364-day Credit Facility. Total credit available to the Company approximates $10 billion , which expires on September 12, 2019 . Interest charged on borrowings under the credit line agreements is based on either bids provided by banks, the prime rate or London Interbank Offered Rates (LIBOR), plus applicable margins. Commitment fees under the agreements are not material. Throughout 2018 , the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $2.8 billion at the end of 2018 , of which $2.6 billion is the current portion of the long term debt, and the remainder principally represents local borrowing by international subsidiaries. Throughout 2017, the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $3.9 billion at the end of 2017, of which $2.3 billion was borrowed under the Commercial Paper Program, $1.5 billion is the current portion of the long-term debt, and the remainder principally represents local borrowing by international subsidiaries. Aggregate maturities of long-term obligations commencing in 2019 are: (Dollars in Millions) 2019 2020 2021 2022 2023 After 2023 $2,636 1,098 1,796 2,134 1,553 21,103

Income Taxes

Income Taxes	12 Months Ended
	Dec. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The provision for taxes on income consists of: (Dollars in Millions) 2018 2017 2016 Currently payable: U.S. taxes $ 1,081 11,969 1,896 U.S. taxes on international operations 203 126 49 International taxes 2,434 1,872 1,659 Total currently payable 3,718 13,967 3,604 Deferred: U.S. taxes (148 ) (1,956 ) 294 U.S. taxes on international operations 1,358 International taxes (2,226 ) 4,362 (635 ) Total deferred (1,016 ) 2,406 (341 ) Provision for taxes on income $ 2,702 16,373 3,263 A comparison of income tax expense at the U.S. statutory rate of 21% in 2018 and 35% in 2017 and 2016 , to the Company’s effective tax rate is as follows: (Dollars in Millions) 2018 2017 2016 U.S. $ 5,575 4,865 7,457 International 12,424 12,808 12,346 Earnings before taxes on income: $ 17,999 17,673 19,803 Tax rates: U.S. statutory rate 21.0 % 35.0 35.0 International operations (1) (3.7 ) (12.8 ) (17.2 ) Research and orphan drug tax credits (1.0 ) (0.4 ) (0.4 ) U.S. state and local 0.8 0.6 (0.1 ) U.S. manufacturing deduction — (0.8 ) (0.6 ) U.S. tax on international income (2) 1.4 0.7 1.3 Tax benefits on share-based compensation (1.5 ) (2.1 ) (1.8 ) U.S. tax benefit on asset/business disposals 0.5 (0.8 ) — All other (0.6 ) (0.1 ) 0.3 TCJA and related impacts (3) (1.9 ) (3) 73.3 (4) — Effective Rate 15.0 % 92.6 16.5 (1) For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflects the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2017 amount also includes tax cost related to the revaluation of deferred tax balances related to the change in the Belgian statutory tax rate increasing the tax provision by approximately 3.4% . (2) Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. (3) Represents impact of adjustments to the 2017 TCJA provisional tax charge. This also includes a net tax benefit from the reduction of a deferred tax liability related to foreign withholding taxes originally accrued as part of the provisional charge. This benefit reduced the Company’s effective tax rate by approximately 11% . Further description is included below. (4) Includes U.S. state and local taxes provisionally recorded as part TCJA provisional charge which was approximately 0.6% of the total effective tax rate. On December 22, 2017, the United States enacted into law new U.S. tax legislation, the Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. This legislation also eliminated or reduced certain corporate income tax deductions as well as introduced new provisions that taxed certain foreign income not previously taxed by the United States. The TCJA also included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings are taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest and these payments began in 2018 and will continue through 2025. The remaining balance at the end of the fiscal year 2018 was approximately $8.2 billion . In December 2017, the SEC provided regulatory guidance for accounting of the impacts of the TCJA, referred to as SAB 118. Under the guidance in SAB 118, the income tax effects, which the accounting under ASC 740 is incomplete, are reported as a provisional amount based on a reasonable estimate. The reasonable estimate is subject to adjustment during a "measurement period", not to exceed one year, until the accounting is complete. The estimate is also subject to the finalization of management’s analysis related to certain matters, such as developing interpretations of the provision of the TCJA, changes to certain estimates and amounts related to the earnings and profits of certain subsidiaries and the filing of tax returns. In the fourth quarter of 2017, the Company recorded a provisional tax cost of approximately $13.0 billion which consisted primarily of the following components: • a $10.1 billion charge on previously undistributed foreign earnings as of December 31, 2017 • a $4.5 billion deferred tax liability for foreign local and withholding taxes, offset by a $1.1 billion deferred tax asset for U.S. foreign tax credits, for repatriation of substantially all those earnings • a $0.6 billion tax benefit relating to the remeasurement of U.S. deferred tax assets and liabilities and the impact of the TCJA on unrecognized tax benefits • a $0.1 billion charge for U.S. state and local taxes on the repatriation of these foreign earnings During the fourth quarter of 2018, the Company completed its full assessment and finalized the accounting for the impact of TCJA. The Company recorded net adjustments to the above components of the provisional charge of approximately $0.2 billion . These revisions were based on updated estimates and additional analysis by management as well as applying interpretative guidance issued by the U.S. Department of Treasury to the facts and circumstances that existed as of the TCJA enactment date. This charge was primarily related to additional deferred tax liabilities for foreign local and withholding taxes for the remaining balance of undistributed foreign earnings as of December 31, 2017 that were not provided for in the provisional charge in the fourth quarter of 2017. The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI). GILTI is described as the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., “period cost”) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to effect the amount of GILTI inclusion in future years upon reversal (i.e., “deferred method”). Through the third fiscal quarter of 2018, the Company had provisionally elected to treat GILTI as a period expense. Upon further analysis of this new tax provision, the Company has elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred. As a result of this election, the Company recorded a deferred tax cost related to GILTI of approximately $1.4 billion in the fourth fiscal quarter of 2018 related to facts and circumstances that existed on the date of TCJA enactment. As a result of the GILTI deferred tax charge and the other adjustments to the provisional amount, the Company recorded a total of $1.6 billion of adjustments to the 2017 provisional charge increasing the Company’s annual effective tax rate by approximately 9% . During 2018, the Company reorganized the ownership structure of certain foreign subsidiaries which resulted in a reduction of certain foreign withholding taxes that it had recognized as part of the provisional TCJA tax charge in the fourth quarter of 2017. Following the completion of this restructuring in the fourth quarter 2018, and as a result of clarification by Swiss tax authorities regarding the applicability of withholding tax to repatriation of certain earnings, the Company reversed a deferred tax liability of $2.8 billion and a related deferred tax asset of $0.9 billion for U.S. foreign tax credits, for a net deferred tax benefit of $1.9 billion . As this restructuring occurred after the TCJA enactment date, the benefit is not considered an adjustment to the provisional amount recorded in 2017 under SAB118. This benefit with the SAB 118 adjustments has been reflected as “TCJA and related impacts” on the Company’s effective tax rate reconciliation. As described in Note 1 to the Consolidated Financial Statements, in 2018 the Company adopted ASU 2016-16: Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory. This standard requires entities to recognize deferred tax assets and liabilities related to transfer of assets, other than inventory, within the consolidated entity. At the beginning of fiscal 2018, the Company recorded a net adjustment to deferred tax assets of approximately $2.0 billion . In the fourth quarter of 2018, as a result of the election to record GILTI on the deferred method, the Company recorded a GILTI deferred tax liability of $1.7 billion related to the adoption provisions of ASU 2016-16 as an adjustment to retained earnings. The 2018 effective tax rate decreased by 77.6% compared to 2017. The 2017 effective tax rate was primarily driven by the approximately $13 billion provisional tax charge recorded in the fourth quarter of 2017 and the impact of a Belgian statutory tax rate change which increased the 2017 effective rate by 3.4% . Additional drivers of the 2018 annual effective tax were: • the reduction of the U.S. statutory corporate tax rate including the effects of tax elections which resulted in the acceleration of certain deductions into the 2017 tax return. The impact of these accelerated deductions decreased the annual effective tax rate by approximately 1.7% • the impact of the adjustments to the 2017 provisional TCJA charge, including both SAB 118 adjustments and the internal restructuring, decreased the effective tax rate by approximately 1.9% • GILTI tax which increased the annual effective tax rate by approximately 1.6% , which excludes the impact of the SAB 118 adjustment for the adoption of the deferred method for GILTI • tax benefits received from stock-based compensation during fiscal 2018 and 2017, reduced the effective tax rate by 1.5% and 2.0% , respectively • in the fourth quarter of 2018, the Company completed the divestiture of its LifeScan business (Note 20), which increased the Company annual effective tax rate by approximately 0.8% • more income in higher tax jurisdictions relative to lower tax jurisdictions as compared to 2017 The 2017 effective tax rate increased by 76.1% as compared to 2016, primarily driven by the enactment of the TCJA in the U.S. in December 2017. The enactment of the TCJA resulted in a provisional tax charge in the fourth quarter of 2017, of approximately $13.0 billion or approximately 73.3 percentage point increase to the effective tax rate. The remainder of the increase in the tax rate for 2017 was related to the remeasurement of the Company’s deferred tax assets in Belgium, as a result of changes in the Belgian statutory corporate tax rate enacted in December 2017, offset by a tax benefit for the closure of the Company’s Animas insulin pump business. Temporary differences and carryforwards for 2018 and 2017 were as follows: 2018 Deferred Tax 2017 Deferred Tax (Dollars in Millions) Asset Liability Asset Liability Employee related obligations $ 2,398 2,259 Stock based compensation 639 507 Depreciation & amortization 1,784 (9 ) Non-deductible intangibles (5,967 ) (6,506 ) International R&D capitalized for tax 1,282 1,307 Reserves & liabilities 1,647 1,718 Income reported for tax purposes 1,104 1,316 Net operating loss carryforward international 786 762 Undistributed foreign earnings 693 (2,240 ) 1,101 (4,457 ) Global intangible low-taxed income (2,971 ) Miscellaneous international 603 (93 ) 755 (194 ) Miscellaneous U.S. 469 177 Total deferred income taxes $ 11,405 (11,271 ) 9,902 (11,166 ) The Company has wholly-owned international subsidiaries that have cumulative net losses. The Company believes that it is more likely than not that these subsidiaries will generate future taxable income sufficient to utilize these deferred tax assets. The following table summarizes the activity related to unrecognized tax benefits: (Dollars in Millions) 2018 2017 2016 Beginning of year $ 3,151 3,041 3,080 Increases related to current year tax positions 242 332 348 Increases related to prior period tax positions 145 232 11 Decreases related to prior period tax positions (137 ) (416 ) (1) (338 ) Settlements (40 ) (2 ) (37 ) Lapse of statute of limitations (35 ) (36 ) (23 ) End of year $ 3,326 3,151 3,041 (1) In 2017, $347 million of this decrease is related to the TCJA The unrecognized tax benefits of $3.3 billion at December 30, 2018 , if recognized, would affect the Company’s annual effective tax rate. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress with a number of tax authorities. The IRS has completed its audit for the tax years through 2009 and is currently auditing the tax years 2010-2012. The Company currently expects completion of this audit during 2019. Final conclusion of the tax audit may result in an outcome that is different than the Company’s estimates and may result in a material impact on the Company’s current and future operating results or cash flows in the period that the audit is concluded. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2006. The Company believes it is possible that audits may be completed by tax authorities in some jurisdictions over the next twelve months. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions. The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities. Interest expense and penalties related to unrecognized tax benefits are classified as income tax expense. The Company recognized after tax interest expense of $53 million , $60 million and $7 million in 2018 , 2017 and 2016 , respectively. The total amount of accrued interest was $503 million and $436 million in 2018 and 2017 , respectively.

Employee Related Obligations

Employee Related Obligations	12 Months Ended
	Dec. 30, 2018
Compensation Related Costs [Abstract]
Employee Related Obligations	Employee Related Obligations At the end of 2018 and 2017 , employee related obligations recorded on the Consolidated Balance Sheets were: (Dollars in Millions) 2018 2017 Pension benefits $ 5,327 5,343 Postretirement benefits 2,283 2,331 Postemployment benefits 2,330 2,250 Deferred compensation 410 475 Total employee obligations 10,350 10,399 Less current benefits payable 399 325 Employee related obligations — non-current $ 9,951 10,074 Prepaid employee related obligations of $475 million and $526 million for 2018 and 2017 , respectively, are included in Other assets on the Consolidated Balance Sheets.

Pensions and Other Benefit Plan

Pensions and Other Benefit Plans	12 Months Ended
	Dec. 30, 2018
Retirement Benefits [Abstract]
Pensions and Other Benefit Plans	Pensions and Other Benefit Plans The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. The Company also provides post-retirement benefits, primarily health care, to all eligible U.S. retired employees and their dependents. Many international employees are covered by government-sponsored programs and the cost to the Company is not significant. Retirement plan benefits for employees hired before January 1, 2015 are primarily based on the employee’s compensation during the last three to five years before retirement and the number of years of service. In 2014, the Company announced that the U.S. Defined Benefit Plan was amended to adopt a new benefit formula, effective for employees hired on or after January 1, 2015. The benefits are calculated using a new formula based on employee compensation over total years of service. International subsidiaries have plans under which funds are deposited with trustees, annuities are purchased under group contracts, or reserves are provided. The Company does not typically fund retiree health care benefits in advance, but may do so at its discretion. The Company also has the right to modify these plans in the future. In 2018 and 2017 the Company used December 31, 2018 and December 31, 2017 , respectively, as the measurement date for all U.S. and international retirement and other benefit plans. Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for 2018 , 2017 and 2016 include the following components: Retirement Plans Other Benefit Plans (Dollars in Millions) 2018 2017 2016 2018 2017 2016 Service cost $ 1,283 1,080 949 269 247 224 Interest cost 996 927 927 148 159 158 Expected return on plan assets (2,212 ) (2,041 ) (1,962 ) (7 ) (6 ) (6 ) Amortization of prior service cost (credit) 3 2 1 (31 ) (30 ) (34 ) Recognized actuarial losses 852 609 496 123 138 135 Curtailments and settlements 1 17 11 — — — Net periodic benefit cost $ 923 594 422 502 508 477 In 2018, as per the adoption of ASU 2017-07, the service cost component of net periodic benefit cost was presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings. Amounts expected to be recognized in net periodic benefit cost in the coming year for the Company’s defined benefit retirement plans and other post-retirement plans: (Dollars in Millions) Amortization of net transition obligation $ — Amortization of net actuarial losses 656 Amortization of prior service credit 27 Unrecognized gains and losses for the U.S. pension plans are amortized over the average remaining future service for each plan. For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses for the other U.S. benefit plans is determined by using a 10% corridor of the greater of the market value of assets or the accumulated postretirement benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service. Prior service costs/benefits for the U.S. pension plans are amortized over the average remaining future service of plan participants at the time of the plan amendment. Prior service cost/benefit for the other U.S. benefit plans is amortized over the average remaining service to full eligibility age of plan participants at the time of the plan amendment. The following table represents the weighted-average actuarial assumptions: Retirement Plans Other Benefit Plans Worldwide Benefit Plans 2018 2017 2016 2018 2017 2016 Net Periodic Benefit Cost Service cost discount rate 3.20 % 3.59 3.98 3.85 4.63 4.77 Interest cost discount rate 3.60 % 3.98 4.24 3.62 3.94 4.10 Rate of increase in compensation levels 3.98 % 4.01 4.02 4.29 4.31 4.32 Expected long-term rate of return on plan assets 8.46 % 8.43 8.55 Benefit Obligation Discount rate 3.76 % 3.30 3.78 4.40 3.78 4.42 Rate of increase in compensation levels 3.97 % 3.99 4.02 4.29 4.30 4.29 The Company’s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities. In the fiscal year 2016, the Company changed its methodology in determining service and interest cost from the single weighted average discount rate approach to duration specific spot rates along that yield curve to the plans’ liability cash flows, which management has concluded is a more precise estimate. Prior to this change in methodology, the Company measured service and interest costs utilizing a single weighted-average discount rate derived from the yield curve used to measure the plan obligations. The Company has accounted for this change as a change in accounting estimate and, accordingly, has accounted for it on a prospective basis. This change does not impact the benefit obligation and did not have a material impact to the 2016 full year results. The expected rates of return on plan asset assumptions represent the Company's assessment of long-term returns on diversified investment portfolios globally. The assessment is determined using projections from external financial sources, long-term historical averages, actual returns by asset class and the various asset class allocations by market. The following table displays the assumed health care cost trend rates, for all individuals: Health Care Plans 2018 2017 Health care cost trend rate assumed for next year 6.12 % 6.33 % Rate to which the cost trend rate is assumed to decline (ultimate trend) 4.55 % 4.55 % Year the rate reaches the ultimate trend rate 2038 2038 A one-percentage-point change in assumed health care cost trend rates would have the following effect: One-Percentage- One-Percentage- (Dollars in Millions) Point Increase Point Decrease Health Care Plans Total interest and service cost $ 28 (22 ) Post-retirement benefit obligation $ 340 (280 ) The following table sets forth information related to the benefit obligation and the fair value of plan assets at year-end 2018 and 2017 for the Company’s defined benefit retirement plans and other post-retirement plans: Retirement Plans Other Benefit Plans (Dollars in Millions) 2018 2017 2018 2017 Change in Benefit Obligation Projected benefit obligation — beginning of year $ 33,221 28,116 4,582 4,605 Service cost 1,283 1,080 269 247 Interest cost 996 927 148 159 Plan participant contributions 66 60 — — Amendments 26 (7 ) — (17 ) Actuarial (gains) losses (2,326 ) 2,996 (119 ) (166 ) Divestitures & acquisitions (29 ) 201 — 88 Curtailments, settlements & restructuring (21 ) (35 ) — 2 Benefits paid from plan (1,018 ) (1,050 ) (383 ) (351 ) Effect of exchange rates (528 ) 933 (17 ) 15 Projected benefit obligation — end of year $ 31,670 33,221 4,480 4,582 Change in Plan Assets Plan assets at fair value — beginning of year $ 28,404 23,633 281 75 Actual return on plan assets (1,269 ) 4,274 — 12 Company contributions 1,140 664 282 545 Plan participant contributions 66 60 — — Settlements (13 ) (32 ) — — Divestitures & acquisitions (17 ) 173 — — Benefits paid from plan assets (1,018 ) (1,050 ) (383 ) (351 ) Effect of exchange rates (475 ) 682 — — Plan assets at fair value — end of year $ 26,818 28,404 180 281 Funded status — end of year $ (4,852 ) (4,817 ) (4,300 ) (4,301 ) Amounts Recognized in the Company’s Balance Sheet consist of the following: Non-current assets $ 475 526 — — Current liabilities (98 ) (92 ) (281 ) (228 ) Non-current liabilities (5,229 ) (5,251 ) (4,019 ) (4,073 ) Total recognized in the consolidated balance sheet — end of year $ (4,852 ) (4,817 ) (4,300 ) (4,301 ) Amounts Recognized in Accumulated Other Comprehensive Income consist of the following: Net actuarial loss $ 8,323 8,140 1,263 1,500 Prior service cost (credit) 2 (25 ) (106 ) (137 ) Unrecognized net transition obligation — — — — Total before tax effects $ 8,325 8,115 1,157 1,363 Accumulated Benefit Obligations — end of year $ 28,533 29,793 Retirement Plans Other Benefit Plans (Dollars in Millions) 2018 2017 2018 2017 Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income Net periodic benefit cost $ 923 594 502 508 Net actuarial (gain) loss 1,153 740 (111 ) (169 ) Amortization of net actuarial loss (852 ) (609 ) (123 ) (138 ) Prior service cost (credit) 26 (7 ) — (17 ) Amortization of prior service (cost) credit (3 ) (2 ) 31 30 Effect of exchange rates (114 ) 256 (3 ) 3 Total loss/(income) recognized in other comprehensive income, before tax $ 210 378 (206 ) (291 ) Total recognized in net periodic benefit cost and other comprehensive income $ 1,133 972 296 217 The Company plans to continue to fund its U.S. Qualified Plans to comply with the Pension Protection Act of 2006. International Plans are funded in accordance with local regulations. Additional discretionary contributions are made when deemed appropriate to meet the long-term obligations of the plans. For certain plans, funding is not a common practice, as funding provides no economic benefit. Consequently, the Company has several pension plans that are not funded. In 2018 , the Company contributed $679 million and $461 million to its U.S. and international pension plans, respectively. The following table displays the funded status of the Company's U.S. Qualified & Non-Qualified pension plans and international funded and unfunded pension plans at December 31, 2018 and December 31, 2017, respectively: U.S. Plans International Plans Qualified Plans Non-Qualified Plans Funded Plans Unfunded Plans (Dollars in Millions) 2018 2017 2018 2017 2018 2017 2018 2017 Plan Assets $ 17,725 18,681 — — 9,093 9,723 — — Projected Benefit Obligation 18,609 19,652 2,176 2,257 10,467 10,863 418 449 Accumulated Benefit Obligation 16,851 17,654 1,793 1,849 9,510 9,893 379 397 Over (Under) Funded Status Projected Benefit Obligation $ (884 ) (971 ) (2,176 ) (2,257 ) (1,374 ) (1,140 ) (418 ) (449 ) Accumulated Benefit Obligation 874 1,027 (1,793 ) (1,849 ) (417 ) (170 ) (379 ) (397 ) Plans with accumulated benefit obligations in excess of plan assets have an accumulated benefit obligation, projected benefit obligation and plan assets of $7.5 billion , $8.8 billion and $4.3 billion , respectively, at the end of 2018 , and $3.8 billion , $4.6 billion and $0.7 billion , respectively, at the end of 2017 . The following table displays the projected future benefit payments from the Company’s retirement and other benefit plans: (Dollars in Millions) 2019 2020 2021 2022 2023 2024-2028 Projected future benefit payments Retirement plans $ 1,062 1,104 1,182 1,257 1,332 7,679 Other benefit plans $ 375 397 411 428 413 2,273 The following table displays the projected future minimum contributions to the unfunded retirement plans. These amounts do not include any discretionary contributions that the Company may elect to make in the future. (Dollars in Millions) 2019 2020 2021 2022 2023 2024-2028 Projected future contributions $ 92 95 101 108 115 697 Each pension plan is overseen by a local committee or board that is responsible for the overall administration and investment of the pension plans. In determining investment policies, strategies and goals, each committee or board considers factors including, local pension rules and regulations; local tax regulations; availability of investment vehicles (separate accounts, commingled accounts, insurance funds, etc.); funded status of the plans; ratio of actives to retirees; duration of liabilities; and other relevant factors including: diversification, liquidity of local markets and liquidity of base currency. A majority of the Company’s pension funds are open to new entrants and are expected to be on-going plans. Permitted investments are primarily liquid and/or listed, with little reliance on illiquid and non-traditional investments such as hedge funds. The Company’s retirement plan asset allocation at the end of 2018 and 2017 and target allocations for 2019 are as follows: Percent of Plan Assets Target Allocation 2018 2017 2019 Worldwide Retirement Plans Equity securities 71 % 76 % 70 % Debt securities 29 24 30 Total plan assets 100 % 100 % 100 % Determination of Fair Value of Plan Assets The Plan has an established and well-documented process for determining fair values. Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves. While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. Valuation Hierarchy The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with Level 1 having the highest priority and Level 3 having the lowest. A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Following is a description of the valuation methodologies used for the investments measured at fair value. • Short-term investment funds — Cash and quoted short-term instruments are valued at the closing price or the amount held on deposit by the custodian bank. Other investments are through investment vehicles valued using the Net Asset Value (NAV) provided by the administrator of the fund. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. The NAV is a quoted price in a market that is not active and classified as Level 2. • Government and agency securities — A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified within Level 1 of the valuation hierarchy. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. When quoted market prices for a security are not available in an active market, they are classified as Level 2. • Debt instruments — A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified as Level 1. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are classified as Level 2. Level 3 debt instruments are priced based on unobservable inputs. • Equity securities — Equity securities are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all common stock is classified within Level 1 of the valuation hierarchy. • Commingled funds — These investment vehicles are valued using the NAV provided by the fund administrator. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. Assets in the Level 2 category have a quoted market price. • Insurance contracts — The instruments are issued by insurance companies. The fair value is based on negotiated value and the underlying investments held in separate account portfolios as well as considering the credit worthiness of the issuer. The underlying investments are government, asset-backed and fixed income securities. In general, insurance contracts are classified as Level 3 as there are no quoted prices nor other observable inputs for pricing. • Other assets — Other assets are represented primarily by limited partnerships and real estate investments, as well as commercial loans and commercial mortgages that are not classified as corporate debt. Other assets that are exchange listed and actively traded are classified as Level 1, while inactively traded assets are classified as Level 2. The following table sets forth the Retirement Plans' investments measured at fair value as of December 31, 2018 and December 31, 2017: Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (a) Investments Measured at Net Asset Value (Level 1) (Level 2) (Level 3) Total Assets (Dollars in Millions) 2018 2017 2018 2017 2018 2017 2018 2017 2018 2017 Short-term investment funds $ 122 429 529 427 — — — — 651 856 Government and agency securities — — 3,595 3,094 — — — — 3,595 3,094 Debt instruments — — 3,105 2,013 — — — — 3,105 2,013 Equity securities 11,298 13,848 4 — — — — — 11,302 13,848 Commingled funds — — 2,304 1,780 133 57 5,201 6,158 7,638 7,995 Insurance contracts — — — — 193 199 — — 193 199 Other assets — — 33 121 — — 301 278 334 399 Investments at fair value $ 11,420 14,277 9,570 7,435 326 256 5,502 6,436 26,818 28,404 (a) The activity for the Level 3 assets is not significant for all years presented. The Company's Other Benefit Plans are unfunded except for U.S. commingled funds (Level 2) of $72 million and $81 million and U.S. short-term investment funds (Level 2) of $108 million and $200 million at December 31, 2018 and December 31, 2017, respectively. The fair value of Johnson & Johnson Common Stock directly held in plan assets was $876 million ( 3.3% of total plan assets) at December 31, 2018 and $938 million ( 3.3% of total plan assets) at December 31, 2017.

Savings Plan

Savings Plan	12 Months Ended
	Dec. 30, 2018
Savings Plan [Abstract]
Savings Plan	Savings Plan The Company has voluntary 401(k) savings plans designed to enhance the existing retirement programs covering eligible employees. The Company matches a percentage of each employee’s contributions consistent with the provisions of the plan for which he/she is eligible. Total Company matching contributions to the plans were $242 million , $214 million and $191 million in 2018 , 2017 and 2016 , respectively.

Capital and Treasury Stock

Capital and Treasury Stock	12 Months Ended
	Dec. 30, 2018
Equity [Abstract]
Capital and Treasury Stock	Capital and Treasury Stock Changes in treasury stock were: Treasury Stock (Amounts in Millions Except Treasury Stock Shares in Thousands) Shares Amount Balance at January 3, 2016 364,681 $ 22,684 Employee compensation and stock option plans (30,839 ) (3,311 ) Repurchase of common stock 79,490 8,979 Balance at January 1, 2017 413,332 28,352 Employee compensation and stock option plans (25,508 ) (3,156 ) Repurchase of common stock 49,494 6,358 Balance at December 31, 2017 437,318 31,554 Employee compensation and stock option plans (22,082 ) (3,060 ) Repurchase of common stock 42,283 5,868 Balance at December 30, 2018 457,519 $ 34,362 Aggregate shares of common stock issued were approximately 3,119,843,000 shares at the end of 2018 , 2017 and 2016 . Cash dividends paid were $3.54 per share in 2018 , compared with dividends of $3.32 per share in 2017 , and $3.15 per share in 2016 . On December 17, 2018, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's shares of common stock. The repurchase program has no time limit and may be suspended for periods or discontinued at any time. Any shares acquired will be available for general corporate purposes. The Company intends to finance the share repurchase program through available cash. As of December 30, 2018, $0.9 billion has been repurchased under the program. On October 13, 2015, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $10.0 billion of the Company's shares of common stock. This share repurchase program was completed as of July 2, 2017.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	12 Months Ended
	Dec. 30, 2018
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) Components of other comprehensive income (loss) consist of the following: (Dollars in Millions) Foreign Gain/(Loss) On Securities Employee Benefit Plans Gain/ Total January 3, 2016 $ (8,435 ) 604 (5,298 ) (36 ) (13,165 ) Net 2016 changes (612 ) (193 ) (682 ) (249 ) (1,736 ) January 1, 2017 (9,047 ) 411 (5,980 ) (285 ) (14,901 ) Net 2017 changes 1,696 (179 ) (170 ) 355 1,702 December 31, 2017 (7,351 ) 232 (6,150 ) 70 (13,199 ) Cumulative adjustment to retained earnings (232 ) (1) (232 ) Net 2018 changes (1,518 ) — (8 ) (265 ) (1,791 ) December 30, 2018 $ (8,869 ) — (6,158 ) (195 ) (15,222 ) (1) See Note 1 to Consolidated Financial Statements for additional details on the adoption of ASU 2016-01 Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. Details on reclassifications out of Accumulated Other Comprehensive Income: Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net. Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 10 for additional details. Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the hedged transaction. See Note 6 for additional details.

International Currency Translat

International Currency Translation	12 Months Ended
	Dec. 30, 2018
Foreign Currency Translation [Abstract]
International Currency Transalation	International Currency Translation For translation of its subsidiaries operating in non-U.S. Dollar currencies, the Company has determined that the local currencies of its international subsidiaries are the functional currencies except those in highly inflationary economies, which are defined as those which have had compound cumulative rates of inflation of 100% or more during the past three years , or where a substantial portion of its cash flows are not in the local currency. Beginning in the fiscal third quarter of 2018, the Company accounted for operations in Argentina as highly inflationary. For the majority of the Company's subsidiaries the local currency is the functional currency. In consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive income. This equity account includes the results of translating certain balance sheet assets and liabilities at current exchange rates and some accounts at historical rates, except for those located in highly inflationary economies. The translation of balance sheet accounts for highly inflationary economies are reflected in the operating results. A rollforward of the changes during 2018 , 2017 and 2016 for foreign currency translation adjustments is included in Note 13. Net currency transaction gains and losses included in Other (income) expense were losses of $265 million , $216 million and $289 million in 2018 , 2017 and 2016 , respectively.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 30, 2018
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended December 30, 2018 , December 31, 2017 and January 1, 2017 : (In Millions Except Per Share Amounts) 2018 2017 2016 Basic net earnings per share $ 5.70 0.48 6.04 Average shares outstanding — basic 2,681.5 2,692.0 2,737.3 Potential shares exercisable under stock option plans 139.0 139.7 142.4 Less: shares repurchased under treasury stock method (92.5 ) (87.3 ) (92.1 ) Convertible debt shares 0.7 0.9 1.3 Adjusted average shares outstanding — diluted 2,728.7 2,745.3 2,788.9 Diluted net earnings per share $ 5.61 0.47 5.93 The diluted net earnings per share calculation included the dilutive effect of convertible debt that is offset by the related reduction in interest expense of $1 million after-tax for 2018 and 2017, and $2 million for 2016. The diluted net earnings per share calculation for 2018, 2017 and 2016 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company's stock.

Rental Expense and Lease Commit

Rental Expense and Lease Commitments	12 Months Ended
	Dec. 30, 2018
Leases, Operating [Abstract]
Rental Expense and Lease Commitments	Rental Expense and Lease Commitments Rentals of space, vehicles, manufacturing equipment and office and data processing equipment under operating leases were approximately $332 million , $372 million and $330 million in 2018 , 2017 and 2016 , respectively. The approximate minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year at December 30, 2018 are: (Dollars in Millions) 2019 2020 2021 2022 2023 After 2023 Total $223 188 154 116 76 139 896 Commitments under capital leases are not significant.

Common Stock, Stock Option Plan

Common Stock, Stock Option Plans and Stock Compensation Agreements	12 Months Ended
	Dec. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Common Stock, Stock Option Plans and Stock Compensation Agreements	Common Stock, Stock Option Plans and Stock Compensation Agreements At December 30, 2018 , the Company had 2 stock-based compensation plans. The shares outstanding are for contracts under the Company's 2005 Long-Term Incentive Plan and the 2012 Long-Term Incentive Plan. The 2005 Long-Term Incentive Plan expired April 26, 2012. All options and restricted shares granted subsequent to that date were under the 2012 Long-Term Incentive Plan. Under the 2012 Long-Term Incentive Plan, the Company may issue up to 650 million shares of common stock, plus any shares canceled, expired, forfeited, or not issued from the 2005 Long-Term Incentive Plan subsequent to April 26, 2012. Shares available for future grants under the 2012 Long-Term Incentive Plan were 351 million at the end of 2018 . The compensation cost that has been charged against income for these plans was $978 million , $962 million and $878 million for 2018 , 2017 and 2016 , respectively. The total income tax benefit recognized in the income statement for share-based compensation costs was $192 million , $275 million and $256 million for 2018 , 2017 and 2016 , respectively. An additional tax benefit of $353 million was recognized in 2016 due to the adoption of a new accounting standard for the reporting of additional tax benefits on share-based compensation. The total unrecognized compensation cost was $827 million , $798 million and $749 million for 2018 , 2017 and 2016 , respectively. The weighted average period for this cost to be recognized was 1.73 years, 1.76 years and 1.09 years for 2018 , 2017 , and 2016 , respectively. Share-based compensation costs capitalized as part of inventory were insignificant in all periods. The Company settles employee benefit equity issuances with treasury shares. Treasury shares are replenished throughout the year for the number of shares used to settle employee benefit equity issuances. Stock Options Stock options expire 10 years from the date of grant and vest over service periods that range from 6 months to 4 years . All options are granted at the average of the high and low prices of the Company’s Common Stock on the New York Stock Exchange on the date of grant. The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. For 2018, 2017 and 2016 grants, expected volatility represents a blended rate of 10-year weekly historical overall volatility rate, and a 5-week average implied volatility rate based on at-the-money traded Johnson & Johnson options with a life of 2 years. For all grants, historical data is used to determine the expected life of the option. The risk-free rate was based on the U.S. Treasury yield curve in effect at the time of grant. The average fair value of options granted was $17.98 , $13.38 and $10.01 , in 2018 , 2017 and 2016 , respectively. The fair value was estimated based on the weighted average assumptions of: 2018 2017 2016 Risk-free rate 2.77 % 2.25 % 1.51 % Expected volatility 15.77 % 15.30 % 15.76 % Expected life (in years) 7.0 7.0 7.0 Expected dividend yield 2.70 % 2.90 % 3.10 % A summary of option activity under the Plan as of December 30, 2018 , December 31, 2017 and January 1, 2017 , and changes during the years ending on those dates is presented below: (Shares in Thousands) Outstanding Shares Weighted Average Exercise Price Aggregate Intrinsic Value (Dollars in Millions) Shares at January 3, 2016 116,517 $ 76.41 $ 3,065 Options granted 22,491 101.87 Options exercised (22,547 ) 65.66 Options canceled/forfeited (3,006 ) 92.83 Shares at January 1, 2017 113,455 83.16 3,636 Options granted 19,287 115.67 Options exercised (18,975 ) 70.87 Options canceled/forfeited (2,461 ) 101.40 Shares at December 31, 2017 111,306 90.48 5,480 Options granted 17,115 129.51 Options exercised (16,228 ) 75.44 Options canceled/forfeited (2,541 ) 112.90 Shares at December 30, 2018 109,652 $ 98.29 $ 3,214 The total intrinsic value of options exercised was $1,028 million , $1,060 million and $980 million in 2018 , 2017 and 2016 , respectively. The following table summarizes stock options outstanding and exercisable at December 30, 2018 : (Shares in Thousands) Outstanding Exercisable Exercise Price Range Options Average Life (1) Average Exercise Price Options Average Exercise Price $52.13-$65.62 13,466 1.8 $62.67 13,466 $62.67 $66.07-$72.54 12,710 4.0 $72.53 12,710 $72.53 $90.44-$100.48 29,162 5.6 $95.34 28,537 $95.23 $101.87-$115.67 37,877 7.6 $108.33 111 $108.04 $115.68-$129.51 16,437 9.1 $129.51 38 $129.51 109,652 6.2 $98.29 54,862 $82.03 (1) Average contractual life remaining in years. Stock options outstanding at December 31, 2017 and January 1, 2017 were 111,306 and an average life of 6.3 years and 113,455 and an average life of 6.2 years, respectively. Stock options exercisable at December 31, 2017 and January 1, 2017 were 52,421 at an average price of $73.61 and 50,414 at an average price of $65.77 , respectively. Restricted Share Units and Performance Share Units The Company grants restricted share units which vest over service periods that range from 6 months to 3 years . The Company also grants performance share units, which are paid in shares of Johnson & Johnson Common Stock after the end of a three -year performance period. Whether any performance share units vest, and the amount that does vest, is tied to the completion of service periods that range from 6 months to 3 years and the achievement, over a three -year period, of three equally-weighted goals that directly align with or help drive long-term total shareholder return: operational sales, adjusted operational earnings per share, and relative total shareholder return. The number of shares actually earned at the end of the three -year period will vary, based only on actual performance, from 0% to 200% of the target number of performance share units granted . In the fourth quarter of 2017, the Company modified the restricted share units that are scheduled to vest between January 1, 2018 and March 15, 2018. This modification guaranteed a minimum aggregate value, below the market value of the total expected payout amount, for all awards expected to vest during this period. The amount that was committed was not material to the Company’s overall financial position. A summary of the restricted share units and performance share units activity under the Plans as of December 30, 2018 is presented below: (Shares in Thousands) Outstanding Restricted Share Units Outstanding Performance Share Units Shares at December 31, 2017 20,161 2,625 Granted 6,074 1,142 Issued (6,684 ) (1,151 ) Canceled/forfeited/adjusted (1,091 ) (122 ) Shares at December 30, 2018 18,460 2,494 The average fair value of the restricted share units granted was $119.67 , $107.69 and $92.45 in 2018 , 2017 and 2016 , respectively, using the fair market value at the date of grant. The fair value of restricted share units was discounted for dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units issued was $613.7 million , $596.5 million and $587.7 million in 2018 , 2017 and 2016 , respectively. The weighted average fair value of the performance share units granted was $120.64 , $114.13 and $105.30 in 2018 , 2017 and 2016 , calculated using the weighted average fair market value for each of the three component goals at the date of grant. The fair values for the sales and earnings per share goals of each performance share unit were estimated on the date of grant using the fair market value of the shares at the time of the award discounted for dividends, which are not paid on the performance share units during the vesting period. The fair value for the relative total shareholder return goal of each performance share unit was estimated on the date of grant using the Monte Carlo valuation model. The fair value of performance share units issued was $128.8 million , $132.5 million and $127.7 million in 2018 , 2017 and 2016 , respectively.

Segments of Business and Geogra

Segments of Business and Geographic Areas	12 Months Ended
	Dec. 30, 2018
Segment Reporting [Abstract]
Segments of Business and Geographic Areas	Segments of Business and Geographic Areas Sales to Customers % Change (Dollars in Millions) 2018 2017 2016 ’18 vs. ’17 ’17 vs. ’16 CONSUMER Baby Care U.S. $ 422 449 488 (6.0 )% (8.0 ) International 1,436 1,467 1,513 (2.1 ) (3.0 ) Worldwide 1,858 1,916 2,001 (3.0 ) (4.2 ) Beauty U.S. 2,403 2,335 2,135 2.9 9.4 International 1,979 1,865 1,762 6.1 5.8 Worldwide 4,382 4,200 3,897 4.3 7.8 Oral Care U.S. 637 616 648 3.4 (4.9 ) International 918 915 920 0.3 (0.5 ) Worldwide 1,555 1,531 1,568 1.6 (2.4 ) OTC U.S. 1,850 1,716 1,675 7.8 2.4 International 2,484 2,410 2,302 3.1 4.7 Worldwide 4,334 4,126 3,977 5.0 3.7 Women's Health U.S. 13 12 19 8.3 (36.8 ) International 1,036 1,038 1,048 (0.2 ) (1.0 ) Worldwide 1,049 1,050 1,067 (0.1 ) (1.6 ) Wound Care/Other U.S. 436 437 455 (0.2 ) (4.0 ) International 239 342 342 (30.1 ) 0.0 Worldwide 675 779 797 (13.4 ) (2.3 ) TOTAL CONSUMER U.S. 5,761 5,565 5,420 3.5 2.7 International 8,092 8,037 7,887 0.7 1.9 Worldwide 13,853 13,602 13,307 1.8 2.2 PHARMACEUTICAL Immunology U.S. 9,073 8,871 8,846 2.3 0.3 International 4,047 3,373 3,122 20.0 8.0 Worldwide 13,120 12,244 11,968 7.2 2.3 REMICADE ® U.S. 3,664 4,525 4,842 (19.0 ) (6.5 ) U.S. Exports 436 563 782 (22.6 ) (28.0 ) International 1,226 1,227 1,342 (0.1 ) (8.6 ) Worldwide 5,326 6,315 6,966 (15.7 ) (9.3 ) SIMPONI / SIMPONI ARIA ® U.S. 1,051 954 959 10.2 (0.5 ) International 1,033 879 786 17.5 11.8 Worldwide 2,084 1,833 1,745 13.7 5.0 STELARA ® U.S. 3,469 2,767 2,263 25.4 22.3 International 1,687 1,244 969 35.6 28.4 Worldwide 5,156 4,011 3,232 28.5 24.1 TREMFAYA ® U.S. 453 62 — * * International 91 1 — * * Worldwide 544 63 — * * OTHER IMMUNOLOGY U.S. — — — — — International 10 22 25 (54.5 ) (12.0 ) Worldwide 10 22 25 (54.5 ) (12.0 ) Infectious Diseases U.S. 1,378 1,358 1,461 1.5 (7.0 ) International 1,926 1,796 1,747 7.2 2.8 Worldwide 3,304 3,154 3,208 4.8 (1.7 ) EDURANT ® / rilpivirine U.S. 58 58 52 0.0 11.5 International 758 656 521 15.5 25.9 Worldwide 816 714 573 14.3 24.6 PREZISTA ® / PREZCOBIX ® / REZOLSTA ® / SYMTUZA ® U.S. 1,169 1,109 1,143 5.4 (3.0 ) International 786 712 708 10.4 0.6 Worldwide 1,955 1,821 1,851 7.4 (1.6 ) OTHER INFECTIOUS DISEASES U.S. 151 191 266 (20.9 ) (28.2 ) International 382 428 518 (10.7 ) (17.4 ) Worldwide 533 619 784 (13.9 ) (21.0 ) Neuroscience U.S. 2,574 2,630 2,628 (2.1 ) 0.1 International 3,503 3,356 3,457 4.4 (2.9 ) Worldwide 6,077 5,986 6,085 1.5 (1.6 ) CONCERTA ® / Methylphenidate U.S. 229 384 468 (40.4 ) (17.9 ) International 434 407 395 6.6 3.0 Worldwide 663 791 863 (16.2 ) (8.3 ) INVEGA SUSTENNA ® / XEPLION ® / INVEGA TRINZA ® / TREVICTA ® U.S. 1,791 1,590 1,343 12.6 18.4 International 1,137 979 871 16.1 12.4 Worldwide 2,928 2,569 2,214 14.0 16.0 RISPERDAL CONSTA ® U.S. 315 360 381 (12.5 ) (5.5 ) International 422 445 512 (5.2 ) (13.1 ) Worldwide 737 805 893 (8.4 ) (9.9 ) OTHER NEUROSCIENCE U.S. 239 296 436 (19.3 ) (32.1 ) International 1,510 1,525 1,679 (1.0 ) (9.2 ) Worldwide 1,749 1,821 2,115 (4.0 ) (13.9 ) Oncology U.S. 4,331 3,098 2,335 39.8 32.7 International 5,513 4,160 3,472 32.5 19.8 Worldwide 9,844 7,258 5,807 35.6 25.0 DARZALEX ® U.S. 1,203 884 471 36.1 87.7 International 822 358 101 * * Worldwide 2,025 1,242 572 63.0 * IMBRUVICA ® U.S. 1,129 841 613 34.2 37.2 International 1,486 1,052 638 41.3 64.9 Worldwide 2,615 1,893 1,251 38.1 51.3 VELCADE ® U.S. — — — — — International 1,116 1,114 1,224 0.2 (9.0 ) Worldwide 1,116 1,114 1,224 0.2 (9.0 ) ZYTIGA ® / abiraterone acetate U.S. 1,771 1,228 1,089 44.2 12.8 International 1,727 1,277 1,171 35.2 9.1 Worldwide 3,498 2,505 2,260 39.6 10.8 OTHER ONCOLOGY U.S. 228 145 162 57.2 (10.5 ) International 362 359 338 0.8 6.2 Worldwide 590 504 500 17.1 0.8 Pulmonary Hypertension U.S. 1,651 773 — * * International 922 554 — 66.4 * Worldwide 2,573 1,327 — 93.9 * OPSUMIT ® U.S. 700 320 — * * International 515 253 — * * Worldwide 1,215 573 — * * TRACLEER ® U.S. 268 161 — 66.5 * International 278 242 — 14.9 * Worldwide 546 403 — 35.5 * UPTRAVI ® U.S. 598 238 — * * International 65 25 — * * Worldwide 663 263 — * * OTHER U.S. 85 54 — 57.4 * International 64 34 — 88.2 * Worldwide 149 88 — 69.3 * Cardiovascular / Metabolism / Other U.S. 4,279 4,744 4,855 (9.8 ) (2.3 ) International 1,537 1,543 1,541 (0.4 ) 0.1 Worldwide 5,816 6,287 6,396 (7.5 ) (1.7 ) XARELTO ® U.S. 2,477 2,500 2,288 (0.9 ) 9.3 International — — — — — Worldwide 2,477 2,500 2,288 (0.9 ) 9.3 INVOKANA ® / INVOKAMET ® U.S. 711 944 1,273 (24.7 ) (25.8 ) International 170 167 134 1.8 24.6 Worldwide 881 1,111 1,407 (20.7 ) (21.0 ) PROCRIT ® / EPREX ® U.S. 674 675 767 (0.1 ) (12.0 ) International 314 297 338 5.7 (12.1 ) Worldwide 988 972 1,105 1.6 (12.0 ) OTHER U.S. 417 625 527 (33.3 ) 18.6 International 1,053 1,079 1,069 (2.4 ) 0.9 Worldwide 1,470 1,704 1,596 (13.7 ) 6.8 TOTAL PHARMACEUTICAL U.S. 23,286 21,474 20,125 8.4 6.7 International 17,448 14,782 13,339 18.0 10.8 Worldwide 40,734 36,256 33,464 12.4 8.3 MEDICAL DEVICES Diabetes Care U.S. 371 612 739 (39.4 ) (17.2 ) International 638 1,003 1,050 (36.4 ) (4.5 ) Worldwide 1,009 1,615 1,789 (37.5 ) (9.7 ) Diagnostics U.S. — — — — — International — 1 66 * * Worldwide — 1 66 * * Interventional Solutions U.S. 1,283 1,148 1,031 11.8 11.3 International 1,363 1,148 1,024 18.7 12.1 Worldwide 2,646 2,296 2,055 15.2 11.7 Orthopaedics U.S. 5,281 5,404 5,438 (2.3 ) (0.6 ) International 3,604 3,654 3,690 (1.4 ) (1.0 ) Worldwide 8,885 9,058 9,128 (1.9 ) (0.8 ) HIPS U.S. 841 827 798 1.7 3.6 International 577 567 563 1.8 0.7 Worldwide 1,418 1,394 1,361 1.7 2.4 KNEES U.S. 911 948 943 (3.9 ) 0.5 International 591 575 581 2.8 (1.0 ) Worldwide 1,502 1,523 1,524 (1.4 ) (0.1 ) TRAUMA U.S. 1,599 1,576 1,545 1.5 2.0 International 1,100 1,040 1,024 5.8 1.6 Worldwide 2,699 2,616 2,569 3.2 1.8 SPINE & OTHER U.S. 1,930 2,053 2,152 (6.0 ) (4.6 ) International 1,336 1,472 1,522 (9.2 ) (3.3 ) Worldwide 3,266 3,525 3,674 (7.3 ) (4.1 ) Surgery U.S. 4,125 4,085 4,026 1.0 1.5 International 5,776 5,474 5,270 5.5 3.9 Worldwide 9,901 9,559 9,296 3.6 2.8 ADVANCED U.S. 1,657 1,620 1,524 2.3 6.3 International 2,345 2,136 1,993 9.8 7.2 Worldwide 4,002 3,756 3,517 6.5 6.8 GENERAL U.S. 1,751 1,728 1,669 1.3 3.5 International 2,806 2,735 2,693 2.6 1.6 Worldwide 4,557 4,463 4,362 2.1 2.3 SPECIALTY U.S. 717 737 833 (2.7 ) (11.5 ) International 625 603 584 3.6 3.3 Worldwide 1,342 1,340 1,417 0.1 (5.4 ) Vision U.S. 1,777 1,575 1,032 12.8 52.6 International 2,776 2,488 1,753 11.6 41.9 Worldwide 4,553 4,063 2,785 12.1 45.9 CONTACT LENSES / OTHER U.S. 1,237 1,122 1,032 10.2 8.7 International 2,065 1,914 1,753 7.9 9.2 Worldwide 3,302 3,036 2,785 8.8 9.0 SURGICAL U.S. 540 453 — 19.2 * International 711 574 — 23.9 * Worldwide 1,251 1,027 — 21.8 * TOTAL MEDICAL DEVICES U.S. 12,837 12,824 12,266 0.1 4.5 International 14,157 13,768 12,853 2.8 7.1 Worldwide 26,994 26,592 25,119 1.5 5.9 WORLDWIDE U.S. 41,884 39,863 37,811 5.1 5.4 International 39,697 36,587 34,079 8.5 7.4 Worldwide $ 81,581 76,450 71,890 6.7 % 6.3 *Percentage greater than 100% or not meaningful Income Before Tax Identifiable Assets (Dollars in Millions) 2018 (3) 2017 (4) 2016 (5) 2018 2017 Consumer $ 2,320 2,524 2,441 $ 25,877 25,030 Pharmaceutical 12,568 11,083 12,827 56,636 59,450 Medical Devices 4,397 5,392 5,578 46,254 45,413 Total 19,285 18,999 20,846 128,767 129,893 Less: Expense not allocated to segments (1) 1,286 1,326 1,043 General corporate (2) 24,187 27,410 Worldwide total $ 17,999 17,673 19,803 $ 152,954 157,303 Additions to Property, Plant & Equipment Depreciation and Amortization (Dollars in Millions) 2018 2017 2016 2018 2017 2016 Consumer $ 438 485 486 $ 688 674 608 Pharmaceutical 1,012 936 927 3,802 2,416 886 Medical Devices 1,843 1,566 1,472 2,103 2,216 1,928 Segments total 3,293 2,987 2,885 6,593 5,306 3,422 General corporate 377 292 341 336 336 332 Worldwide total $ 3,670 3,279 3,226 $ 6,929 5,642 3,754 Sales to Customers Long-Lived Assets (6) (Dollars in Millions) 2018 2017 2016 2018 2017 United States $ 41,884 39,863 37,811 $ 37,117 38,556 Europe 18,753 17,126 15,770 51,433 56,677 Western Hemisphere excluding U.S. 6,113 6,041 5,734 2,752 2,990 Asia-Pacific, Africa 14,831 13,420 12,575 2,733 2,773 Segments total 81,581 76,450 71,890 94,035 100,996 General corporate 1,064 1,143 Other non long-lived assets 57,855 55,164 Worldwide total $ 81,581 76,450 71,890 $ 152,954 157,303 ­ See Note 1 for a description of the segments in which the Company operates. Export sales are not significant. In 2018, the Company had three wholesalers distributing products for all three segments that represented approximately 14.0% , 11.0% and 11.0% of the total consolidated revenues. In 2017, the Company had two wholesalers distributing products for all three segments that represented approximately 14.0% and 10.0% of the total consolidated revenues. In 2016, the Company had two wholesalers distributing products for all three segments that represented approximately 13.5% and 10.7% of the total consolidated revenues. (1) Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. (2) General corporate includes cash, cash equivalents and marketable securities. (3) The Consumer segment includes a gain of $0.3 billion from the divestiture of NIZORAL ® and litigation expense of $0.3 billion . The Pharmaceutical segment includes an in-process research and development charge of $1.1 billion related to the Alios and XO1 assets and the corresponding XO1 contingent liability reversal of $0.2 billion , Actelion acquisition related costs of $0.2 billion , unrealized loss on securities of $0.2 billion and a gain of $0.2 billion from the divestiture of certain non-strategic Pharmaceutical products. The Medical Devices segment includes net litigation expense of $1.7 billion , a restructuring related charge of $0.6 billion , AMO acquisition related costs of $0.1 billion and a gain of $0.5 billion from the divestiture of the LifeScan business in the fiscal fourth quarter. (4) The Pharmaceutical segment includes $0.8 billion for Actelion acquisition related costs, an in-process research and development expense of $0.4 billion and litigation expense of $0.1 billion . The Medical Devices segment includes litigation expense of $1.1 billion , a restructuring related charge of $0.8 billion , an asset impairment of $0.2 billion primarily related to the insulin pump business and $0.1 billion for AMO acquisition related costs. The Medical Devices segment includes a gain of $0.7 billion from the divestiture of Codman Neurosurgery. The Consumer segment includes a gain of $0.5 billion from the divestiture of COMPEED ® . (5) Includes net litigation expense of $0.8 billion and a restructuring related charge of $0.7 billion in the Medical Devices segment. The Pharmaceutical segment includes a positive adjustment of $0.5 billion to previous reserve estimates and gains from the divestitures of the controlled substance raw material and active pharmaceutical ingredient (API) business and certain anesthetic products in Europe. (6) Long-lived assets include property, plant and equipment, net for 2018 , and 2017 of $17,035 and $17,005 , respectively, and intangible assets and goodwill, net for 2018 and 2017 of $78,064 and $85,134 , respectively.

Selected Quarterly Financial Da

Selected Quarterly Financial Data (unaudited)	12 Months Ended
	Dec. 30, 2018
Selected Quarterly Financial Information [Abstract]
Selected Quarterly Financial Data (unaudited)	Selected Quarterly Financial Data (unaudited) Selected unaudited quarterly financial data for the years 2018 and 2017 are summarized below: 2018 2017 (Dollars in Millions Except Per Share Data) First Quarter (1) Second Quarter (2) Third Quarter (3) Fourth Quarter (4) First Quarter (5) Second Quarter (6) Third Quarter (7) Fourth Quarter (8) Segment sales to customers Consumer $ 3,398 3,504 3,415 3,536 3,228 3,478 3,356 3,540 Pharmaceutical 9,844 10,354 10,346 10,190 8,245 8,635 9,695 9,681 Medical Devices 6,767 6,972 6,587 6,668 6,293 6,726 6,599 6,974 Total sales 20,009 20,830 20,348 20,394 17,766 18,839 19,650 20,195 Gross profit 13,395 13,903 13,759 13,433 12,357 12,993 12,725 12,936 Earnings before provision for taxes on income 5,481 4,973 4,423 3,122 5,575 4,748 4,790 2,560 Net earnings (loss) 4,367 3,954 3,934 3,042 4,422 3,827 3,764 (10,713 ) Basic net earnings (loss) per share $ 1.63 1.47 1.47 1.14 1.63 1.42 1.40 (3.99 ) Diluted net earnings (loss) per share $ 1.60 1.45 1.44 1.12 1.61 1.40 1.37 (3.99 ) (1) The first quarter of 2018 includes an Actelion acquisition related cost of $92 million after-tax ( $96 million before-tax) and a restructuring related charge of $81 million after-tax ( $107 million before-tax). (2) The second quarter of 2018 includes a litigation expense of $609 million after-tax ( $703 million before-tax) and a restructuring related charge of $152 million after-tax ( $176 million before-tax). (3) The third quarter of 2018 includes an in-process research and development expense of $859 million after-tax ( $1,126 million before-tax) related to the Alios and XO1 assets and the corresponding XO1 contingent liability reversal of $184 million after and before tax, a restructuring related charge of $162 million after-tax ( $190 million before-tax) and a $265 million benefit after-tax from the impact of tax legislation. (4) The fourth quarter of 2018 includes a litigation expense of $1,113 million after-tax ( $1,288 million before-tax), a restructuring related charge of $190 million after-tax ( $227 million before-tax) and a $137 million benefit after-tax from the impact of tax legislation. (5) The first quarter of 2017 includes a restructuring charge of $121 million after-tax ( $161 million before-tax) and an AMO acquisition related cost of $251 million after-tax ( $38 million before-tax). (6) The second quarter of 2017 includes a litigation expense of $352 million after-tax ( $493 million before-tax), Actelion acquisition related costs of $199 million after-tax ( $213 million before-tax) a restructuring charge of $101 million after-tax ( $128 million before-tax) and an asset impairment charge of $125 million after-tax ( $182 million before-tax). (7) The third quarter of 2017 includes a litigation expense of $97 million after-tax ( $118 million before-tax), Actelion acquisition related costs of $255 million after-tax ( $367 million before-tax) and a restructuring charge of $136 million after-tax ( $187 million before-tax). (8) The fourth quarter of 2017 includes a litigation expense of $506 million after-tax ( $645 million before-tax), Actelion acquisition related costs of $313 million after-tax ( $217 million before-tax), a restructuring charge of $237 million after-tax ( $284 million before-tax), an in-process research and development expense of $266 million after-tax ( $408 million before-tax) and an after-tax benefit of $116 million related to the insulin pump business. Additionally, the fourth quarter of 2017 includes a provisional charge of $13.6 billion for recently enacted tax legislation.

Business Combinations and Dives

Business Combinations and Divestitures	12 Months Ended
	Dec. 30, 2018
Business Combinations [Abstract]
Business Combinations and Divestitures	Business Combinations and Divestitures Certain businesses were acquired for $0.9 billion in cash and $0.1 billion of liabilities assumed during 2018. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. The 2018 acquisitions primarily included: Zarbee’s, Inc., a privately held company that is a leader in naturally-based consumer healthcare products; Medical Enterprises Distribution LLC, a privately held healthcare technology firm focused on surgical procedure innovation; BeneVir Biopharm, Inc. (BeneVir), a privately-held, biopharmaceutical company specializing in the development of oncolytic immunotherapies and Orthotaxy, a privately-held developer of software-enabled surgery technologies, including a differentiated robotic-assisted surgery solution. The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $1.0 billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. On October 23, 2018, the Company entered into an agreement to acquire Ci:z Holdings Co., Ltd., a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products for a total purchase price of approximately ¥230 billion , which equates to approximately $2.1 billion , using the exchange rate of 109.06 Japanese Yen to each U.S. Dollar on January 16, 2019. The acquisition was completed on January 17, 2019, through a series of transactions that included an all-cash tender offer to acquire the publicly held shares not already held by the Company for ¥5,900 per share. Upon completion of the tender offer and the related transactions, the Company acquired 89% of the outstanding shares. The Company plans to acquire the remaining shares that were not tendered in the tender offer through a share consolidation under Japanese law during the first half of 2019 and take appropriate actions to delist from the Tokyo Stock Exchange. The acquisition will include the range of brands comprising DR.CI:LABO, LABO LABO and GENOMER line of skincare products. The Company expects to treat this transaction as a business combination and will include it in the Consumer segment. On February 13, 2019, the Company entered into a definitive agreement to acquire Auris Health, Inc. for approximately $3.4 billion in cash. Additional contingent payments of up to $2.35 billion , in the aggregate, may be payable upon reaching certain predetermined milestones. Auris Health is a privately held developer of robotic technologies, initially focused in lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. The closing is subject to antitrust clearance and other customary closing conditions. The transaction is expected to close by the end of the second quarter of 2019. The Company expects to treat this transaction as a business combination and will include it in the Medical Devices segment. During 2017 certain businesses were acquired for $35.2 billion in cash and $1.8 billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. The 2017 acquisitions primarily included: Actelion Ltd, an established leading franchise of differentiated, innovative products for pulmonary arterial hypertension (PAH); Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott Laboratories, which included ophthalmic products related to: cataract surgery, laser refractive surgery and consumer eye health; Neuravi Limited, a privately-held medical device company that develops and markets medical devices for neurointerventional therapy; TearScience Inc., a manufacturer of products dedicated to treating meibomian gland dysfunction; Sightbox, Inc., a privately-held company that developed a subscription vision care service that connects consumers with eye care professionals and a supply of contact lenses; Torax Medical, Inc., a privately-held medical device company that manufactures and markets the LINX™ Reflux Management System for the surgical treatment of gastroesophageal reflux disease and Megadyne Medical Products, Inc., a privately-held medical device company that develops, manufactures and markets electrosurgical tools. The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $34.4 billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. Of this amount, approximately $1.1 billion has been identified as the value of IPR&D, primarily associated with the acquisition of Actelion Ltd. The value of the IPR&D was calculated using cash flow projections discounted for the inherent risk in the projects. During 2017, the Company completed the acquisition of Actelion Ltd through an all cash tender offer in Switzerland for $280 per share, amounting to $29.6 billion , net of cash acquired. As part of the transaction, immediately prior to the completion of the acquisition, Actelion spun out its drug discovery operations and early-stage clinical development assets into a newly created Swiss biopharmaceutical company, Idorsia Ltd. The shares of Idorsia are listed on the SIX Swiss Exchange (SIX). In 2017 the Company held 9.9% of the shares of Idorsia and had rights to an additional 22.1% of Idorsia equity through a convertible loan with a principal amount of approximately $0.5 billion . As a result of Idorsia raising additional capital in July 2018, the Company currently holds 9.0% of the shares of Idorsia and has rights to an additional 20.8% of Idorsia equity through a convertible loan with a principal amount of approximately $0.5 billion . The convertible loan may be converted into Idorsia shares as follows: (i) up to an aggregate shareholding of 16% of Idorsia shares as a result of certain shareholders holding more than 20% of the issued Idorsia shares, and (ii) up to the balance of the remaining amount within 20 business days of the maturity date of the convertible loan, which has a 10 year term, or if Idorsia undergoes a change of control transaction. The investment in Idorsia was recorded as a cost method investment in Other assets in the Company's consolidated Balance Sheet. The Company also exercised the option acquired on ACT-132577, a product within Idorsia being developed for resistant hypertension currently in phase 2 of clinical development. The Company has also entered into an agreement to provide Idorsia with a Swiss franc denominated credit facility of approximately $250 million . As of December 30, 2018, Idorsia has not made any draw-downs under the credit facility. Actelion has entered into a transitional services agreement with Idorsia. Actelion has established a leading franchise of differentiated, innovative products for pulmonary arterial hypertension (PAH) that are highly complementary to the existing portfolio of the Company. The addition of Actelion’s specialty in-market medicines and late-stage products is consistent with the Company's efforts to grow in attractive and complementary therapeutic areas and serve patients with serious illnesses and significant unmet medical need. During the fiscal second quarter of 2018, the Company finalized the purchase price allocation to the individual assets acquired and liabilities assumed using the acquisition method. The following table presents the amounts recognized for assets acquired and liabilities assumed as of the acquisition date with adjustments made through the second quarter of 2018: (Dollars in Millions) Cash & Cash equivalents 469 Inventory (1) 759 Accounts Receivable 485 Other current assets 93 Property, plant and equipment 104 Goodwill 6,161 Intangible assets 25,010 Deferred Taxes 99 Other non-current assets 19 Total Assets Acquired 33,199 Current liabilities 956 Deferred Taxes 1,776 Other non-current liabilities 413 Total Liabilities Assumed 3,145 Net Assets Acquired 30,054 (1) Includes adjustment of $642 million to write-up the acquired inventory to its estimated fair value. The adjustments made since the date of acquisition were $0.2 billion to the deferred taxes and $0.4 billion to the current liabilities with the offset to goodwill. The assets acquired are recorded in the Pharmaceutical segment. The acquisition of Actelion resulted in approximately $6.2 billion of goodwill. The goodwill is primarily attributable to synergies expected to arise from the acquisition. The goodwill is not expected to be deductible for tax purposes. The purchase price allocation to the identifiable intangible assets is as follows: (Dollars in Millions) Intangible assets with definite lives: Patents and trademarks* $ 24,230 Total amortizable intangibles 24,230 In-process research and development 780 Total intangible assets $ 25,010 *Includes $0.4 billion related to VALCHLOR ® , one of the acquired products, which was divested in the fiscal second quarter of 2018. The patents and trademarks acquired are comprised of developed technology with a weighted average life of 9 years and was primarily based on the patent life of the marketed products. The intangible assets with definite lives were assigned asset lives ranging from 4 to 10 years . The in-process research and development intangible assets were valued for technology programs for unapproved products. The value of the IPR&D was calculated using probability adjusted cash flow projections discounted for the risk inherent in such projects. The discount rate applied was 9% . The acquisition was accounted for using the acquisition method and, accordingly, the results of operations of Actelion were reported in the Company's financial statements beginning on June 16, 2017, the date of acquisition. For the year ended December 31, 2017, total sales and a net loss for Actelion from the date of acquisition were $1.4 billion and $1.4 billion , respectively. The following table provides pro forma results of operations for the fiscal year ended December 31, 2017 and January 1, 2017, as if Actelion had been acquired as of January 4, 2016. The pro forma results include the effect of certain purchase accounting adjustments such as the estimated changes in depreciation and amortization expense on the acquired tangible and intangible assets. However, pro forma results do not include any anticipated cost savings or other effects of the planned integration of Actelion. Accordingly, such amounts are not necessarily indicative of the results if the acquisition had occurred on the dates indicated or which may occur in the future. Unaudited Pro forma Consolidated Results (Dollars in Millions Except Per Share Data) 2017 2016 Net Sales 77,681 74,339 Net Earnings 1,509 13,916 Diluted Net Earnings per Common Share 0.55 4.99 The Company recorded Actelion acquisition related costs before tax of approximately $0.2 billion and $0.8 billion in 2018 and 2017, respectively, which was recorded in Other (income)/expense and Cost of products sold. During 2017, the Company acquired Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott Laboratories, for $4.3 billion , net of cash acquired. The acquisition included ophthalmic products related to: cataract surgery, laser refractive surgery and consumer eye health. The net purchase price was primarily recorded as amortizable intangible assets for $2.3 billion and goodwill for $1.7 billion . The weighted average life of total amortizable intangibles, the majority being customer relationships, is approximately 14.4 years . The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not deductible for tax purposes. The intangible assets and goodwill amounts are based on the final purchase price allocation. The assets acquired were recorded in the Medical Devices segment. Certain businesses were acquired for $4.5 billion in cash and $0.1 billion of liabilities assumed during 2016. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. The 2016 acquisitions primarily included: Vogue International LLC, a privately-held company focused on the marketing, development and distribution of salon-influenced and nature inspired hair care and other personal products; NeuWave Medical, Inc., a privately-held medical device company that manufactures and markets minimally invasive soft tissue microwave ablation systems; NeoStrata Company, Inc., a global leader in dermocosmetics; and the global rights for the commercialization of RHINOCORT ® allergy spray outside the United States. The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $4.1 billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. The net purchase price for Vogue International LLC of $3.3 billion was primarily recorded as amortizable intangible assets for $2.3 billion and goodwill for $1.1 billion . The weighted average life for the $2.3 billion of total amortizable intangibles is approximately 22 years . The trademark asset values were determined to have definite lives ranging from 10 to 22 years, with the majority being 22 years. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is expected to be deductible for tax purposes. The assets acquired were recorded in the Consumer segment. In 2012, the Company completed the acquisition of Synthes, Inc. for a purchase price of $20.2 billion in cash and stock. In connection with the acquisition of Synthes, Inc. the Company entered into two accelerated share repurchase (ASR) agreements. In 2013, the Company settled the remaining liabilities under the ASR agreements. While the Company believes that the transactions under each ASR agreement and a series of related internal transactions were consummated in a tax efficient manner in accordance with applicable law, it is possible that the Internal Revenue Service could assert one or more contrary positions to challenge the transactions from a tax perspective. If challenged, an amount up to the total purchase price for the Synthes shares could be treated as subject to applicable U.S. tax at approximately the statutory rate to the Company, plus interest. With the exception of the Actelion Ltd acquisition, supplemental pro forma information for 2018, 2017 and 2016 in accordance with U.S. GAAP standards related to business combinations, and goodwill and other intangible assets, is not provided, as the impact of the aforementioned acquisitions did not have a material effect on the Company’s results of operations, cash flows or financial position. During 2018, the Company divested the LifeScan Inc business for approximately $2.1 billion and retained certain net liabilities. Other divestitures in 2018 included: NIZORAL ® , RoC ® and certain non-strategic Pharmaceutical products. In 2018, the pre-tax gains on the divestitures were approximately $1.2 billion . Additionally, in 2018, the Company accepted the binding offer from Fortive Corporation to acquire its Advanced Sterilization Products (ASP) business for approximately $2.7 billion , subject to customary adjustments. The transaction is expected to close in 2019. As of December 30, 2018, the assets held for sale on the Consolidated Balance Sheet were $0.2 billion of inventory, $0.1 billion of property, plant and equipment and $0.3 billion of goodwill. The Company will retain certain net receivables of approximately $0.1 billion associated with the ASP business. In 2018, the Company accepted a binding offer to form a strategic collaboration with Jabil Inc., one of the world’s leading manufacturing services providers for health care products and technology products. The Company is expanding a 12-year relationship with Jabil to produce a range of products within the Ethicon Endo-Surgery and DePuy Synthes businesses. This transaction includes the transfer of employees and manufacturing sites. As of December 30, 2018, the assets held for sale on the Consolidated Balance Sheet were $0.3 billion of inventory and $0.1 billion of property, plant and equipment, net. For additional details on the global supply chain restructuring see Note 22 to the Consolidated Financial Statements. During 2017, the Company divestitures primarily included: the Codman Neurosurgery business, to Integra LifeSciences Holdings Corporation and the divestiture of COMPEED ® to HRA Pharma. In 2017, the pre-tax gains on the divestitures were approximately $1.3 billion . During 2016, the Company divestitures included: the controlled substance raw material and active pharmaceutical ingredient (API) business; certain anesthetic products in Europe; and certain non-strategic Consumer brands. In 2016, the pre-tax gains on the divestitures were approximately $0.6 billion .

Legal Proceedings

Legal Proceedings	12 Months Ended
	Dec. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	Legal Proceedings Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability, intellectual property, commercial, supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. As of December 30, 2018 , the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts already accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions. The ability to make such estimates and judgments can be affected by various factors, including whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; or there are numerous parties involved. In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period. PRODUCT LIABILITY Johnson & Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available. The most significant of these cases include: the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System; the PINNACLE ® Acetabular Cup System; pelvic meshes; RISPERDAL ® ; XARELTO ® ; body powders containing talc, primarily JOHNSONS ® Baby Powder; INVOKANA ® ; and ETHICON PHYSIOMESH ® Flexible Composite Mesh. As of December 30, 2018 , in the United States there were approximately 1,800 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System; 10,500 with respect to the PINNACLE ® Acetabular Cup System; 34,800 with respect to pelvic meshes; 13,400 with respect to RISPERDAL ® ; 25,600 with respect to XARELTO ® ; 13,000 with respect to body powders containing talc; 1,050 with respect to INVOKANA ® ; and 2,100 with respect to ETHICON PHYSIOMESH ® Flexible Composite Mesh. In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR ™ XL Acetabular System and DePuy ASR ™ Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson & Johnson. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip System plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 31, 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 31, 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, therefore bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle two pending class actions which have been approved by the Québec Superior Court and the Supreme Court of British Columbia. The British Columbia order is currently the subject of an appeal. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and DePuy ASR ™ Hip-related product liability litigation. Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson & Johnson (collectively, DePuy) relating to the PINNACLE ® Acetabular Cup System used in hip replacement surgery. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation has also been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial, the second remains under appeal and the third is pending decision on post-trial motions in the district court. The Company has established an accrual for product liability litigation associated with the PINNACLE ® Acetabular Cup System. The Company is negotiating settlements of these cases and the related costs are reflected in the Company’s accruals. Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson & Johnson arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Southern District of West Virginia. The Company has settled or otherwise resolved a majority of the United States cases and the costs associated with these settlements are reflected in the Company's accruals. In addition, class actions and individual personal injury cases or claims have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands and Belgium, and class actions in Israel, Australia and Canada, seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices. In Australia, a trial of class action issues has been completed and the parties are awaiting a decision. The Company has established accruals with respect to product liability litigation associated with Ethicon's pelvic mesh products. Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH ® Flexible Composite Mesh, claims for personal injury have been made against Ethicon, Inc. and Johnson & Johnson alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi county litigation (MCL) has also been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH ® Flexible Composite Mesh. Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson & Johnson arising out of the use of RISPERDAL ® , indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism, and related compounds. Lawsuits have been primarily filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the United States cases and the costs associated with these settlements are reflected in the Company's accruals. Claims for personal injury arising out of the use of XARELTO ® , an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson & Johnson; and JPI's collaboration partner for XARELTO ® Bayer AG and certain of its affiliates. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases have been consolidated into a state mass tort litigation in Philadelphia, Pennsylvania; and there are coordinated proceedings in Delaware, California and Missouri. Class action lawsuits also have been filed in Canada. The Company has established an accrual for defense costs only in connection with product liability litigation associated with XARELTO ® . Personal injury claims alleging that talc causes cancer have been made against Johnson & Johnson Consumer Inc. and Johnson & Johnson arising out of the use of body powders containing talc, primarily JOHNSONS ® Baby Powder. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Lawsuits have been primarily filed in state courts in Missouri, New Jersey and California. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the District of New Jersey. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in July 2018 of $4.7 billion . The Company believes that it has strong grounds on appeal to overturn these verdicts. The Company has established an accrual for defense costs only in connection with product liability litigation associated with body powders containing talc. In February 2018, a securities class action lawsuit was filed against Johnson & Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson & Johnson violated the federal securities laws by failing to adequately disclose the alleged asbestos contamination in body powders containing talc, primarily JOHNSON'S ® Baby Powder, and that purchasers of Johnson & Johnson’s shares suffered losses as a result. Plaintiffs are seeking damages. In October 2018, a shareholder derivative lawsuit was filed against Johnson & Johnson as the nominal defendant and its current directors as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S ® Baby Powder, and that Johnson & Johnson has suffered damages as a result of those alleged breaches. Plaintiff is seeking damages and an order for the Company to reform its internal policies and procedures. In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson & Johnson Savings Plan against Johnson & Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson & Johnson stock as a Johnson & Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S ® Baby Powder. Plaintiffs are seeking damages and injunctive relief. Each of these matters will be adjudicated in conjunction with the multi-district litigation referenced in the prior paragraph. In addition, the Company has received preliminary inquiries and subpoenas to produce documents regarding these matters from Senator Murray, a member of the Senate Committee on Health, Education, Labor and Pensions, the Department of Justice and the Securities and Exchange Commission. The Company is cooperating with these government inquiries and will be producing documents in response. Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson & Johnson, arising out of the use of INVOKANA ® , a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. Lawsuits filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts in Pennsylvania, California and New Jersey. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company's accruals. INTELLECTUAL PROPERTY Certain subsidiaries of Johnson & Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company’s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. The most significant of these matters are described below. Medical Devices In June 2009, Rembrandt Vision Technologies, L.P. (Rembrandt) filed a patent infringement lawsuit against Johnson & Johnson Vision Care, Inc. (JJVCI) in the United States District Court for the Eastern District of Texas alleging that JJVCI's manufacture and sale of its ACUVUE ® ADVANCE and ACUVUE OASYS ® Hydrogel Contact Lenses infringed Rembrandt’s United States Patent No. 5,712,327 and seeking monetary relief. The case was transferred to the United States District Court for the Middle District of Florida, where a trial in May 2012 resulted in a verdict of non-infringement that was subsequently upheld on appeal. In July 2014, Rembrandt sought a new trial based on alleged new evidence, which the district court denied. In April 2016, the Court of Appeals overturned that ruling and remanded the case to the district court for a new trial. A new trial was held in August 2017, and the jury returned a verdict of non-infringement in favor of JJVCI. Rembrandt has appealed the verdict to the United States Court of Appeals for the Federal Circuit (CAFC). In February 2019, the CAFC affirmed the judgment in favor of JJVCI. In March 2013, Medinol Ltd. (Medinol) filed a patent infringement lawsuit against Cordis Corporation (Cordis) and Johnson & Johnson in the United States District Court for the Southern District of New York alleging that Cordis’s sales of the CYPHER ™ and CYPHER SELECT ™ stents made in the United States since 2005 willfully infringed four of Medinol's patents directed to the geometry of articulated stents. Medinol is seeking damages and attorneys’ fees. Although Johnson & Johnson has since sold Cordis, it has retained liability for this case. After trial in January 2014, the district court dismissed the case, finding Medinol unreasonably delayed bringing its claims (the laches defense). In September 2014, the district court denied a motion by Medinol to vacate the judgment and grant it a new trial. Medinol appealed the decision to the United States Court of Appeals for the Federal Circuit. In March 2017, the United States Supreme Court held that the laches defense is not available in patent cases. In April 2018, the United States Court of Appeals for the Federal Circuit remanded the case back to the district court to reconsider Medinol’s motion for a new trial, and briefing in the district court was completed in June 2018. In November 2016, MedIdea, L.L.C. (MedIdea) filed a patent infringement lawsuit against DePuy Orthopaedics, Inc. in the United States District Court for the Northern District of Illinois alleging infringement by the ATTUNE ® Knee System. In April 2017, MedIdea filed an amended complaint adding DePuy Synthes Products, Inc. and DePuy Synthes Sales, Inc. as named defendants. MedIdea alleges infringement of United States Patent Nos. 6,558,426 (’426); 8,273,132 (’132); 8,721,730 (’730) and 9,492,280 (’280) relating to posterior stabilized knee systems. Specifically, MedIdea alleges that the SOFCAM TM Contact feature of the ATTUNE ® posterior stabilized knee products infringes the patents-in-suit. MedIdea is seeking monetary damages and injunctive relief. In June 2017, the case was transferred to the United States District Court for the District of Massachusetts. A claim construction hearing was held in October 2018, and a claim construction order was issued in November 2018. In December 2018, MedIdea stipulated to non-infringement of the ’132, ’730 and ’280 patents, based on the district court’s claim construction and reserving its right to appeal that construction, leaving only the ’426 patent at issue before the district court. In January 2019, the district court stayed the case pending a decision in the Inter Partes Review proceeding on the ’426 patent (see below). In December 2017, DePuy Synthes Products, Inc. filed a Petition for Inter Partes Review with the United States Patent and Trademark Office (USPTO), seeking to invalidate the two claims of the ’426 patent asserted in the district court litigation, and in June 2018, the USPTO instituted review of those claims. A hearing trial is scheduled for March 2019, and a decision in the proceeding is due by June 2019. In December 2016, Ethicon Endo-Surgery, Inc. and Ethicon Endo-Surgery, LLC (now known as Ethicon LLC) sued Covidien, Inc. in the United States District Court for the District of Massachusetts seeking a declaration that United States Patent Nos. 6,585,735 (the ’735 patent); 7,118,587; 7,473,253; 8,070,748 and 8,241,284 (the ’284 patent), are either invalid or not infringed by Ethicon’s ENSEAL ® X1 Large Jaw Tissue Sealer product. In April 2017, Covidien LP, Covidien Sales LLC, and Covidien AG (collectively, Covidien) answered and counterclaimed, denying the allegations, asserting willful infringement of the ’735 patent, the ’284 patent and United States Patent Nos. 8,323,310 (the ’310 patent); 9,084,608; 9,241,759 (the ’759 patent) and 9,113,882, and seeking damages and an injunction. Covidien filed a motion for preliminary injunction, which was denied in October 2017. The parties have entered joint stipulations such that only the ’735 patent, the ’310 patent and the ’759 patent remain in dispute. Trial is scheduled to begin in September 2019. In November 2017, Board of Regents, The University of Texas System and Tissuegen, Inc. (collectively, UT) filed a lawsuit in the United States District Court for the Western District of Texas against Ethicon, Inc. and Ethicon US, LLC alleging the manufacture and sale of VICRYL ® Plus Antibacterial Sutures, MONOCRYL ® Plus Antibacterial Sutures, PDS ® Plus Antibacterial Sutures, STRATAFIX ® POS ® Antibacterial Sutures and STRATAFIX ® MONOCRYL ® Plus Antibacterial Sutures infringe plaintiffs’ United States Patent Nos. 6,596,296 and 7,033,603 directed to implantable polymer drug releasing biodegradable fibers containing a therapeutic agent. UT is seeking damages and an injunction. In December 2018, Ethicon filed petitions with the USPTO, seeking Inter Partes Review (IPR) of both asserted patents. Those petitions have been stayed by the USPTO pending a decision by the U.S. Court of Appeals for the Federal Circuit in an unrelated case. Pharmaceutical In April 2016, MorphoSys AG, a German biotech company, filed a patent infringement lawsuit against Janssen Biotech, Inc. (JBI), Genmab U.S. Inc. and Genmab A/S (collectively, Genmab) in the United States District Court for the District of Delaware. MorphoSys alleged that JBI’s manufacture and sale of DARZALEX ® (daratumumab) willfully infringed MorphoSys’ United States Patent Nos. 8,263,746, 9,200,061 and 9,785,590. MorphoSys sought money damages. JBI licenses patents and the commercial rights to DARZALEX ® from Genmab. In January 2019, the district court granted summary judgment in JBI and Genmab’s favor, invalidating the asserted claims of the patents-in-suit, and the parties filed a joint stipulation of dismissal of the action. In August 2016, Sandoz Ltd and Hexal AG (collectively, Sandoz) filed a lawsuit in the English High Court against G.D. Searle LLC, a Pfizer company (Searle) and Janssen Sciences Ireland UC (JSI) alleging that Searle’s supplementary protection certificate SPC/GB07/038 (SPC), which is exclusively licensed to JSI, is invalid and should be revoked. Janssen-Cilag Limited sells PREZISTA ® (darunavir) in the United Kingdom pursuant to this license. In October 2016, Searle and JSI counterclaimed against Sandoz for threatened infringement of the SPC based on statements of its plans to launch generic darunavir in the United Kingdom. Sandoz admitted that its generic darunavir product would infringe the SPC if it is found valid. Searle and JSI are seeking an order enjoining Sandoz from marketing its generic darunavir before the expiration of the SPC. Following a trial in April 2017, the court entered a decision holding that the SPC is valid and granting a final injunction. Sandoz has appealed the court’s decision and the injunction is stayed pending the appeal. In January 2018, the court referred the issue on appeal to the Court of Justice for the European Union (CJEU) and stayed the proceedings pending the CJEU’s ruling on the issue. In April 2018, Acerta Pharma B.V., AstraZeneca UK Ltd and AstraZeneca Pharmaceuticals LP filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Pharmacylics LLC and Abbvie Inc. (collectively, Abbvie), alleging that the manufacture and sale of IMBRUVICA ® infringes U.S. Patent No. 7,459,554. Janssen Biotech, Inc., which commercializes IMBRUVICA ® jointly with Abbvie, intervened in the action in November 2018. A trial is scheduled to begin in January 2021. REMICADE ® Related Cases In August 2014, Celltrion Healthcare Co. Ltd. and Celltrion Inc. (collectively, Celltrion) filed an application with the United States Food and Drug Administration (FDA) for approval to make and sell its own infliximab biosimilar. In March 2015, Janssen Biotech, Inc. (JBI) filed a lawsuit in the United States District Court for the District of Massachusetts against Celltrion and Hospira Healthcare Corporation (Hospira), which has exclusive marketing rights for Celltrion’s infliximab biosimilar in the United States, seeking, among other things, a declaratory judgment that their biosimilar product infringes or potentially infringes several JBI patents, including United States Patent No. 6,284,471 relating to REMICADE ® (infliximab) (the ’471 patent) and United States Patent No. 7,598,083 (the ’083 patent) directed to the cell culture media used to make Celltrion’s biosimilar. In August 2016, the district court granted both Celltrion’s and Hospira’s motions for summary judgment of invalidity of the ’471 patent. JBI appealed those decisions to the United States Court of Appeals for the Federal Circuit. In January 2018, the Federal Circuit dismissed the appeal as moot based on its affirmance of a decision by the USPTO’s Patent Trial and Appeal Board affirming invalidity of the ’471 patent. In June 2016, JBI filed two additional patent infringement lawsuits asserting the ’083 patent, one against Celltrion and Hospira in the United States District Court for the District of Massachusetts and the other against HyClone Laboratories, Inc., the manufacturer of the cell culture media that Celltrion uses to make its biosimilar product, in the United States District Court for the District of Utah. On July 30, 2018 the district court granted Celltrion’s motion for summary judgment of non-infringement and entered an order dismissing the ’083 lawsuit against Celltrion and Hospira. JBI appealed to the United States Court of Appeals for the Federal Circuit. The litigation against HyClone in Utah is stayed pending the outcome of the Massachusetts actions. The FDA approved the first infliximab biosimilar for sale in the United States in 2016, and a number of such products have been launched. Litigation Against Filers of Abbreviated New Drug Applications (ANDAs) The following summarizes lawsuits pending against generic companies that have filed Abbreviated New Drug Applications (ANDAs) with the FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson & Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. In the event the subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the third-party companies involved would have the ability, upon approval of the FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. The Inter Partes Review (IPR) process with the United States Patent and Trademark Office (USPTO), created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents. ZYTIGA ® In July 2015, Janssen Biotech, Inc., Janssen Oncology, Inc. and Janssen Research & Development, LLC (collectively, Janssen) and BTG International Ltd. (BTG) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against a number of generic companies (and certain of their affiliates and/or suppliers) who filed ANDAs seeking approval to market a generic version of ZYTIGA ® 250mg before the expiration of United States Patent No. 8,822,438 (the ’438 patent). The generic companies include Amneal Pharmaceuticals, LLC and Amneal Pharmaceuticals of New York, LLC (collectively, Amneal); Apotex Inc. and Apotex Corp. (collectively, Apotex); Citron Pharma LLC (Citron); Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively, Dr. Reddy’s); Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively, Mylan); Par Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. (collectively, Par); Sun Pharmaceutical Industries Ltd. and Sun Pharmaceuticals Industries, Inc. (collectively, Sun); Teva Pharmaceuticals USA, Inc. (Teva); Wockhardt Bio A.G.; Wockhardt USA LLC and Wockhardt Ltd. (collectively, Wockhardt); West-Ward Pharmaceutical Corp. (West-Ward) and Hikma Pharmaceuticals, LLC (Hikma). Janssen and BTG also initiated patent infringement lawsuits in the United States District Court for the District of New Jersey against Amerigen Pharmaceuticals Limited (Amerigen) in May 2016, and Glenmark Pharmaceuticals, Inc. (Glenmark) in June 2016, each of whom filed an ANDA seeking approval to market its generic version of ZYTIGA ® before the expiration of the ’438 patent. These lawsuits have been consolidated with the lawsuit filed in July 2015. In August 2015, Janssen and BTG filed an additional jurisdictional protective lawsuit against the Mylan defendants in the United States District Court for the Northern District of West Virginia, which has been stayed. In August 2017, Janssen and BTG initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva, who filed an ANDA seeking approval to market a generic version of ZYTIGA ® 500mg before the expiration of the ’438 patent. This lawsuit has been consolidated with the lawsuit filed in July 2015. In February 2018, Janssen and BTG filed a patent infringement lawsuit against MSN Pharmaceuticals, Inc. and MSN Laboratories Private Limited (collectively, MSN) in United States District Court for the District of New Jersey based on its ANDA seeking approval for a generic version of ZYTIGA ® prior to the expiration of the ’438 patent. In November 2018, Janssen and BTG initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Qilu Pharmaceutical Co., Ltd. and Qilu Pharma, Inc. (collectively, Qilu), who filed an ANDA seeking approval to market a generic version of ZYTIGA ® before the expiration of the ’438 patent. In December 2017, Janssen and BTG entered into a settlement agreement with Glenmark. In January 2018, Jansse

Restructuring

Restructuring	12 Months Ended
	Dec. 30, 2018
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In the first quarter of 2016, the Company announced restructuring actions in its Medical Devices segment to better serve the needs of patients and customers in today’s evolving healthcare marketplace. The Company has undertaken actions to strengthen its go-to-market model, accelerate the pace of innovation, further prioritize key platforms and geographies, and streamline operations while maintaining high quality standards. In 2018, the Company recorded a pre-tax charge of $462 million , of which $46 million was included in cost of products sold and $227 million was included in other (income) expense. Total project costs of $2.5 billion have been recorded since the restructuring has been announced. This restructuring program was completed in the fiscal fourth quarter of 2018. On April 17, 2018, the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. For additional details on the global supply chain restructuring strategic collaborations see Note 20 to the Consolidated Financial Statements. In 2018, the Company recorded a pre-tax charge of $238 million , of which $59 million was included in cost of products sold and $117 million was included in other (income) expense. See the following table for additional details on the restructuring programs. In total, the Company expects the Global Supply Chain actions to generate approximately $0.6 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by 2022. The Company expects to record pre-tax restructuring charges of approximately $1.9 billion to $2.3 billion , over the 4 to 5 year period of this activity. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization. The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2018: (Dollars in Millions) Severance Asset Write-offs Other** Total Reserve balance, January 3, 2016 $ 484 — 17 501 2016 activity (104 ) — (16 ) (120 ) Reserve balance, January 1, 2017 380 — 1 381 2017 activity (151 ) — 37 (114 ) Reserve balance, December 31, 2017 229 — 38 267 Current year activity: Charges — 132 568 700 Cash payments (35 ) — (558 ) (593 ) Settled non cash — (132 ) — (132 ) Reserve balance, December 30, 2018* $ 194 — 48 242 *Cash outlays for severance are expected to be substantially paid out over the next 2 years in accordance with the Company's plans and local laws. **Other includes project expense such as salaries for employees supporting the initiative and consulting expenses. Although the Medical Devices restructuring program was completed in 2018, the Company expects that severance charges will continue beyond that date. The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments has extended due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable. Approximately 2,375 individuals received separation payments since these restructuring announcements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 30, 2018
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Johnson & Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated.
Description of the Company And Business Segments	Description of the Company and Business Segments The Company has approximately 135,100 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a broad range of products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health and wound care markets. These products are marketed to the general public and sold both to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on six therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use. The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, interventional solutions (cardiovascular and neurovascular), diabetes care (divested in the fiscal fourth quarter of 2018) and vision fields, which are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.
New Accounting Pronouncements	New Accounting Standards Recently Adopted Accounting Standards ASU 2014-09 : Revenue from Contracts with Customers On January 1, 2018, the Company adopted the new accounting standard, ASC 606, Revenue from Contracts with Customers and all the related amendments (new revenue standard) to all contracts using the modified retrospective method. The cumulative effect of initially applying the new revenue standard was recognized as an adjustment to the opening balance of retained earnings. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. The adoption of the new revenue standard has not had a material impact to either reported Sales to customers or Net earnings. Additionally, the Company will continue to recognize revenue from product sales as goods are shipped or delivered to the customer, as control of goods transfers at the same time. In accordance with the new revenue standard requirements, the disclosure of the impact of adoption on the Company's Consolidated Statement of Earnings and Balance Sheet was as follows: Statement of Earnings - For the fiscal year ended December 30, 2018 (Dollars in millions) As Reported Effect of change Balance without adoption of ASC 606 Sales to customers $ 81,581 (35 ) 81,546 Net earnings 15,297 (28 ) 15,269 Balance Sheet - As of December 30, 2018 As Reported Effect of change Balance without adoption of ASC 606 Assets 152,954 23 152,977 Liabilities 93,202 4 93,206 Equity $ 59,752 19 59,771 The Company made a cumulative effect adjustment to the 2018 opening balance of retained earnings upon adoption of ASU 2014-09, which decreased beginning retained earnings by $47 million . As part of the adoption of ASC 606 see Note 18 to the Consolidated Financial Statements for further disaggregation of revenue. ASU 2016-01 : Financial Instruments: Recognition and Measurement of Financial Assets and Financial Liabilities The Company adopted this standard as of the beginning of the fiscal year 2018 on a modified retrospective basis. The amendments in this update supersede the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and require equity securities to be measured at fair value with changes in the fair value recognized through net earnings. The standard amends financial reporting by providing relevant information about an entity’s equity investments and reducing the number of items that are recognized in other comprehensive income. The Company made a cumulative effect adjustment to the opening balance of retained earnings upon adoption of ASU 2016-01 that increased retained earnings by $232 million net of tax and decreased accumulated other comprehensive income for previously unrealized gains from equity investments. For additional details see Note 6 to the Consolidated Financial Statements. ASU 2016-16 : Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory The Company adopted this standard as of the beginning of the fiscal year 2018. This update removes the current exception in U.S. GAAP prohibiting entities from recognizing current and deferred income tax expenses or benefits related to transfer of assets, other than inventory, within the consolidated entity. The current exception to defer the recognition of any tax impact on the transfer of inventory within the consolidated entity until it is sold to a third party remains unaffected. As discussed further in Note 8 to the Consolidated Financial Statements, in the fourth fiscal quarter of 2018 the Company elected an accounting policy to treat the tax on global intangible low-taxed income (GILTI) under the deferred tax accounting model. As a result, the Company is required to record an additional deferred tax liability related to the basis difference of these intra-entity asset transfers. The Company recorded net adjustments including an increase to deferred tax assets of approximately $2.0 billion , an increase to deferred tax liabilities of approximately $1.7 billion , related to the GILTI accounting policy election in the fourth fiscal quarter of 2018, a decrease to Other Assets of approximately $0.7 billion and a decrease to retained earnings of approximately $0.4 billion . The adoption of this standard did not have a material impact on the Company's consolidated financial statements. ASU 2017-01 : Clarifying the Definition of a Business The Company adopted this standard as of the beginning of the fiscal year 2018. This update narrows the definition of a business by providing a screen to determine when an integrated set of assets and activities is not a business. The screen specifies that an integrated set of assets and activities is not a business if substantially all of the fair value of the gross assets acquired or disposed of is concentrated in a single or a group of similar identifiable assets. This update was applied prospectively. The adoption of this standard did not have a material impact on the Company's consolidated financial statements. ASU 2017-07 : Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost The Company adopted this standard as of the beginning of the fiscal year 2018. This update requires that an employer disaggregate the service cost component from the other components of net periodic benefit cost (NPBC). In addition, only the service cost component will be eligible for capitalization. The amendments in this update are required to be applied retrospectively for the presentation of the service cost component and the other components of NPBC in the Consolidated Statement of Earnings and prospectively, on and after the adoption date, for the capitalization of the service cost component of NPBC in assets. As required by the transition provisions of this update, the following table shows the impact of the adoption on the respective line items in the Consolidated Statement of Earnings for 2018 and the reclassifications to the 2017 and 2016 fiscal year Consolidated Statement of Earnings to retroactively apply classification of the service cost component and the other components of NPBC: (Dollars In millions) Increase (Decrease) to Net Expense 2018 2017 2016 Cost of products sold $ 51 85 104 Selling, marketing and administrative expenses 55 100 122 Research and development expense 21 40 48 Other (income) expense, net (127 ) (225 ) (274 ) Earnings before provision for taxes on income $ — — — The following table summarizes the cumulative effect adjustments made to the 2018 opening balance of retained earnings upon adoption of the new accounting standards mentioned above: (Dollars in Millions) Cumulative Effect Adjustment Increase (Decrease) to Retained Earnings ASU 2014-09 - Revenue from Contracts with Customers $ (47 ) ASU 2016-01 - Financial Instruments 232 ASU 2016-16 - Income Taxes: Intra-Entity Transfers (439 ) Total $ (254 ) ASU 2017-12 : Targeted Improvements to Accounting for Hedging Activities The Company elected to early adopt this standard as of the beginning of the fiscal second quarter of 2018. This update makes more financial and nonfinancial hedging strategies eligible for hedge accounting. It also amends the presentation and disclosure requirements and changes how companies assess effectiveness. The adoption of this standard did not have a material impact on the Company's consolidated financial statements. For additional required disclosures see Note 6 to the Consolidated Financial Statements. Recently Issued Accounting Standards Not Adopted as of December 30, 2018 ASU 2018-18 : Collaborative Arrangements This update clarifies the interaction between ASC 808, Collaborative Arrangements and ASC 606, Revenue from Contracts with Customers. The update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue if the counterparty is not a customer for that transaction. This update will be effective for the Company for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. ASU 2018-18 should be applied retrospectively to the date of initial application of ASC 606 and early adoption is permitted. The Company is currently assessing the impact of this update on the Company’s consolidated financial statements and related disclosures. ASU 2018-16: Derivatives and Hedging (Topic ASC 815) This update adds the Overnight Index Swap (OIS) rate based on the Secured Overnight Financing Rate (SOFR) as an eligible benchmark interest rate permitted in the application of hedge accounting. This update will be effective for the Company for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early adoption is permitted if an entity has adopted ASU 2017-12. The Company is currently assessing the impact of this update on the Company’s consolidated financial statements and related disclosures. ASU 2018-02 : Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income This update allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Job Act enacted in December 2017. This update will be effective for the Company for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. The Company does not expect this standard to have a material impact on the Company's consolidated financial statements. ASU 2016-13 : Financial Instruments - Credit Losses This update introduces the current expected credit loss (CECL) model, which will require an entity to measure credit losses for certain financial instruments and financial assets, including trade receivables. Under this update, on initial recognition and at each reporting period, an entity will be required to recognize an allowance that reflects the entity’s current estimate of credit losses expected to be incurred over the life of the financial instrument. This update will be effective for the Company for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. Early adoption is permitted. The Company is currently assessing the impact of this update on the Company’s consolidated financial statements and related disclosures. ASU 2016-02 : Leases This update requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. This update requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under current generally accepted accounting principles. This update will be effective for the Company for all annual periods beginning after December 15, 2018, including interim periods within those fiscal years. The Company will apply the new standard at its adoption date rather than at the earliest comparative period presented in the financial statements. The Company’s operating leases will result in the recognition of additional assets and the corresponding liabilities on its Consolidated Balance Sheets. The adoption of this standard will not have a material impact on the Company's consolidated financial statements.
Cash Equivalents	Cash Equivalents The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating. The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs). RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value. The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.
Investments	Investments Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments in equity securities for impairment and adjusts these investments to fair value through earnings, as required.
Property, Plant and Equipment and Depreciation	Property, Plant and Equipment and Depreciation Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets: Building and building equipment 20 - 30 years Land and leasehold improvements 10 - 20 years Machinery and equipment 2 - 13 years The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8 years. The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.
Revenue Recognition	Revenue Recognition The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales. Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information. Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals. Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company’s accounting policies, the Company generally issues credit to customers for returned goods. The Company’s sales returns reserves are accounted for in accordance with the U.S. GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the Medical Devices segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during the fiscal reporting years 2018, 2017 and 2016. Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. For all years presented, profit-share payments were less than 2.0% of the total revenues and are included in sales to customers.
Shipping and Handling	Shipping and Handling Shipping and handling costs incurred were $1,090 million , $1,042 million and $974 million in 2018 , 2017 and 2016 , respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 0.5% of sales to customers for all periods presented.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.
Intangible Assets and Goodwill	Intangible Assets and Goodwill The authoritative literature on U.S. GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed the annual impairment test for 2018 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions. See Note 5 for further details on Intangible Assets and Goodwill.
Financial Instruments	Financial Instruments As required by U.S. GAAP, all derivative instruments are recorded on the balance sheet at fair value. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level 1 having the highest priority and Level 3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1) minimize foreign currency exposure’s impact on the Company’s financial performance; (2) protect the Company’s cash flow from adverse movements in foreign exchange rates; (3) ensure the appropriateness of financial instruments; and (4) manage the enterprise risk associated with financial institutions. See Note 6 for additional information on Financial Instruments.
Product Liability	Product Liability Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. As a result of cost and availability factors, effective November 1, 2005, the Company ceased purchasing third-party product liability insurance. The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated.
Research and Development	Research and Development Research and development expenses are expensed as incurred in accordance with ASC 730, Research and Development. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization. The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company’s operations. In general, the income statement presentation for these collaborations is as follows: Nature/Type of Collaboration Statement of Earnings Presentation Third-party sale of product & profit share payments received Sales to customers Royalties/milestones paid to collaborative partner (post-regulatory approval)* Cost of products sold Royalties received from collaborative partner Other income (expense), net Upfront payments & milestones paid to collaborative partner (pre-regulatory approval) Research and development expense Research and development payments to collaborative partner Research and development expense Research and development payments received from collaborative partner Reduction of Research and development expense * Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life. For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense. The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO ® , co-developed with Bayer HealthCare AG and IMBRUVICA ® , developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company. The Company has a number of licensing arrangements for products and compounds including DARZALEX ® , licensed from Genmab A/S.
Advertising	Advertising Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses.
Income Taxes	Income Taxes Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position. In the fourth fiscal quarter of 2018, the Company has elected to account for the GILTI tax under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred. The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the total tax effect of this repatriation would be approximately $0.7 billion under current enacted tax laws and regulations and at current currency exchange rates.
Net Earnings Per Share	Net Earnings Per Share Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. The Company follows the provisions of U.S. GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.
Annual Closing Date	Annual Closing Date The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52 weeks, but every five or six years the fiscal year consists of 53 weeks , and therefore includes additional shipping days, as was the case in 2015, and will be the case again in 2020.
Reclassification	Reclassification Certain prior period amounts have been reclassified to conform to current year presentation.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 30, 2018
Accounting Policies [Abstract]
Schedule of New Accounting Pronouncements	As required by the transition provisions of this update, the following table shows the impact of the adoption on the respective line items in the Consolidated Statement of Earnings for 2018 and the reclassifications to the 2017 and 2016 fiscal year Consolidated Statement of Earnings to retroactively apply classification of the service cost component and the other components of NPBC: (Dollars In millions) Increase (Decrease) to Net Expense 2018 2017 2016 Cost of products sold $ 51 85 104 Selling, marketing and administrative expenses 55 100 122 Research and development expense 21 40 48 Other (income) expense, net (127 ) (225 ) (274 ) Earnings before provision for taxes on income $ — — — The following table summarizes the cumulative effect adjustments made to the 2018 opening balance of retained earnings upon adoption of the new accounting standards mentioned above: (Dollars in Millions) Cumulative Effect Adjustment Increase (Decrease) to Retained Earnings ASU 2014-09 - Revenue from Contracts with Customers $ (47 ) ASU 2016-01 - Financial Instruments 232 ASU 2016-16 - Income Taxes: Intra-Entity Transfers (439 ) Total $ (254 ) In accordance with the new revenue standard requirements, the disclosure of the impact of adoption on the Company's Consolidated Statement of Earnings and Balance Sheet was as follows: Statement of Earnings - For the fiscal year ended December 30, 2018 (Dollars in millions) As Reported Effect of change Balance without adoption of ASC 606 Sales to customers $ 81,581 (35 ) 81,546 Net earnings 15,297 (28 ) 15,269 Balance Sheet - As of December 30, 2018 As Reported Effect of change Balance without adoption of ASC 606 Assets 152,954 23 152,977 Liabilities 93,202 4 93,206 Equity $ 59,752 19 59,771
Estimated Useful Lives of Assets	Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets: Building and building equipment 20 - 30 years Land and leasehold improvements 10 - 20 years Machinery and equipment 2 - 13 years

Cash, Cash Equivalents and Cu_2

Cash, Cash Equivalents and Current Marketable Securities (Tables)	12 Months Ended
	Dec. 30, 2018
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalent Composition	At the end of 2018 and 2017 , cash, cash equivalents and current marketable securities were comprised of: (Dollars in Millions) 2018 Carrying Amount Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,619 2,619 2,619 — U.S. Reverse repurchase agreements 3,009 3,009 3,009 — Other Reverse repurchase agreements 443 443 443 — Money market funds 3,397 3,397 3,397 — Time deposits (1) 485 485 485 — Subtotal $ 9,953 9,953 9,953 — Gov't Securities $ 9,474 9,474 8,144 1,330 Corporate debt securities 260 260 10 250 Subtotal available for sale (2) $ 9,734 9,734 8,154 1,580 Total cash, cash equivalents and current marketable securities $ 18,107 1,580 In 2018, the carrying amount was the same as the estimated fair value. In 2017, the carrying amount was the same as the estimated fair value. (Dollars in Millions) 2017 Carrying Amount Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,929 2,929 2,929 — Other Sovereign Securities (1) 279 279 219 60 U.S. Reverse repurchase agreements 4,025 4,025 4,025 — Corporate debt securities (1) 289 289 244 45 Money market funds 4,288 4,288 4,288 — Time deposits (1) 1,176 1,176 1,175 1 Subtotal $ 12,986 12,986 12,880 106 Gov't Securities $ 4,864 4,864 4,833 31 Other Sovereign Securities 186 186 80 106 Corporate debt securities 260 260 31 229 Subtotal available for sale (2) $ 5,310 5,310 4,944 366 Total cash, cash equivalents and current marketable securities $ 17,824 472 (1) Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
Contractual Maturities of Available for Sale Securities	The contractual maturities of the available for sale debt securities at December 30, 2018 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 9,670 9,670 Due after one year through five years 64 64 Due after five years through ten years — — Total debt securities $ 9,734 9,734

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 30, 2018
Inventory Disclosure [Abstract]
Summary of Inventories	At the end of 2018 and 2017 , inventories were comprised of: (Dollars in Millions) 2018 2017 Raw materials and supplies $ 1,114 1,140 Goods in process 2,109 2,317 Finished goods 5,376 5,308 Total inventories $ 8,599 (1) 8,765 (1) Net of assets held for sale on the Consolidated Balance Sheet for approximately $0.2 billion related to the divestiture of the Advanced Sterilization Products business and $0.3 billion related to the strategic collaboration with Jabil Inc., both of which were pending as of December 30, 2018.

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 30, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment at Cost and Accumulated Depreciation	At the end of 2018 and 2017 , property, plant and equipment at cost and accumulated depreciation were: (Dollars in Millions) 2018 2017 Land and land improvements $ 807 829 Buildings and building equipment 11,176 11,240 Machinery and equipment 25,992 25,949 Construction in progress 3,876 3,448 Total property, plant and equipment, gross $ 41,851 41,466 Less accumulated depreciation 24,816 24,461 Total property, plant and equipment, net $ 17,035 (1) 17,005 (1) Net of assets held for sale on the Consolidated Balance Sheet for approximately $0.1 billion related to the divestiture of the Advanced Sterilization Products business and $0.1 billion related to the strategic collaboration with Jabil Inc., both of which were pending as of December 30, 2018.

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	12 Months Ended
	Dec. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill	At the end of 2018 and 2017 , the gross and net amounts of intangible assets were: (Dollars in Millions) 2018 2017 Intangible assets with definite lives: Patents and trademarks — gross $ 35,194 36,427 Less accumulated amortization 9,784 7,223 Patents and trademarks — net $ 25,410 29,204 Customer relationships and other intangibles — gross $ 21,334 20,204 Less accumulated amortization 8,323 7,463 Customer relationships and other intangibles — net $ 13,011 12,741 Intangible assets with indefinite lives: Trademarks $ 6,937 7,082 Purchased in-process research and development (1) 2,253 4,201 Total intangible assets with indefinite lives $ 9,190 11,283 Total intangible assets — net $ 47,611 53,228 (1) The decrease was primarily attributable to the write-down of $1.1 billion related to the assets acquired in the acquisitions of Alios Biopharma Inc. (Alios) and XO1 Limited (XO1). Of the $1.1 billion , the Company recorded a partial impairment charge of $0.8 billion related to the development program of AL-8176, an investigational drug for the treatment of Respiratory Syncytial Virus (RSV) and human metapneumovirus (hMPV) acquired with the 2014 acquisition of Alios. The impairment charge was calculated based on updated cash flow projections discounted for the inherent risk in the asset development and reflects the impact of the phase 2b clinical trial suspension, a decrease in the probability of success factors and the ongoing analysis of asset development activities. In addition, an impairment charge of $0.3 billion was recorded for the discontinuation of the development project for an anti-thrombin antibody associated with the 2015 acquisition of XO1. Additionally, $0.8 billion of IPR&D related to ERLEADA ™ was reclassified to definite lived intangible assets upon commercialization.
Goodwill	Goodwill as of December 30, 2018 and December 31, 2017 , as allocated by segment of business, was as follows: (Dollars in Millions) Consumer Pharmaceutical Medical Devices Total Goodwill at January 1, 2017 $ 8,263 2,840 11,702 22,805 Goodwill, related to acquisitions (1) 102 6,161 2,200 8,463 Goodwill, related to divestitures (74 ) (1 ) (102 ) (177 ) Currency translation/other 584 109 122 815 Goodwill at December 31, 2017 $ 8,875 9,109 13,922 31,906 Goodwill, related to acquisitions 168 51 184 403 Goodwill, related to divestitures — — (1,348 ) (2) (1,348 ) Currency translation/other (373 ) (97 ) (38 ) (508 ) Goodwill at December 30, 2018 $ 8,670 9,063 12,720 30,453 (1) Goodwill of $6.2 billion related to the Actelion acquisition acquired in the fiscal second quarter of 2017, within the Pharmaceutical segment and $1.7 billion related to the AMO acquisition acquired in the fiscal first quarter of 2017, within the Medical Devices segment. (2) Goodwill of $1.0 billion is related to the divestiture of the LifeScan business. Goodwill of $0.3 billion is related to the divestiture of the Advanced Sterilization Products business, which was pending and classified as assets held for sale on the Consolidated Balance Sheet as of December 30, 2018.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 30, 2018
Fair Value Disclosures [Abstract]
Summary of Derivative Activity	The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended December 30, 2018 and December 31, 2017 : December 30, 2018 December 31, 2017 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $ — — — 5 — — — — 5 — Derivatives designated as hedging instruments — — — (5 ) — — — — (5 ) — Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 56 — — — — — — Amount of gain or (loss) recognized in AOCI — — — 56 — — — — — — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income (1) 47 200 (220 ) — (24 ) (31 ) (159 ) (165 ) — (87 ) Amount of gain or (loss) recognized in AOCI (1) (32 ) (17 ) (193 ) — (4 ) 49 96 (199 ) — (60 ) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 133 — — — — 83 — Amount of gain or (loss) recognized in AOCI $ — — — 117 — — — — 110 — (1) Includes equity collar contracts. The equity collar contracts expired in December of 2017.
Schedule of Derivatives Recorded in Consolidated Balance Sheets	For the fiscal years ended December 30, 2018 and December 31, 2017 , the following amounts were recorded on the Consolidated Balance Sheet Line item in the Consolidated Balance Sheet in which the hedged item is included Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability (Dollars in Millions) December 30, 2018 December 31, 2017 December 30, 2018 December 31, 2017 Current Portion of Long-term Debt $ 494 597 5 2 Long-term Debt — 496 — 3
Schedule of Effect of Derivatives not Designated as Hedging Instruments	The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended December 30, 2018 and December 31, 2017: (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Gain/(Loss) Recognized In Income on Derivative Derivatives Not Designated as Hedging Instruments December 30, 2018 December 31, 2017 Foreign Exchange Contracts Other (income) expense (68 ) (5 )
Schedule of Effect of Net Investment Hedges	The following table is the effect of net investment hedges for the fiscal years ended December 30, 2018 and December 31, 2017: Gain/(Loss) Recognized In Accumulated OCI Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From Accumulated OCI Into Income (Dollars in Millions) Fiscal Nine Months Ended December 30, 2018 December 31, 2017 December 30, 2018 December 31, 2017 Debt $ 218 (597 ) Other (income) expense — — Cross Currency interest rate swaps $ 150 — Other (income) expense — —
Summary of Activity Related to Equity Investments	The following table is a summary of the activity related to equity investments as of December 30, 2018 : (Dollars in Millions) December 31, 2017 December 30, 2018 Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 751 (247 ) 7 511 511 Equity Investments without readily determinable value $ 510 13 158 681 681 (1) Recorded in Other Income/Expense (2) Other includes impact of currency
Financial Assets and Liabilities at Fair Value	The Company’s significant financial assets and liabilities measured at fair value as of December 30, 2018 and December 31, 2017 were as follows: 2018 2017 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 501 — 501 418 Interest rate contracts (2)(4) — 161 — 161 7 Total — 662 — 662 425 Liabilities: Forward foreign exchange contracts — 548 — 548 402 Interest rate contracts (3)(4) — 292 — 292 165 Total — 840 — 840 567 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts — 32 — 32 38 Liabilities: Forward foreign exchange contracts — 32 — 32 38 Available For Sale Other Investments: Equity investments (5) 511 — — 511 751 Debt securities (6) $ — 9,734 — 9,734 5,310 Gross to Net Derivative Reconciliation 2018 2017 (Dollars in Millions) Total Gross Assets $ 694 463 Credit Support Agreement (CSA) (423 ) (76 ) Total Net Asset 271 387 Total Gross Liabilities 872 605 Credit Support Agreement (CSA) (605 ) (238 ) Total Net Liabilities $ 267 367 (1) 2017 assets and liabilities are all classified as Level 2 with the exception of equity investments of $751 million , which are classified as Level 1. (2) Includes $6 million and $7 million of non-current assets for the fiscal years ending December 30, 2018 and December 31, 2017 , respectively. (3) Includes $3 million and $9 million of non-current liabilities for the fiscal years ending December 30, 2018 and December 31, 2017 , respectively. (4) Includes cross currency interest rate swaps and interest rate swaps. (5) Classified as non-current other assets. The carrying amount of the equity investments were $511 million and $751 million as of December 30, 2018 and December 31, 2017 , respectively. (6) Classified as cash equivalents and current marketable securities.

Borrowings (Tables)

Borrowings (Tables)	12 Months Ended
	Dec. 30, 2018
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	The components of long-term debt are as follows: (Dollars in Millions) 2018 Effective Rate % 2017 Effective Rate % 5.15% Debentures due 2018 $ — 900 5.18 1.65% Notes due 2018 — 597 1.70 4.75% Notes due 2019 (1B Euro 1.14) (2) /(1B Euro 1.1947) (3) 1,139 (2) 5.83 1,192 (3) 5.83 1.875% Notes due 2019 494 1.93 496 1.93 0.89% Notes due 2019 300 1.32 300 1.75 1.125% Notes due 2019 699 1.13 699 1.13 3% Zero Coupon Convertible Subordinated Debentures due 2020 51 3.00 60 3.00 2.95% Debentures due 2020 548 3.15 547 3.15 1.950% Notes due 2020 499 1.99 499 1.99 3.55% Notes due 2021 449 3.67 448 3.67 2.45% Notes due 2021 349 2.48 349 2.48 1.65% Notes due 2021 998 1.65 998 1.65 0.250% Notes due 2022 (1B Euro 1.14) (2) /(1B Euro 1.1947) (3) 1,137 (2) 0.26 1,191 (3) 0.26 2.25% Notes due 2022 996 2.31 995 2.31 6.73% Debentures due 2023 250 6.73 250 6.73 3.375% Notes due 2023 805 3.17 806 3.17 2.05% Notes due 2023 498 2.09 498 2.09 0.650% Notes due 2024 (750MM Euro 1.14) (2) /(750MM Euro 1.1947) (3) 851 (2) 0.68 891 (3) 0.68 5.50% Notes due 2024 (500MM GBP 1.2636) (2) /(500MM GBP 1.3444) (3) 627 (2) 6.75 666 (3) 6.75 2.625% Notes due 2025 748 2.63 747 2.63 2.45% Notes due 2026 1,992 2.47 1,990 2.47 2.95% Notes due 2027 996 2.96 995 2.96 1.150% Notes due 2028 (750MM Euro 1.14) (2) /(750MM Euro 1.1947) (3) 847 (2) 1.21 887 (3) 1.21 2.900% Notes due 2028 1,493 2.91 1,492 2.91 6.95% Notes due 2029 297 7.14 296 7.14 4.95% Debentures due 2033 498 4.95 498 4.95 4.375% Notes due 2033 856 4.24 856 4.24 1.650% Notes due 2035 (1.5B Euro 1.14) (2) /(1.5B Euro 1.1947) (3) 1,693 (2) 1.68 1,774 (3) 1.68 3.55% Notes due 2036 988 3.59 987 3.59 5.95% Notes due 2037 991 5.99 991 5.99 3.625% Notes due 2037 1,486 3.64 1,486 3.64 5.85% Debentures due 2038 696 5.85 696 5.85 3.400% Notes due 2038 990 3.42 990 3.42 4.50% Debentures due 2040 538 4.63 538 4.63 4.85% Notes due 2041 297 4.89 296 4.89 4.50% Notes due 2043 495 4.52 495 4.52 3.70% Notes due 2046 1,972 3.74 1,971 3.74 3.75% Notes due 2047 991 3.76 990 3.76 3.500% Notes due 2048 742 3.52 742 3.52 Other 24 — 75 — Subtotal 30,320 (4) 3.19 % (1) 32,174 (4) 3.19 (1 ) Less current portion 2,636 1,499 Total long-term debt $ 27,684 30,675 (1) Weighted average effective rate. (2) Translation rate at December 30, 2018 . (3) Translation rate at December 31, 2017 . (4) The excess of the fair value over the carrying value of debt was $0.3 billion in 2018 and $2.0 billion in 2017 .
Aggregate Maturities of Long Term Obligations	Aggregate maturities of long-term obligations commencing in 2019 are: (Dollars in Millions) 2019 2020 2021 2022 2023 After 2023 $2,636 1,098 1,796 2,134 1,553 21,103

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 30, 2018
Income Tax Disclosure [Abstract]
Provision for Income Taxes	The provision for taxes on income consists of: (Dollars in Millions) 2018 2017 2016 Currently payable: U.S. taxes $ 1,081 11,969 1,896 U.S. taxes on international operations 203 126 49 International taxes 2,434 1,872 1,659 Total currently payable 3,718 13,967 3,604 Deferred: U.S. taxes (148 ) (1,956 ) 294 U.S. taxes on international operations 1,358 International taxes (2,226 ) 4,362 (635 ) Total deferred (1,016 ) 2,406 (341 ) Provision for taxes on income $ 2,702 16,373 3,263
Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate	A comparison of income tax expense at the U.S. statutory rate of 21% in 2018 and 35% in 2017 and 2016 , to the Company’s effective tax rate is as follows: (Dollars in Millions) 2018 2017 2016 U.S. $ 5,575 4,865 7,457 International 12,424 12,808 12,346 Earnings before taxes on income: $ 17,999 17,673 19,803 Tax rates: U.S. statutory rate 21.0 % 35.0 35.0 International operations (1) (3.7 ) (12.8 ) (17.2 ) Research and orphan drug tax credits (1.0 ) (0.4 ) (0.4 ) U.S. state and local 0.8 0.6 (0.1 ) U.S. manufacturing deduction — (0.8 ) (0.6 ) U.S. tax on international income (2) 1.4 0.7 1.3 Tax benefits on share-based compensation (1.5 ) (2.1 ) (1.8 ) U.S. tax benefit on asset/business disposals 0.5 (0.8 ) — All other (0.6 ) (0.1 ) 0.3 TCJA and related impacts (3) (1.9 ) (3) 73.3 (4) — Effective Rate 15.0 % 92.6 16.5 (1) For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflects the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2017 amount also includes tax cost related to the revaluation of deferred tax balances related to the change in the Belgian statutory tax rate increasing the tax provision by approximately 3.4% . (2) Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. (3) Represents impact of adjustments to the 2017 TCJA provisional tax charge. This also includes a net tax benefit from the reduction of a deferred tax liability related to foreign withholding taxes originally accrued as part of the provisional charge. This benefit reduced the Company’s effective tax rate by approximately 11% . Further description is included below. (4) Includes U.S. state and local taxes provisionally recorded as part TCJA provisional charge which was approximately 0.6% of the total effective tax rate.
Temporary Differences and Carryforwards	Temporary differences and carryforwards for 2018 and 2017 were as follows: 2018 Deferred Tax 2017 Deferred Tax (Dollars in Millions) Asset Liability Asset Liability Employee related obligations $ 2,398 2,259 Stock based compensation 639 507 Depreciation & amortization 1,784 (9 ) Non-deductible intangibles (5,967 ) (6,506 ) International R&D capitalized for tax 1,282 1,307 Reserves & liabilities 1,647 1,718 Income reported for tax purposes 1,104 1,316 Net operating loss carryforward international 786 762 Undistributed foreign earnings 693 (2,240 ) 1,101 (4,457 ) Global intangible low-taxed income (2,971 ) Miscellaneous international 603 (93 ) 755 (194 ) Miscellaneous U.S. 469 177 Total deferred income taxes $ 11,405 (11,271 ) 9,902 (11,166 )
Summary of Activity Related to Unrecognized Tax Benefits	The following table summarizes the activity related to unrecognized tax benefits: (Dollars in Millions) 2018 2017 2016 Beginning of year $ 3,151 3,041 3,080 Increases related to current year tax positions 242 332 348 Increases related to prior period tax positions 145 232 11 Decreases related to prior period tax positions (137 ) (416 ) (1) (338 ) Settlements (40 ) (2 ) (37 ) Lapse of statute of limitations (35 ) (36 ) (23 ) End of year $ 3,326 3,151 3,041 (1) In 2017, $347 million of this decrease is related to the TCJA

Employee Related Obligations (T

Employee Related Obligations (Tables)	12 Months Ended
	Dec. 30, 2018
Compensation Related Costs [Abstract]
Employee Related Obligations	At the end of 2018 and 2017 , employee related obligations recorded on the Consolidated Balance Sheets were: (Dollars in Millions) 2018 2017 Pension benefits $ 5,327 5,343 Postretirement benefits 2,283 2,331 Postemployment benefits 2,330 2,250 Deferred compensation 410 475 Total employee obligations 10,350 10,399 Less current benefits payable 399 325 Employee related obligations — non-current $ 9,951 10,074

Pensions and Other Benefit Pl_2

Pensions and Other Benefit Plans (Tables)	12 Months Ended
	Dec. 30, 2018
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost	Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for 2018 , 2017 and 2016 include the following components: Retirement Plans Other Benefit Plans (Dollars in Millions) 2018 2017 2016 2018 2017 2016 Service cost $ 1,283 1,080 949 269 247 224 Interest cost 996 927 927 148 159 158 Expected return on plan assets (2,212 ) (2,041 ) (1,962 ) (7 ) (6 ) (6 ) Amortization of prior service cost (credit) 3 2 1 (31 ) (30 ) (34 ) Recognized actuarial losses 852 609 496 123 138 135 Curtailments and settlements 1 17 11 — — — Net periodic benefit cost $ 923 594 422 502 508 477
Amounts Expected to be Recognized in Net Periodic Benefit Cost	Amounts expected to be recognized in net periodic benefit cost in the coming year for the Company’s defined benefit retirement plans and other post-retirement plans: (Dollars in Millions) Amortization of net transition obligation $ — Amortization of net actuarial losses 656 Amortization of prior service credit 27
Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation	The following table represents the weighted-average actuarial assumptions: Retirement Plans Other Benefit Plans Worldwide Benefit Plans 2018 2017 2016 2018 2017 2016 Net Periodic Benefit Cost Service cost discount rate 3.20 % 3.59 3.98 3.85 4.63 4.77 Interest cost discount rate 3.60 % 3.98 4.24 3.62 3.94 4.10 Rate of increase in compensation levels 3.98 % 4.01 4.02 4.29 4.31 4.32 Expected long-term rate of return on plan assets 8.46 % 8.43 8.55 Benefit Obligation Discount rate 3.76 % 3.30 3.78 4.40 3.78 4.42 Rate of increase in compensation levels 3.97 % 3.99 4.02 4.29 4.30 4.29
Assumed Health Care Cost Trend Rates	The following table displays the assumed health care cost trend rates, for all individuals: Health Care Plans 2018 2017 Health care cost trend rate assumed for next year 6.12 % 6.33 % Rate to which the cost trend rate is assumed to decline (ultimate trend) 4.55 % 4.55 % Year the rate reaches the ultimate trend rate 2038 2038
Effect of One Percentage Point Change in Assumed Health Care Cost Trend Rates	A one-percentage-point change in assumed health care cost trend rates would have the following effect: One-Percentage- One-Percentage- (Dollars in Millions) Point Increase Point Decrease Health Care Plans Total interest and service cost $ 28 (22 ) Post-retirement benefit obligation $ 340 (280 )
Schedule of Net Funded Status	The following table sets forth information related to the benefit obligation and the fair value of plan assets at year-end 2018 and 2017 for the Company’s defined benefit retirement plans and other post-retirement plans: Retirement Plans Other Benefit Plans (Dollars in Millions) 2018 2017 2018 2017 Change in Benefit Obligation Projected benefit obligation — beginning of year $ 33,221 28,116 4,582 4,605 Service cost 1,283 1,080 269 247 Interest cost 996 927 148 159 Plan participant contributions 66 60 — — Amendments 26 (7 ) — (17 ) Actuarial (gains) losses (2,326 ) 2,996 (119 ) (166 ) Divestitures & acquisitions (29 ) 201 — 88 Curtailments, settlements & restructuring (21 ) (35 ) — 2 Benefits paid from plan (1,018 ) (1,050 ) (383 ) (351 ) Effect of exchange rates (528 ) 933 (17 ) 15 Projected benefit obligation — end of year $ 31,670 33,221 4,480 4,582 Change in Plan Assets Plan assets at fair value — beginning of year $ 28,404 23,633 281 75 Actual return on plan assets (1,269 ) 4,274 — 12 Company contributions 1,140 664 282 545 Plan participant contributions 66 60 — — Settlements (13 ) (32 ) — — Divestitures & acquisitions (17 ) 173 — — Benefits paid from plan assets (1,018 ) (1,050 ) (383 ) (351 ) Effect of exchange rates (475 ) 682 — — Plan assets at fair value — end of year $ 26,818 28,404 180 281 Funded status — end of year $ (4,852 ) (4,817 ) (4,300 ) (4,301 ) Amounts Recognized in the Company’s Balance Sheet consist of the following: Non-current assets $ 475 526 — — Current liabilities (98 ) (92 ) (281 ) (228 ) Non-current liabilities (5,229 ) (5,251 ) (4,019 ) (4,073 ) Total recognized in the consolidated balance sheet — end of year $ (4,852 ) (4,817 ) (4,300 ) (4,301 ) Amounts Recognized in Accumulated Other Comprehensive Income consist of the following: Net actuarial loss $ 8,323 8,140 1,263 1,500 Prior service cost (credit) 2 (25 ) (106 ) (137 ) Unrecognized net transition obligation — — — — Total before tax effects $ 8,325 8,115 1,157 1,363 Accumulated Benefit Obligations — end of year $ 28,533 29,793 Retirement Plans Other Benefit Plans (Dollars in Millions) 2018 2017 2018 2017 Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income Net periodic benefit cost $ 923 594 502 508 Net actuarial (gain) loss 1,153 740 (111 ) (169 ) Amortization of net actuarial loss (852 ) (609 ) (123 ) (138 ) Prior service cost (credit) 26 (7 ) — (17 ) Amortization of prior service (cost) credit (3 ) (2 ) 31 30 Effect of exchange rates (114 ) 256 (3 ) 3 Total loss/(income) recognized in other comprehensive income, before tax $ 210 378 (206 ) (291 ) Total recognized in net periodic benefit cost and other comprehensive income $ 1,133 972 296 217
Information Related to the Benefit Obligation and the Fair Value of Plan Assets	The following table displays the funded status of the Company's U.S. Qualified & Non-Qualified pension plans and international funded and unfunded pension plans at December 31, 2018 and December 31, 2017, respectively: U.S. Plans International Plans Qualified Plans Non-Qualified Plans Funded Plans Unfunded Plans (Dollars in Millions) 2018 2017 2018 2017 2018 2017 2018 2017 Plan Assets $ 17,725 18,681 — — 9,093 9,723 — — Projected Benefit Obligation 18,609 19,652 2,176 2,257 10,467 10,863 418 449 Accumulated Benefit Obligation 16,851 17,654 1,793 1,849 9,510 9,893 379 397 Over (Under) Funded Status Projected Benefit Obligation $ (884 ) (971 ) (2,176 ) (2,257 ) (1,374 ) (1,140 ) (418 ) (449 ) Accumulated Benefit Obligation 874 1,027 (1,793 ) (1,849 ) (417 ) (170 ) (379 ) (397 )
Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans	The following table displays the projected future benefit payments from the Company’s retirement and other benefit plans: (Dollars in Millions) 2019 2020 2021 2022 2023 2024-2028 Projected future benefit payments Retirement plans $ 1,062 1,104 1,182 1,257 1,332 7,679 Other benefit plans $ 375 397 411 428 413 2,273
Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans	The following table displays the projected future minimum contributions to the unfunded retirement plans. These amounts do not include any discretionary contributions that the Company may elect to make in the future. (Dollars in Millions) 2019 2020 2021 2022 2023 2024-2028 Projected future contributions $ 92 95 101 108 115 697
Company' Retirement Plan Asset Allocation and Target Allocations	The Company’s retirement plan asset allocation at the end of 2018 and 2017 and target allocations for 2019 are as follows: Percent of Plan Assets Target Allocation 2018 2017 2019 Worldwide Retirement Plans Equity securities 71 % 76 % 70 % Debt securities 29 24 30 Total plan assets 100 % 100 % 100 %
Schedule of Defined Benefit Plans Disclosures	The following table sets forth the Retirement Plans' investments measured at fair value as of December 31, 2018 and December 31, 2017: Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (a) Investments Measured at Net Asset Value (Level 1) (Level 2) (Level 3) Total Assets (Dollars in Millions) 2018 2017 2018 2017 2018 2017 2018 2017 2018 2017 Short-term investment funds $ 122 429 529 427 — — — — 651 856 Government and agency securities — — 3,595 3,094 — — — — 3,595 3,094 Debt instruments — — 3,105 2,013 — — — — 3,105 2,013 Equity securities 11,298 13,848 4 — — — — — 11,302 13,848 Commingled funds — — 2,304 1,780 133 57 5,201 6,158 7,638 7,995 Insurance contracts — — — — 193 199 — — 193 199 Other assets — — 33 121 — — 301 278 334 399 Investments at fair value $ 11,420 14,277 9,570 7,435 326 256 5,502 6,436 26,818 28,404 (a) The activity for the Level 3 assets is not significant for all years presented.

Capital and Treasury Stock (Tab

Capital and Treasury Stock (Tables)	12 Months Ended
	Dec. 30, 2018
Equity [Abstract]
Changes in Treasury Stock	Changes in treasury stock were: Treasury Stock (Amounts in Millions Except Treasury Stock Shares in Thousands) Shares Amount Balance at January 3, 2016 364,681 $ 22,684 Employee compensation and stock option plans (30,839 ) (3,311 ) Repurchase of common stock 79,490 8,979 Balance at January 1, 2017 413,332 28,352 Employee compensation and stock option plans (25,508 ) (3,156 ) Repurchase of common stock 49,494 6,358 Balance at December 31, 2017 437,318 31,554 Employee compensation and stock option plans (22,082 ) (3,060 ) Repurchase of common stock 42,283 5,868 Balance at December 30, 2018 457,519 $ 34,362

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	Dec. 30, 2018
Equity [Abstract]
Components of Accumulated Other Comprehensive Income	Components of other comprehensive income (loss) consist of the following: (Dollars in Millions) Foreign Gain/(Loss) On Securities Employee Benefit Plans Gain/ Total January 3, 2016 $ (8,435 ) 604 (5,298 ) (36 ) (13,165 ) Net 2016 changes (612 ) (193 ) (682 ) (249 ) (1,736 ) January 1, 2017 (9,047 ) 411 (5,980 ) (285 ) (14,901 ) Net 2017 changes 1,696 (179 ) (170 ) 355 1,702 December 31, 2017 (7,351 ) 232 (6,150 ) 70 (13,199 ) Cumulative adjustment to retained earnings (232 ) (1) (232 ) Net 2018 changes (1,518 ) — (8 ) (265 ) (1,791 ) December 30, 2018 $ (8,869 ) — (6,158 ) (195 ) (15,222 ) (1) See Note 1 to Consolidated Financial Statements for additional details on the adoption of ASU 2016-01

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 30, 2018
Earnings Per Share [Abstract]
Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share	The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended December 30, 2018 , December 31, 2017 and January 1, 2017 : (In Millions Except Per Share Amounts) 2018 2017 2016 Basic net earnings per share $ 5.70 0.48 6.04 Average shares outstanding — basic 2,681.5 2,692.0 2,737.3 Potential shares exercisable under stock option plans 139.0 139.7 142.4 Less: shares repurchased under treasury stock method (92.5 ) (87.3 ) (92.1 ) Convertible debt shares 0.7 0.9 1.3 Adjusted average shares outstanding — diluted 2,728.7 2,745.3 2,788.9 Diluted net earnings per share $ 5.61 0.47 5.93

Rental Expense and Lease Comm_2

Rental Expense and Lease Commitments (Tables)	12 Months Ended
	Dec. 30, 2018
Leases, Operating [Abstract]
Schedule of Minimum Rental Payments Under Operating Leases	The approximate minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year at December 30, 2018 are: (Dollars in Millions) 2019 2020 2021 2022 2023 After 2023 Total $223 188 154 116 76 139 896

Common Stock, Stock Option Pl_2

Common Stock, Stock Option Plans and Stock Compensation Agreements (Tables)	12 Months Ended
	Dec. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule Valuation Assumptions	The average fair value of options granted was $17.98 , $13.38 and $10.01 , in 2018 , 2017 and 2016 , respectively. The fair value was estimated based on the weighted average assumptions of: 2018 2017 2016 Risk-free rate 2.77 % 2.25 % 1.51 % Expected volatility 15.77 % 15.30 % 15.76 % Expected life (in years) 7.0 7.0 7.0 Expected dividend yield 2.70 % 2.90 % 3.10 %
Summary of Stock Option Activity	A summary of option activity under the Plan as of December 30, 2018 , December 31, 2017 and January 1, 2017 , and changes during the years ending on those dates is presented below: (Shares in Thousands) Outstanding Shares Weighted Average Exercise Price Aggregate Intrinsic Value (Dollars in Millions) Shares at January 3, 2016 116,517 $ 76.41 $ 3,065 Options granted 22,491 101.87 Options exercised (22,547 ) 65.66 Options canceled/forfeited (3,006 ) 92.83 Shares at January 1, 2017 113,455 83.16 3,636 Options granted 19,287 115.67 Options exercised (18,975 ) 70.87 Options canceled/forfeited (2,461 ) 101.40 Shares at December 31, 2017 111,306 90.48 5,480 Options granted 17,115 129.51 Options exercised (16,228 ) 75.44 Options canceled/forfeited (2,541 ) 112.90 Shares at December 30, 2018 109,652 $ 98.29 $ 3,214
Summary of Options Outstanding	The following table summarizes stock options outstanding and exercisable at December 30, 2018 : (Shares in Thousands) Outstanding Exercisable Exercise Price Range Options Average Life (1) Average Exercise Price Options Average Exercise Price $52.13-$65.62 13,466 1.8 $62.67 13,466 $62.67 $66.07-$72.54 12,710 4.0 $72.53 12,710 $72.53 $90.44-$100.48 29,162 5.6 $95.34 28,537 $95.23 $101.87-$115.67 37,877 7.6 $108.33 111 $108.04 $115.68-$129.51 16,437 9.1 $129.51 38 $129.51 109,652 6.2 $98.29 54,862 $82.03 (1) Average contractual life remaining in years.
Summary of Restricted Share Units	A summary of the restricted share units and performance share units activity under the Plans as of December 30, 2018 is presented below: (Shares in Thousands) Outstanding Restricted Share Units Outstanding Performance Share Units Shares at December 31, 2017 20,161 2,625 Granted 6,074 1,142 Issued (6,684 ) (1,151 ) Canceled/forfeited/adjusted (1,091 ) (122 ) Shares at December 30, 2018 18,460 2,494

Segments of Business and Geog_2

Segments of Business and Geographic Areas (Tables)	12 Months Ended
	Dec. 30, 2018
Segment Reporting [Abstract]
Schedule of Sales by Segment of Business	Sales to Customers % Change (Dollars in Millions) 2018 2017 2016 ’18 vs. ’17 ’17 vs. ’16 CONSUMER Baby Care U.S. $ 422 449 488 (6.0 )% (8.0 ) International 1,436 1,467 1,513 (2.1 ) (3.0 ) Worldwide 1,858 1,916 2,001 (3.0 ) (4.2 ) Beauty U.S. 2,403 2,335 2,135 2.9 9.4 International 1,979 1,865 1,762 6.1 5.8 Worldwide 4,382 4,200 3,897 4.3 7.8 Oral Care U.S. 637 616 648 3.4 (4.9 ) International 918 915 920 0.3 (0.5 ) Worldwide 1,555 1,531 1,568 1.6 (2.4 ) OTC U.S. 1,850 1,716 1,675 7.8 2.4 International 2,484 2,410 2,302 3.1 4.7 Worldwide 4,334 4,126 3,977 5.0 3.7 Women's Health U.S. 13 12 19 8.3 (36.8 ) International 1,036 1,038 1,048 (0.2 ) (1.0 ) Worldwide 1,049 1,050 1,067 (0.1 ) (1.6 ) Wound Care/Other U.S. 436 437 455 (0.2 ) (4.0 ) International 239 342 342 (30.1 ) 0.0 Worldwide 675 779 797 (13.4 ) (2.3 ) TOTAL CONSUMER U.S. 5,761 5,565 5,420 3.5 2.7 International 8,092 8,037 7,887 0.7 1.9 Worldwide 13,853 13,602 13,307 1.8 2.2 PHARMACEUTICAL Immunology U.S. 9,073 8,871 8,846 2.3 0.3 International 4,047 3,373 3,122 20.0 8.0 Worldwide 13,120 12,244 11,968 7.2 2.3 REMICADE ® U.S. 3,664 4,525 4,842 (19.0 ) (6.5 ) U.S. Exports 436 563 782 (22.6 ) (28.0 ) International 1,226 1,227 1,342 (0.1 ) (8.6 ) Worldwide 5,326 6,315 6,966 (15.7 ) (9.3 ) SIMPONI / SIMPONI ARIA ® U.S. 1,051 954 959 10.2 (0.5 ) International 1,033 879 786 17.5 11.8 Worldwide 2,084 1,833 1,745 13.7 5.0 STELARA ® U.S. 3,469 2,767 2,263 25.4 22.3 International 1,687 1,244 969 35.6 28.4 Worldwide 5,156 4,011 3,232 28.5 24.1 TREMFAYA ® U.S. 453 62 — * * International 91 1 — * * Worldwide 544 63 — * * OTHER IMMUNOLOGY U.S. — — — — — International 10 22 25 (54.5 ) (12.0 ) Worldwide 10 22 25 (54.5 ) (12.0 ) Infectious Diseases U.S. 1,378 1,358 1,461 1.5 (7.0 ) International 1,926 1,796 1,747 7.2 2.8 Worldwide 3,304 3,154 3,208 4.8 (1.7 ) EDURANT ® / rilpivirine U.S. 58 58 52 0.0 11.5 International 758 656 521 15.5 25.9 Worldwide 816 714 573 14.3 24.6 PREZISTA ® / PREZCOBIX ® / REZOLSTA ® / SYMTUZA ® U.S. 1,169 1,109 1,143 5.4 (3.0 ) International 786 712 708 10.4 0.6 Worldwide 1,955 1,821 1,851 7.4 (1.6 ) OTHER INFECTIOUS DISEASES U.S. 151 191 266 (20.9 ) (28.2 ) International 382 428 518 (10.7 ) (17.4 ) Worldwide 533 619 784 (13.9 ) (21.0 ) Neuroscience U.S. 2,574 2,630 2,628 (2.1 ) 0.1 International 3,503 3,356 3,457 4.4 (2.9 ) Worldwide 6,077 5,986 6,085 1.5 (1.6 ) CONCERTA ® / Methylphenidate U.S. 229 384 468 (40.4 ) (17.9 ) International 434 407 395 6.6 3.0 Worldwide 663 791 863 (16.2 ) (8.3 ) INVEGA SUSTENNA ® / XEPLION ® / INVEGA TRINZA ® / TREVICTA ® U.S. 1,791 1,590 1,343 12.6 18.4 International 1,137 979 871 16.1 12.4 Worldwide 2,928 2,569 2,214 14.0 16.0 RISPERDAL CONSTA ® U.S. 315 360 381 (12.5 ) (5.5 ) International 422 445 512 (5.2 ) (13.1 ) Worldwide 737 805 893 (8.4 ) (9.9 ) OTHER NEUROSCIENCE U.S. 239 296 436 (19.3 ) (32.1 ) International 1,510 1,525 1,679 (1.0 ) (9.2 ) Worldwide 1,749 1,821 2,115 (4.0 ) (13.9 ) Oncology U.S. 4,331 3,098 2,335 39.8 32.7 International 5,513 4,160 3,472 32.5 19.8 Worldwide 9,844 7,258 5,807 35.6 25.0 DARZALEX ® U.S. 1,203 884 471 36.1 87.7 International 822 358 101 * * Worldwide 2,025 1,242 572 63.0 * IMBRUVICA ® U.S. 1,129 841 613 34.2 37.2 International 1,486 1,052 638 41.3 64.9 Worldwide 2,615 1,893 1,251 38.1 51.3 VELCADE ® U.S. — — — — — International 1,116 1,114 1,224 0.2 (9.0 ) Worldwide 1,116 1,114 1,224 0.2 (9.0 ) ZYTIGA ® / abiraterone acetate U.S. 1,771 1,228 1,089 44.2 12.8 International 1,727 1,277 1,171 35.2 9.1 Worldwide 3,498 2,505 2,260 39.6 10.8 OTHER ONCOLOGY U.S. 228 145 162 57.2 (10.5 ) International 362 359 338 0.8 6.2 Worldwide 590 504 500 17.1 0.8 Pulmonary Hypertension U.S. 1,651 773 — * * International 922 554 — 66.4 * Worldwide 2,573 1,327 — 93.9 * OPSUMIT ® U.S. 700 320 — * * International 515 253 — * * Worldwide 1,215 573 — * * TRACLEER ® U.S. 268 161 — 66.5 * International 278 242 — 14.9 * Worldwide 546 403 — 35.5 * UPTRAVI ® U.S. 598 238 — * * International 65 25 — * * Worldwide 663 263 — * * OTHER U.S. 85 54 — 57.4 * International 64 34 — 88.2 * Worldwide 149 88 — 69.3 * Cardiovascular / Metabolism / Other U.S. 4,279 4,744 4,855 (9.8 ) (2.3 ) International 1,537 1,543 1,541 (0.4 ) 0.1 Worldwide 5,816 6,287 6,396 (7.5 ) (1.7 ) XARELTO ® U.S. 2,477 2,500 2,288 (0.9 ) 9.3 International — — — — — Worldwide 2,477 2,500 2,288 (0.9 ) 9.3 INVOKANA ® / INVOKAMET ® U.S. 711 944 1,273 (24.7 ) (25.8 ) International 170 167 134 1.8 24.6 Worldwide 881 1,111 1,407 (20.7 ) (21.0 ) PROCRIT ® / EPREX ® U.S. 674 675 767 (0.1 ) (12.0 ) International 314 297 338 5.7 (12.1 ) Worldwide 988 972 1,105 1.6 (12.0 ) OTHER U.S. 417 625 527 (33.3 ) 18.6 International 1,053 1,079 1,069 (2.4 ) 0.9 Worldwide 1,470 1,704 1,596 (13.7 ) 6.8 TOTAL PHARMACEUTICAL U.S. 23,286 21,474 20,125 8.4 6.7 International 17,448 14,782 13,339 18.0 10.8 Worldwide 40,734 36,256 33,464 12.4 8.3 MEDICAL DEVICES Diabetes Care U.S. 371 612 739 (39.4 ) (17.2 ) International 638 1,003 1,050 (36.4 ) (4.5 ) Worldwide 1,009 1,615 1,789 (37.5 ) (9.7 ) Diagnostics U.S. — — — — — International — 1 66 * * Worldwide — 1 66 * * Interventional Solutions U.S. 1,283 1,148 1,031 11.8 11.3 International 1,363 1,148 1,024 18.7 12.1 Worldwide 2,646 2,296 2,055 15.2 11.7 Orthopaedics U.S. 5,281 5,404 5,438 (2.3 ) (0.6 ) International 3,604 3,654 3,690 (1.4 ) (1.0 ) Worldwide 8,885 9,058 9,128 (1.9 ) (0.8 ) HIPS U.S. 841 827 798 1.7 3.6 International 577 567 563 1.8 0.7 Worldwide 1,418 1,394 1,361 1.7 2.4 KNEES U.S. 911 948 943 (3.9 ) 0.5 International 591 575 581 2.8 (1.0 ) Worldwide 1,502 1,523 1,524 (1.4 ) (0.1 ) TRAUMA U.S. 1,599 1,576 1,545 1.5 2.0 International 1,100 1,040 1,024 5.8 1.6 Worldwide 2,699 2,616 2,569 3.2 1.8 SPINE & OTHER U.S. 1,930 2,053 2,152 (6.0 ) (4.6 ) International 1,336 1,472 1,522 (9.2 ) (3.3 ) Worldwide 3,266 3,525 3,674 (7.3 ) (4.1 ) Surgery U.S. 4,125 4,085 4,026 1.0 1.5 International 5,776 5,474 5,270 5.5 3.9 Worldwide 9,901 9,559 9,296 3.6 2.8 ADVANCED U.S. 1,657 1,620 1,524 2.3 6.3 International 2,345 2,136 1,993 9.8 7.2 Worldwide 4,002 3,756 3,517 6.5 6.8 GENERAL U.S. 1,751 1,728 1,669 1.3 3.5 International 2,806 2,735 2,693 2.6 1.6 Worldwide 4,557 4,463 4,362 2.1 2.3 SPECIALTY U.S. 717 737 833 (2.7 ) (11.5 ) International 625 603 584 3.6 3.3 Worldwide 1,342 1,340 1,417 0.1 (5.4 ) Vision U.S. 1,777 1,575 1,032 12.8 52.6 International 2,776 2,488 1,753 11.6 41.9 Worldwide 4,553 4,063 2,785 12.1 45.9 CONTACT LENSES / OTHER U.S. 1,237 1,122 1,032 10.2 8.7 International 2,065 1,914 1,753 7.9 9.2 Worldwide 3,302 3,036 2,785 8.8 9.0 SURGICAL U.S. 540 453 — 19.2 * International 711 574 — 23.9 * Worldwide 1,251 1,027 — 21.8 * TOTAL MEDICAL DEVICES U.S. 12,837 12,824 12,266 0.1 4.5 International 14,157 13,768 12,853 2.8 7.1 Worldwide 26,994 26,592 25,119 1.5 5.9 WORLDWIDE U.S. 41,884 39,863 37,811 5.1 5.4 International 39,697 36,587 34,079 8.5 7.4 Worldwide $ 81,581 76,450 71,890 6.7 % 6.3 *Percentage greater than 100% or not meaningful
Schedule of Segment Reporting Information	Income Before Tax Identifiable Assets (Dollars in Millions) 2018 (3) 2017 (4) 2016 (5) 2018 2017 Consumer $ 2,320 2,524 2,441 $ 25,877 25,030 Pharmaceutical 12,568 11,083 12,827 56,636 59,450 Medical Devices 4,397 5,392 5,578 46,254 45,413 Total 19,285 18,999 20,846 128,767 129,893 Less: Expense not allocated to segments (1) 1,286 1,326 1,043 General corporate (2) 24,187 27,410 Worldwide total $ 17,999 17,673 19,803 $ 152,954 157,303 Additions to Property, Plant & Equipment Depreciation and Amortization (Dollars in Millions) 2018 2017 2016 2018 2017 2016 Consumer $ 438 485 486 $ 688 674 608 Pharmaceutical 1,012 936 927 3,802 2,416 886 Medical Devices 1,843 1,566 1,472 2,103 2,216 1,928 Segments total 3,293 2,987 2,885 6,593 5,306 3,422 General corporate 377 292 341 336 336 332 Worldwide total $ 3,670 3,279 3,226 $ 6,929 5,642 3,754
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	Sales to Customers Long-Lived Assets (6) (Dollars in Millions) 2018 2017 2016 2018 2017 United States $ 41,884 39,863 37,811 $ 37,117 38,556 Europe 18,753 17,126 15,770 51,433 56,677 Western Hemisphere excluding U.S. 6,113 6,041 5,734 2,752 2,990 Asia-Pacific, Africa 14,831 13,420 12,575 2,733 2,773 Segments total 81,581 76,450 71,890 94,035 100,996 General corporate 1,064 1,143 Other non long-lived assets 57,855 55,164 Worldwide total $ 81,581 76,450 71,890 $ 152,954 157,303 ­ See Note 1 for a description of the segments in which the Company operates. Export sales are not significant. In 2018, the Company had three wholesalers distributing products for all three segments that represented approximately 14.0% , 11.0% and 11.0% of the total consolidated revenues. In 2017, the Company had two wholesalers distributing products for all three segments that represented approximately 14.0% and 10.0% of the total consolidated revenues. In 2016, the Company had two wholesalers distributing products for all three segments that represented approximately 13.5% and 10.7% of the total consolidated revenues. (1) Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. (2) General corporate includes cash, cash equivalents and marketable securities. (3) The Consumer segment includes a gain of $0.3 billion from the divestiture of NIZORAL ® and litigation expense of $0.3 billion . The Pharmaceutical segment includes an in-process research and development charge of $1.1 billion related to the Alios and XO1 assets and the corresponding XO1 contingent liability reversal of $0.2 billion , Actelion acquisition related costs of $0.2 billion , unrealized loss on securities of $0.2 billion and a gain of $0.2 billion from the divestiture of certain non-strategic Pharmaceutical products. The Medical Devices segment includes net litigation expense of $1.7 billion , a restructuring related charge of $0.6 billion , AMO acquisition related costs of $0.1 billion and a gain of $0.5 billion from the divestiture of the LifeScan business in the fiscal fourth quarter. (4) The Pharmaceutical segment includes $0.8 billion for Actelion acquisition related costs, an in-process research and development expense of $0.4 billion and litigation expense of $0.1 billion . The Medical Devices segment includes litigation expense of $1.1 billion , a restructuring related charge of $0.8 billion , an asset impairment of $0.2 billion primarily related to the insulin pump business and $0.1 billion for AMO acquisition related costs. The Medical Devices segment includes a gain of $0.7 billion from the divestiture of Codman Neurosurgery. The Consumer segment includes a gain of $0.5 billion from the divestiture of COMPEED ® . (5) Includes net litigation expense of $0.8 billion and a restructuring related charge of $0.7 billion in the Medical Devices segment. The Pharmaceutical segment includes a positive adjustment of $0.5 billion to previous reserve estimates and gains from the divestitures of the controlled substance raw material and active pharmaceutical ingredient (API) business and certain anesthetic products in Europe. (6) Long-lived assets include property, plant and equipment, net for 2018 , and 2017 of $17,035 and $17,005 , respectively, and intangible assets and goodwill, net for 2018 and 2017 of $78,064 and $85,134 , respectively.

Selected Quarterly Financial _2

Selected Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
	Dec. 30, 2018
Selected Quarterly Financial Information [Abstract]
Summary of Selected Quarterly Financial Data (unaudited)	Selected unaudited quarterly financial data for the years 2018 and 2017 are summarized below: 2018 2017 (Dollars in Millions Except Per Share Data) First Quarter (1) Second Quarter (2) Third Quarter (3) Fourth Quarter (4) First Quarter (5) Second Quarter (6) Third Quarter (7) Fourth Quarter (8) Segment sales to customers Consumer $ 3,398 3,504 3,415 3,536 3,228 3,478 3,356 3,540 Pharmaceutical 9,844 10,354 10,346 10,190 8,245 8,635 9,695 9,681 Medical Devices 6,767 6,972 6,587 6,668 6,293 6,726 6,599 6,974 Total sales 20,009 20,830 20,348 20,394 17,766 18,839 19,650 20,195 Gross profit 13,395 13,903 13,759 13,433 12,357 12,993 12,725 12,936 Earnings before provision for taxes on income 5,481 4,973 4,423 3,122 5,575 4,748 4,790 2,560 Net earnings (loss) 4,367 3,954 3,934 3,042 4,422 3,827 3,764 (10,713 ) Basic net earnings (loss) per share $ 1.63 1.47 1.47 1.14 1.63 1.42 1.40 (3.99 ) Diluted net earnings (loss) per share $ 1.60 1.45 1.44 1.12 1.61 1.40 1.37 (3.99 ) (1) The first quarter of 2018 includes an Actelion acquisition related cost of $92 million after-tax ( $96 million before-tax) and a restructuring related charge of $81 million after-tax ( $107 million before-tax). (2) The second quarter of 2018 includes a litigation expense of $609 million after-tax ( $703 million before-tax) and a restructuring related charge of $152 million after-tax ( $176 million before-tax). (3) The third quarter of 2018 includes an in-process research and development expense of $859 million after-tax ( $1,126 million before-tax) related to the Alios and XO1 assets and the corresponding XO1 contingent liability reversal of $184 million after and before tax, a restructuring related charge of $162 million after-tax ( $190 million before-tax) and a $265 million benefit after-tax from the impact of tax legislation. (4) The fourth quarter of 2018 includes a litigation expense of $1,113 million after-tax ( $1,288 million before-tax), a restructuring related charge of $190 million after-tax ( $227 million before-tax) and a $137 million benefit after-tax from the impact of tax legislation. (5) The first quarter of 2017 includes a restructuring charge of $121 million after-tax ( $161 million before-tax) and an AMO acquisition related cost of $251 million after-tax ( $38 million before-tax). (6) The second quarter of 2017 includes a litigation expense of $352 million after-tax ( $493 million before-tax), Actelion acquisition related costs of $199 million after-tax ( $213 million before-tax) a restructuring charge of $101 million after-tax ( $128 million before-tax) and an asset impairment charge of $125 million after-tax ( $182 million before-tax). (7) The third quarter of 2017 includes a litigation expense of $97 million after-tax ( $118 million before-tax), Actelion acquisition related costs of $255 million after-tax ( $367 million before-tax) and a restructuring charge of $136 million after-tax ( $187 million before-tax). (8) The fourth quarter of 2017 includes a litigation expense of $506 million after-tax ( $645 million before-tax), Actelion acquisition related costs of $313 million after-tax ( $217 million before-tax), a restructuring charge of $237 million after-tax ( $284 million before-tax), an in-process research and development expense of $266 million after-tax ( $408 million before-tax) and an after-tax benefit of $116 million related to the insulin pump business. Additionally, the fourth quarter of 2017 includes a provisional charge of $13.6 billion for recently enacted tax legislation.

Business Combinations and Div_2

Business Combinations and Divestitures (Tables)	12 Months Ended
	Dec. 30, 2018
Business Combinations [Abstract]
Schedule of Preliminary Amounts Recognized for Assets Acquired and Liabilities Assumed	(Dollars in Millions) Cash & Cash equivalents 469 Inventory (1) 759 Accounts Receivable 485 Other current assets 93 Property, plant and equipment 104 Goodwill 6,161 Intangible assets 25,010 Deferred Taxes 99 Other non-current assets 19 Total Assets Acquired 33,199 Current liabilities 956 Deferred Taxes 1,776 Other non-current liabilities 413 Total Liabilities Assumed 3,145 Net Assets Acquired 30,054 (1) Includes adjustment of $642 million to write-up the acquired inventory to its estimated fair value.
Purchase Price Allocation of Identifiable Intangible Assets	The purchase price allocation to the identifiable intangible assets is as follows: (Dollars in Millions) Intangible assets with definite lives: Patents and trademarks* $ 24,230 Total amortizable intangibles 24,230 In-process research and development 780 Total intangible assets $ 25,010
Schedule of Pro Forma Results	The following table provides pro forma results of operations for the fiscal year ended December 31, 2017 and January 1, 2017, as if Actelion had been acquired as of January 4, 2016. The pro forma results include the effect of certain purchase accounting adjustments such as the estimated changes in depreciation and amortization expense on the acquired tangible and intangible assets. However, pro forma results do not include any anticipated cost savings or other effects of the planned integration of Actelion. Accordingly, such amounts are not necessarily indicative of the results if the acquisition had occurred on the dates indicated or which may occur in the future. Unaudited Pro forma Consolidated Results (Dollars in Millions Except Per Share Data) 2017 2016 Net Sales 77,681 74,339 Net Earnings 1,509 13,916 Diluted Net Earnings per Common Share 0.55 4.99

Restructuring (Tables)

Restructuring (Tables)	12 Months Ended
	Dec. 30, 2018
Restructuring and Related Activities [Abstract]
Summary of Severance Charges and Associated Spending	The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2018: (Dollars in Millions) Severance Asset Write-offs Other** Total Reserve balance, January 3, 2016 $ 484 — 17 501 2016 activity (104 ) — (16 ) (120 ) Reserve balance, January 1, 2017 380 — 1 381 2017 activity (151 ) — 37 (114 ) Reserve balance, December 31, 2017 229 — 38 267 Current year activity: Charges — 132 568 700 Cash payments (35 ) — (558 ) (593 ) Settled non cash — (132 ) — (132 ) Reserve balance, December 30, 2018* $ 194 — 48 242 *Cash outlays for severance are expected to be substantially paid out over the next 2 years in accordance with the Company's plans and local laws. **Other includes project expense such as salaries for employees supporting the initiative and consulting expenses.

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2017USD ($)	Dec. 30, 2018USD ($)EmployeeSegment	Dec. 31, 2017USD ($)	Jan. 01, 2017USD ($)	Jan. 01, 2018USD ($)
Concentration of Credit Risk [Line Items]
Number of employees | Employee		135,100
Number of business segments | Segment		3
Excess tax benefits				$ 353
GILTI, deferred tax liability	$ 1,600		$ 1,600
Deferred taxes on income	7,105	$ 7,640	7,105
Other assets	4,971	4,182	4,971
Retained earnings	101,793	$ 106,216	$ 101,793
Minimum reverse repurchase agreement collateral (as a percent)		102.00%
Sales return reserve (as a percent)		1.00%	1.00%	1.00%
Percentage of profit share payments (less than)		2.00%	2.00%	2.00%
Shipping and handling costs		$ 1,090	$ 1,042	$ 974
Shipping and handling costs as a percent of sales		0.50%
Advertising expense		$ 2,600	2,500	$ 2,400
Provisional toll tax charge	10,100
Deferred tax liability foreign taxes	4,457	$ 2,240	4,457
Deferred tax asset offset	$ 1,100		$ 1,100
Minimum | Software Development
Concentration of Credit Risk [Line Items]
Estimated useful lives of the assets		3 years
Maximum | Software Development
Concentration of Credit Risk [Line Items]
Estimated useful lives of the assets		8 years
R&D Expense
Concentration of Credit Risk [Line Items]
Concentration risk (as a percent)		5.00%
ASU 2016-16 - Income Taxes: Intra-Entity Transfers
Concentration of Credit Risk [Line Items]
Deferred taxes, net					$ 2,000
Other assets					(700)
Retained earnings					400
Retained Earnings
Concentration of Credit Risk [Line Items]
GILTI, deferred tax liability		$ 1,700			1,700
Retained Earnings | ASU 2014-09 - Revenue from Contracts with Customers
Concentration of Credit Risk [Line Items]
Cumulative effect adjustment					(47)
Retained Earnings | ASU 2016-01 - Financial Instruments
Concentration of Credit Risk [Line Items]
Cumulative effect adjustment					232
Retained Earnings | ASU 2016-16 - Income Taxes: Intra-Entity Transfers
Concentration of Credit Risk [Line Items]
Cumulative effect adjustment					$ (439)

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Impact of Adoption (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 31, 2017	Oct. 01, 2017	Jul. 02, 2017	Apr. 02, 2017	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Sales to customers	$ 20,394	$ 20,348	$ 20,830	$ 20,009	$ 20,195	$ 19,650	$ 18,839	$ 17,766	$ 81,581	$ 76,450	$ 71,890
Net earnings	3,042	$ 3,934	$ 3,954	$ 4,367	(10,713)	$ 3,764	$ 3,827	$ 4,422	15,297	1,300	16,540
Assets	152,954				157,303				152,954	157,303
Liabilities	93,202				97,143				93,202	97,143
Equity	59,752				$ 60,160				59,752	$ 60,160	$ 70,418	$ 71,150
Balance without adoption of ASC 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Sales to customers									81,546
Net earnings									15,269
Assets	152,977								152,977
Liabilities	93,206								93,206
Equity	59,771								59,771
ASU 2014-09 - Revenue from Contracts with Customers | Effect of change
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Sales to customers									(35)
Net earnings									(28)
Assets	23								23
Liabilities	4								4
Equity	$ 19								$ 19

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Adjustments for Accounting Standards Update 2017-07 (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 31, 2017	Oct. 01, 2017	Jul. 02, 2017	Apr. 02, 2017	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Selling, marketing and administrative expenses									$ 22,540	$ 21,520	$ 20,067
Research and development expense									10,775	10,594	9,143
Other (income) expense, net									1,405	(42)	210
Earnings before provision for taxes on income	$ 3,122	$ 4,423	$ 4,973	$ 5,481	$ 2,560	$ 4,790	$ 4,748	$ 5,575	17,999	17,673	19,803
Accounting Standards Update 2017-07
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cost of products sold									51	85	104
Selling, marketing and administrative expenses									55	100	122
Research and development expense									21	40	48
Other (income) expense, net									(127)	(225)	(274)
Earnings before provision for taxes on income									$ 0	$ 0	$ 0

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Cumulative Effect Adjustments (Details) $ in Millions	Jan. 01, 2018USD ($)
Adjustments for New Accounting Pronouncement | Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment	$ (254)
ASU 2014-09 - Revenue from Contracts with Customers | Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment	(47)
ASU 2016-01 - Financial Instruments | Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment	232
ASU 2016-16 - Income Taxes: Intra-Entity Transfers
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred taxes, net	2,000
ASU 2016-16 - Income Taxes: Intra-Entity Transfers | Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment	$ (439)

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)	12 Months Ended
	Dec. 30, 2018
Minimum | Building and building equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	20 years
Minimum | Land And Leasehold Improvements
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	10 years
Minimum | Machinery and Equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	2 years
Maximum | Building and building equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	30 years
Maximum | Land And Leasehold Improvements
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	20 years
Maximum | Machinery and Equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	13 years

Cash, Cash Equivalents and Cu_3

Cash, Cash Equivalents and Current Marketable Securities - Cash and Cash Equivalent Composition (Details) - USD ($) $ in Millions	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Cash & Cash Equivalents	$ 18,107	$ 17,824	$ 18,972	$ 13,732
Current Marketable Securities	1,580	472
Held-to-maturity Securities
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount	9,953	12,986
Estimated Fair Value	9,953	12,986
Cash & Cash Equivalents	9,953	12,880
Current Marketable Securities	0	106
Held-to-maturity Securities | Cash
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount	2,619	2,929
Estimated Fair Value	2,619	2,929
Cash & Cash Equivalents	2,619	2,929
Current Marketable Securities	0	0
Held-to-maturity Securities | Other Sovereign Securities(1)
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount		279
Estimated Fair Value		279
Cash & Cash Equivalents		219
Current Marketable Securities		60
Held-to-maturity Securities | U.S. Reverse repurchase agreements
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount	3,009	4,025
Estimated Fair Value	3,009	4,025
Cash & Cash Equivalents	3,009	4,025
Current Marketable Securities	0	0
Held-to-maturity Securities | Other Reverse repurchase agreements
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount	443
Estimated Fair Value	443
Cash & Cash Equivalents	443
Current Marketable Securities	0
Held-to-maturity Securities | Corporate debt securities(1)
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount		289
Estimated Fair Value		289
Cash & Cash Equivalents		244
Current Marketable Securities		45
Held-to-maturity Securities | Money market funds
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount	3,397	4,288
Estimated Fair Value	3,397	4,288
Cash & Cash Equivalents	3,397	4,288
Current Marketable Securities	0	0
Held-to-maturity Securities | Time deposits(1)
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount	485	1,176
Estimated Fair Value	485	1,176
Cash & Cash Equivalents	485	1,175
Current Marketable Securities	0	1
Available-for-sale Securities
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Cash & Cash Equivalents	8,154	4,944
Current Marketable Securities	1,580	366
Available-for-sale Securities, Amortized Cost Basis	9,734	5,310
Available-for-sale Securities	9,734	5,310
Available-for-sale Securities | Gov't Securities
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Cash & Cash Equivalents	8,144	4,833
Current Marketable Securities	1,330	31
Available-for-sale Securities, Amortized Cost Basis	9,474	4,864
Available-for-sale Securities	9,474	4,864
Available-for-sale Securities | Other Sovereign Securities(1)
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Cash & Cash Equivalents		80
Current Marketable Securities		106
Available-for-sale Securities, Amortized Cost Basis		186
Available-for-sale Securities		186
Available-for-sale Securities | Corporate debt securities(1)
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Cash & Cash Equivalents	10	31
Current Marketable Securities	250	229
Available-for-sale Securities, Amortized Cost Basis	260	260
Available-for-sale Securities	$ 260	$ 260

Cash, Cash Equivalents and Cu_4

Cash, Cash Equivalents and Current Marketable Securities - Contractual Maturities of Available for Sale Securities (Details) $ in Millions	Dec. 30, 2018USD ($)
Cost Basis
Due within one year	$ 9,670
Due after one year through five years	64
Due after five years through ten years	0
Total debt securities	9,734
Fair Value
Due within one year	9,670
Due after one year through five years	64
Due after five years through ten years	0
Total debt securities	$ 9,734

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Dec. 30, 2018	Dec. 31, 2017
Summary of Inventories
Raw materials and supplies	$ 1,114	$ 1,140
Goods in process	2,109	2,317
Finished goods	5,376	5,308
Total inventories	8,599	$ 8,765
Discontinued Operations, Held-for-sale or Disposed of by Sale | AdvancedSterilizationProducts
Inventory [Line Items]
Disposal Group, Including Discontinued Operation, Inventory, Current	200
Discontinued Operations, Held-for-sale or Disposed of by Sale | Supply Chain
Inventory [Line Items]
Disposal Group, Including Discontinued Operation, Inventory, Current	$ 300

Property, Plant and Equipment

Property, Plant and Equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details) - USD ($) $ in Millions	Dec. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment, Net [Abstract]
Land and land improvements	$ 807	$ 829
Buildings and building equipment	11,176	11,240
Machinery and equipment	25,992	25,949
Construction in progress	3,876	3,448
Total property, plant and equipment, gross	41,851	41,466
Less accumulated depreciation	24,816	24,461
Total property, plant and equipment, net	$ 17,035	$ 17,005

Property, Plant and Equipment_2

Property, Plant and Equipment - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Property, Plant and Equipment [Line Items]
Interest expense capitalized	$ 86	$ 94	$ 102
Depreciation expense, including the amortization of capitalized interest	2,600	$ 2,600	$ 2,500
AdvancedSterilizationProducts | Discontinued Operations, Held-for-sale or Disposed of by Sale
Property, Plant and Equipment [Line Items]
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment	100
Supply Chain | Discontinued Operations, Held-for-sale or Disposed of by Sale
Property, Plant and Equipment [Line Items]
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment	$ 100

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Schedule of Intangible Assets and Goodwill (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017
Intangible assets with indefinite lives:
Indefinite lived intangible assets	$ 9,190	$ 11,283
Total intangible assets - net	47,611	53,228
Trademarks
Intangible assets with indefinite lives:
Indefinite lived intangible assets	6,937	7,082
Purchased in-process research and development
Intangible assets with indefinite lives:
Indefinite lived intangible assets	2,253	4,201
Patents And Trademarks
Intangible assets with definite lives:
Finite lived intangible assets gross	35,194	36,427
Less accumulated amortization	9,784	7,223
Finite lived intangible assets net	25,410	29,204
Customer relationships and other intangible assets
Intangible assets with definite lives:
Finite lived intangible assets gross	21,334	20,204
Less accumulated amortization	8,323	7,463
Finite lived intangible assets net	13,011	$ 12,741
Purchased in-process research and development
Intangible assets with indefinite lives:
Reclassified to definite lived intangible assets upon commercialization	800
Alios Biopharma Inc and XO1 Limited | Purchased in-process research and development
Intangible assets with indefinite lives:
Indefinite lived intangible assets	1,100
Alios Biopharma | Purchased in-process research and development
Intangible assets with indefinite lives:
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	800
XO1 | Purchased in-process research and development
Intangible assets with indefinite lives:
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	$ 300

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Goodwill (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017
Goodwill [Roll Forward]
Goodwill beginning of period	$ 31,906	$ 22,805
Goodwill, related to acquisitions (1)	403	8,463
Goodwill, related to divestitures	(1,348)	(177)
Currency translation/other	(508)	815
Goodwill end of period	30,453	31,906
Consumer
Goodwill [Roll Forward]
Goodwill beginning of period	8,875	8,263
Goodwill, related to acquisitions (1)	168	102
Goodwill, related to divestitures	0	(74)
Currency translation/other	(373)	584
Goodwill end of period	8,670	8,875
Pharmaceutical
Goodwill [Roll Forward]
Goodwill beginning of period	9,109	2,840
Goodwill, related to acquisitions (1)	51	6,161
Goodwill, related to divestitures	0	(1)
Currency translation/other	(97)	109
Goodwill end of period	9,063	9,109
Medical Devices
Goodwill [Roll Forward]
Goodwill beginning of period	13,922	11,702
Goodwill, related to acquisitions (1)	184	2,200
Goodwill, related to divestitures	(1,348)	(102)
Currency translation/other	(38)	122
Goodwill end of period	12,720	13,922
Actelion
Goodwill [Roll Forward]
Goodwill end of period	6,161
AMO | Medical Devices
Goodwill [Roll Forward]
Goodwill beginning of period	$ 1,700
Goodwill end of period		$ 1,700

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017	Jul. 02, 2017	Apr. 02, 2017
Finite-Lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	$ 9,190	$ 11,283
Amortization expense of amortizable intangible assets	4,400	3,000	$ 1,200
Finite lived intangibles, amortization expense next twelve months	4,300
Finite lived intangibles, amortization expense, year two	4,300
Finite lived intangibles, amortization expense, year three	4,300
Finite lived intangibles, amortization expense, year four	4,300
Finite lived intangibles, amortization expense, year five	4,300
Goodwill	$ 30,453	31,906	22,805
Patents And Trademarks
Finite-Lived Intangible Assets [Line Items]
Intangible assets useful life	11 years
Customer relationships and other intangible assets
Finite-Lived Intangible Assets [Line Items]
Intangible assets useful life	22 years
Actelion
Finite-Lived Intangible Assets [Line Items]
Goodwill	$ 6,161
Consumer
Finite-Lived Intangible Assets [Line Items]
Goodwill	8,670	8,875	8,263
Medical Devices
Finite-Lived Intangible Assets [Line Items]
Goodwill	12,720	13,922	11,702
Medical Devices | AMO
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets Acquired		2,300
Goodwill		1,700			$ 1,700
Pharmaceutical
Finite-Lived Intangible Assets [Line Items]
Goodwill	9,063	9,109	$ 2,840
Pharmaceutical | Actelion
Finite-Lived Intangible Assets [Line Items]
Goodwill				$ 6,200
Goodwill | AdvancedSterilizationProducts | Medical Devices
Finite-Lived Intangible Assets [Line Items]
Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent	300
Goodwill | LifeScan | Medical Devices
Finite-Lived Intangible Assets [Line Items]
Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent	1,000
Purchased in-process research and development
Finite-Lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	$ 2,253	$ 4,201

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017	Jan. 01, 2018
Derivative [Line Items]
Other Assets, Noncurrent	$ 4,182	$ 4,971
Foreign currency translation	(1,518)	1,696	$ (612)
Deferred net losses (gains) on derivatives included in accumulated other comprehensive income	$ 195
Description of Reclassification of Cash Flow Hedge Gain (Loss)	next 12 months
Maximum length of time for hedging transaction exposure	18 months
Unrealized holding gain (loss) arising during period	$ (1)	159	$ (52)
Foreign exchange contracts
Derivative [Line Items]
Collateral paid	182
Derivative, notional amount	41,100	34,500
Cross currency interest rate swaps
Derivative [Line Items]
Derivative, notional amount	7,300	2,300
Interest rate swaps contracts:
Derivative [Line Items]
Derivative, notional amount	500	1,100
Equity securities | Equity Investments with Readily Determinable Value
Derivative [Line Items]
Marketable Securities, Noncurrent	511	751
Other Assets, Noncurrent	511
Equity, Fair Value Adjustment	(247)
Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period	7
Unrealized holding gain (loss) arising during period		232
Equity securities | Equity Investments without Readily Determinable Value
Derivative [Line Items]
Equity, Fair Value Adjustment, Impairment Loss	54
Other Assets, Noncurrent	681
Equity, Fair Value Adjustment	13
Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period	158
Cost Method Investments	681	$ 510
Equity, Fair Value Adjustment, Change in Observable Prices	$ 67
ASU 2016-01 - Financial Instruments | Retained Earnings
Derivative [Line Items]
Cumulative effect adjustment				$ 232

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	$ (73)	$ (4)	$ (359)
Sales | Interest rate swaps contracts: | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments		0
Sales | Cross currency interest rate swaps contracts: | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	0	0
Unrealized gain (loss) arising during period	0	0
Sales | Cross currency interest rate swaps contracts: | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	0	0
Sales | Forward foreign exchange contracts: | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	(32)	49
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	47	(31)
Cost of Products Sold | Interest rate swaps contracts: | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	0	0
Cost of Products Sold | Cross currency interest rate swaps contracts: | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	0	0
Unrealized gain (loss) arising during period	0	0
Cost of Products Sold | Cross currency interest rate swaps contracts: | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	0	0
Cost of Products Sold | Forward foreign exchange contracts: | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	(17)	96
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	200	(159)
R&D Expense | Interest rate swaps contracts: | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	0	0
R&D Expense | Cross currency interest rate swaps contracts: | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	0	0
Unrealized gain (loss) arising during period	0	0
R&D Expense | Cross currency interest rate swaps contracts: | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	0	0
R&D Expense | Forward foreign exchange contracts: | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	(193)	(199)
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	(220)	(165)
Interest (Income) Expense | Interest rate swaps contracts: | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	5	5
Interest (Income) Expense | Cross currency interest rate swaps contracts: | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	56	0
Unrealized gain (loss) arising during period	56	0
Interest (Income) Expense | Cross currency interest rate swaps contracts: | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	117	110
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	133	83
Interest (Income) Expense | Forward foreign exchange contracts: | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	0	0
Other (Income) Expense
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	0	0
Other (Income) Expense | Interest rate swaps contracts: | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	0	0
Other (Income) Expense | Cross currency interest rate swaps contracts: | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	0	0
Unrealized gain (loss) arising during period	0	0
Other (Income) Expense | Cross currency interest rate swaps contracts: | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	0	0
Other (Income) Expense | Forward foreign exchange contracts: | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	(4)	(60)
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	(24)	(87)
Designated as Hedging Instrument | Sales | Interest rate swaps contracts: | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	0	0
Designated as Hedging Instrument | Cost of Products Sold | Interest rate swaps contracts: | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	0	0
Designated as Hedging Instrument | R&D Expense | Interest rate swaps contracts: | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	0	0
Designated as Hedging Instrument | Interest (Income) Expense | Interest rate swaps contracts: | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	(5)	(5)
Designated as Hedging Instrument | Other (Income) Expense | Interest rate swaps contracts: | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	$ 0	$ 0

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details) - USD ($) $ in Millions	Dec. 30, 2018	Dec. 31, 2017
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Liability	$ 267	$ 367
Current Portion of Long-term Debt
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Liability	494	597
Deferred (Gain) Loss on Discontinuation of Fair Value Hedge	5	2
Long-term Debt
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Liability	0	496
Deferred (Gain) Loss on Discontinuation of Fair Value Hedge	$ 0	$ 3

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017
Forward foreign exchange contracts: | Not Designated as Hedging Instrument | Other (Income) Expense
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	$ (68)	$ (5)
Fair Value Hedging | Interest rate swaps contracts: | Sales
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments		0
Fair Value Hedging | Interest rate swaps contracts: | Other (Income) Expense
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	$ 0	$ 0

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax	$ 218	$ (597)
Cross currency interest rate swaps contracts:
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax	150	0
Sale of Subsidiary Gain (Loss)
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	0	0
Other (Income) Expense
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	$ 0	$ 0

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017
Equity Investment [Roll Forward]
Other Assets, Noncurrent	$ 4,182	$ 4,971
Equity securities | Equity Investments with Readily Determinable Value
Other Investment Not Readily Marketable [Line Items]
Marketable Securities, Noncurrent	511	751
Equity Investment [Roll Forward]
Equity, Fair Value Adjustment	(247)
Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period	7
Other Assets, Noncurrent	511
Equity securities | Equity Investments without Readily Determinable Value
Equity Investment [Roll Forward]
Equity, Fair Value Adjustment	13
Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period	158
Other Assets, Noncurrent	681
Cost Method Investments	$ 681	$ 510

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($) $ in Millions	Dec. 30, 2018	Dec. 31, 2017
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset	$ 694	$ 463
Derivative Asset, Fair Value, Gross Liability	(423)	(76)
Financial assets and liabilities at fair value
Derivative assets	271	387
Derivative liabilities	267	367
Derivative Liability, Fair Value, Gross Liability	872	605
Derivative Liability, Fair Value, Gross Asset	(605)	(238)
Equity Securities
Financial assets and liabilities at fair value
Equity investments	511	751
Level 1
Financial assets and liabilities at fair value
Equity method investments, fair market disclosure	511	751
Debt securities	0
Level 2
Financial assets and liabilities at fair value
Equity method investments, fair market disclosure	0
Debt securities	9,734	5,310
Level 3
Financial assets and liabilities at fair value
Equity method investments, fair market disclosure	0
Debt securities	0
Interest rate swaps contracts:
Financial assets and liabilities at fair value
Non-current assets included in interest rate contracts	6	7
Non-current liabilities included in interest rate contracts	3	9
Designated as Hedging Instrument
Financial assets and liabilities at fair value
Derivative assets	662
Derivative liabilities	840
Designated as Hedging Instrument | Level 1
Financial assets and liabilities at fair value
Derivative assets	0
Derivative liabilities	0
Designated as Hedging Instrument | Level 2
Financial assets and liabilities at fair value
Derivative assets	662	425
Derivative liabilities	840	567
Designated as Hedging Instrument | Level 3
Financial assets and liabilities at fair value
Derivative assets	0
Derivative liabilities	0
Designated as Hedging Instrument | Interest rate swaps contracts:
Financial assets and liabilities at fair value
Derivative assets	161
Derivative liabilities	292
Designated as Hedging Instrument | Interest rate swaps contracts: | Level 1
Financial assets and liabilities at fair value
Derivative assets	0
Derivative liabilities	0
Designated as Hedging Instrument | Interest rate swaps contracts: | Level 2
Financial assets and liabilities at fair value
Derivative assets	161	7
Derivative liabilities	292	165
Designated as Hedging Instrument | Interest rate swaps contracts: | Level 3
Financial assets and liabilities at fair value
Derivative assets	0
Derivative liabilities	0
Designated as Hedging Instrument | Foreign exchange contracts
Financial assets and liabilities at fair value
Derivative assets	501
Derivative liabilities	548
Designated as Hedging Instrument | Foreign exchange contracts | Level 1
Financial assets and liabilities at fair value
Derivative assets	0
Derivative liabilities	0
Designated as Hedging Instrument | Foreign exchange contracts | Level 2
Financial assets and liabilities at fair value
Derivative assets	501	418
Derivative liabilities	548	402
Designated as Hedging Instrument | Foreign exchange contracts | Level 3
Financial assets and liabilities at fair value
Derivative assets	0
Derivative liabilities	0
Not Designated as Hedging Instrument | Foreign exchange contracts
Financial assets and liabilities at fair value
Derivative assets	32
Derivative liabilities	32
Not Designated as Hedging Instrument | Foreign exchange contracts | Level 1
Financial assets and liabilities at fair value
Derivative assets	0
Derivative liabilities	0
Not Designated as Hedging Instrument | Foreign exchange contracts | Level 2
Financial assets and liabilities at fair value
Derivative assets	32	38
Derivative liabilities	32	$ 38
Not Designated as Hedging Instrument | Foreign exchange contracts | Level 3
Financial assets and liabilities at fair value
Derivative assets	0
Derivative liabilities	$ 0

Borrowings - Schedule of Long-t

Borrowings - Schedule of Long-term Debt Instruments (Details) € in Millions, $ in Millions, £ in Billions	Dec. 30, 2018USD ($)	Dec. 30, 2018GBP (£)	Dec. 30, 2018EUR (€)	Dec. 31, 2017USD ($)	Dec. 31, 2017GBP (£)	Dec. 31, 2017EUR (€)
Debt Instrument [Line Items]
Effective interest rate	3.19%	3.19%	3.19%	3.19%	3.19%	3.19%
Borrowed under the commercial paper program				$ 2,300
Less current portion	$ 2,600			1,500
Total long-term debt	27,684			30,675
Carrying (Reported) Amount, Fair Value Disclosure
Debt Instrument [Line Items]
Long-term Debt	30,320			32,174
Less current portion	2,636			1,499
Total long-term debt	$ 27,684			$ 30,675
5.15% Debentures due 2018
Debt Instrument [Line Items]
Effective interest rate				5.18%	5.18%	5.18%
Borrowed under the commercial paper program				$ 900
Stated interest rate (as a percent)				5.15%	5.15%	5.15%
1.65% Notes due 2018
Debt Instrument [Line Items]
Effective interest rate				1.70%	1.70%	1.70%
Borrowed under the commercial paper program				$ 597
Stated interest rate (as a percent)				1.65%	1.65%	1.65%
4.75% Notes due 2019 (1B Euro 1.14)(2)/(1B Euro 1.1947)(3)
Debt Instrument [Line Items]
Effective interest rate	5.83%	5.83%	5.83%	5.83%	5.83%	5.83%
Long-term Debt	$ 1,139			$ 1,192
Stated interest rate (as a percent)	4.75%	4.75%	4.75%	4.75%	4.75%	4.75%
Debt Instrument, Face Amount | €			€ 1,000			€ 1,000
Foreign Currency Exchange Rate, Translation	1.14	1.14	1.14	1.1947	1.1947	1.1947
1.875% Notes due 2019
Debt Instrument [Line Items]
Effective interest rate	1.93%	1.93%	1.93%	1.93%	1.93%	1.93%
Long-term Debt	$ 494			$ 496
Stated interest rate (as a percent)	1.875%	1.875%	1.875%	1.875%	1.875%	1.875%
0.89% Notes due 2019
Debt Instrument [Line Items]
Effective interest rate	1.32%	1.32%	1.32%	1.75%	1.75%	1.75%
Long-term Debt	$ 300			$ 300
Stated interest rate (as a percent)	0.89%	0.89%	0.89%	0.89%	0.89%	0.89%
1.125% Notes due 2019
Debt Instrument [Line Items]
Effective interest rate	1.13%	1.13%	1.13%	1.13%	1.13%	1.13%
Long-term Debt	$ 699			$ 699
Stated interest rate (as a percent)	1.125%	1.125%	1.125%	1.125%	1.125%	1.125%
3% Zero Coupon Convertible Subordinated Debentures due 2020
Debt Instrument [Line Items]
Effective interest rate	3.00%	3.00%	3.00%	3.00%	3.00%	3.00%
Long-term Debt	$ 51			$ 60
Stated interest rate (as a percent)	3.00%	3.00%	3.00%	3.00%	3.00%	3.00%
2.95% Debentures due 2020
Debt Instrument [Line Items]
Effective interest rate	3.15%	3.15%	3.15%	3.15%	3.15%	3.15%
Long-term Debt	$ 548			$ 547
Stated interest rate (as a percent)	2.95%	2.95%	2.95%	2.95%	2.95%	2.95%
1.950% Notes due 2020
Debt Instrument [Line Items]
Effective interest rate	1.99%	1.99%	1.99%	1.99%	1.99%	1.99%
Long-term Debt	$ 499			$ 499
Stated interest rate (as a percent)	1.95%	1.95%	1.95%	1.95%	1.95%	1.95%
3.55% Notes due 2021
Debt Instrument [Line Items]
Effective interest rate	3.67%	3.67%	3.67%	3.67%	3.67%	3.67%
Long-term Debt	$ 449			$ 448
Stated interest rate (as a percent)	3.55%	3.55%	3.55%	3.55%	3.55%	3.55%
2.45% Notes due 2021
Debt Instrument [Line Items]
Effective interest rate	2.48%	2.48%	2.48%	2.48%	2.48%	2.48%
Long-term Debt	$ 349			$ 349
Stated interest rate (as a percent)	2.45%	2.45%	2.45%	2.45%	2.45%	2.45%
1.65% Notes due 2021
Debt Instrument [Line Items]
Effective interest rate	1.65%	1.65%	1.65%	1.65%	1.65%	1.65%
Long-term Debt	$ 998			$ 998
Stated interest rate (as a percent)	1.65%	1.65%	1.65%	1.65%	1.65%	1.65%
0.250% Notes due 2022 (1B Euro 1.14)(2)/(1B Euro 1.1947)(3)
Debt Instrument [Line Items]
Effective interest rate	0.26%	0.26%	0.26%	0.26%	0.26%	0.26%
Long-term Debt	$ 1,137			$ 1,191
Stated interest rate (as a percent)	0.25%	0.25%	0.25%	0.25%	0.25%	0.25%
Debt Instrument, Face Amount | €			€ 1,000			€ 1,000
Foreign Currency Exchange Rate, Translation	1.14	1.14	1.14	1.1947	1.1947	1.1947
2.25% Notes due 2022
Debt Instrument [Line Items]
Effective interest rate	2.31%	2.31%	2.31%	2.31%	2.31%	2.31%
Long-term Debt	$ 996			$ 995
Stated interest rate (as a percent)	2.25%	2.25%	2.25%	2.25%	2.25%	2.25%
6.73% Debentures due 2023
Debt Instrument [Line Items]
Effective interest rate	6.73%	6.73%	6.73%	6.73%	6.73%	6.73%
Long-term Debt	$ 250			$ 250
Stated interest rate (as a percent)	6.73%	6.73%	6.73%	6.73%	6.73%	6.73%
3.375% Notes due 2023
Debt Instrument [Line Items]
Effective interest rate	3.17%	3.17%	3.17%	3.17%	3.17%	3.17%
Long-term Debt	$ 805			$ 806
Stated interest rate (as a percent)	3.375%	3.375%	3.375%	3.375%	3.375%	3.375%
2.05% Notes due 2023
Debt Instrument [Line Items]
Effective interest rate	2.09%	2.09%	2.09%	2.09%	2.09%	2.09%
Long-term Debt	$ 498			$ 498
Stated interest rate (as a percent)	2.05%	2.05%	2.05%	2.05%	2.05%	2.05%
0.650% Notes due 2024 (750MM Euro 1.14)(2)/(750MM Euro 1.1947)(3)
Debt Instrument [Line Items]
Effective interest rate	0.68%	0.68%	0.68%	0.68%	0.68%	0.68%
Long-term Debt	$ 851			$ 891
Stated interest rate (as a percent)	0.65%	0.65%	0.65%	0.65%	0.65%	0.65%
Debt Instrument, Face Amount | €			€ 750			€ 750
Foreign Currency Exchange Rate, Translation	1.14	1.14	1.14	1.1947	1.1947	1.1947
5.50% Notes due 2024 (500MM GBP 1.2636)(2)/(500MM GBP 1.3444)(3)
Debt Instrument [Line Items]
Effective interest rate	6.75%	6.75%	6.75%	6.75%	6.75%	6.75%
Long-term Debt	$ 627			$ 666
Stated interest rate (as a percent)	5.50%	5.50%	5.50%	5.50%	5.50%	5.50%
Debt Instrument, Face Amount | £		£ 0.5			£ 0.5
Foreign Currency Exchange Rate, Translation	1.2636	1.2636	1.2636	1.3444	1.3444	1.3444
2.625% Notes due 2025
Debt Instrument [Line Items]
Effective interest rate	2.63%	2.63%	2.63%	2.63%	2.63%	2.63%
Long-term Debt	$ 748			$ 747
Stated interest rate (as a percent)	2.625%	2.625%	2.625%	2.625%	2.625%	2.625%
2.45% Notes due 2026
Debt Instrument [Line Items]
Effective interest rate	2.47%	2.47%	2.47%	2.47%	2.47%	2.47%
Long-term Debt	$ 1,992			$ 1,990
Stated interest rate (as a percent)	2.45%	2.45%	2.45%	2.45%	2.45%	2.45%
2.95% Notes due 2027
Debt Instrument [Line Items]
Effective interest rate	2.96%	2.96%	2.96%	2.96%	2.96%	2.96%
Long-term Debt	$ 996			$ 995
Stated interest rate (as a percent)	2.95%	2.95%	2.95%	2.95%	2.95%	2.95%
1.150% Notes due 2028 (750MM Euro 1.14)(2)/(750MM Euro 1.1947)(3)
Debt Instrument [Line Items]
Effective interest rate	1.21%	1.21%	1.21%	1.21%	1.21%	1.21%
Long-term Debt	$ 847			$ 887
Stated interest rate (as a percent)	1.15%	1.15%	1.15%	1.15%	1.15%	1.15%
Debt Instrument, Face Amount | €			€ 750			€ 750
Foreign Currency Exchange Rate, Translation	1.14	1.14	1.14	1.1947	1.1947	1.1947
2.900% Notes due 2028
Debt Instrument [Line Items]
Effective interest rate	2.91%	2.91%	2.91%	2.91%	2.91%	2.91%
Long-term Debt	$ 1,493			$ 1,492
Stated interest rate (as a percent)	2.90%	2.90%	2.90%	2.90%	2.90%	2.90%
6.95% Notes due 2029
Debt Instrument [Line Items]
Effective interest rate	7.14%	7.14%	7.14%	7.14%	7.14%	7.14%
Long-term Debt	$ 297			$ 296
Stated interest rate (as a percent)	6.95%	6.95%	6.95%	6.95%	6.95%	6.95%
4.95% Debentures due 2033
Debt Instrument [Line Items]
Effective interest rate	4.95%	4.95%	4.95%	4.95%	4.95%	4.95%
Long-term Debt	$ 498			$ 498
Stated interest rate (as a percent)	4.95%	4.95%	4.95%	4.95%	4.95%	4.95%
4.375% Notes due 2033
Debt Instrument [Line Items]
Effective interest rate	4.24%	4.24%	4.24%	4.24%	4.24%	4.24%
Long-term Debt	$ 856			$ 856
Stated interest rate (as a percent)	4.375%	4.375%	4.375%	4.375%	4.375%	4.375%
1.650% Notes due 2035 (1.5B Euro 1.14)(2)/(1.5B Euro 1.1947)(3)
Debt Instrument [Line Items]
Effective interest rate	1.68%	1.68%	1.68%	1.68%	1.68%	1.68%
Long-term Debt	$ 1,693			$ 1,774
Stated interest rate (as a percent)	1.65%	1.65%	1.65%	1.65%	1.65%	1.65%
Debt Instrument, Face Amount | €			€ 1,500			€ 1,500
Foreign Currency Exchange Rate, Translation	1.14	1.14	1.14	1.1947	1.1947	1.1947
3.55% Notes due 2036
Debt Instrument [Line Items]
Effective interest rate	3.59%	3.59%	3.59%	3.59%	3.59%	3.59%
Long-term Debt	$ 988			$ 987
Stated interest rate (as a percent)	3.55%	3.55%	3.55%	3.55%	3.55%	3.55%
5.95% Notes due 2037
Debt Instrument [Line Items]
Effective interest rate	5.99%	5.99%	5.99%	5.99%	5.99%	5.99%
Long-term Debt	$ 991			$ 991
Stated interest rate (as a percent)	5.95%	5.95%	5.95%	5.95%	5.95%	5.95%
3.625% Notes due 2037
Debt Instrument [Line Items]
Effective interest rate	3.64%	3.64%	3.64%	3.64%	3.64%	3.64%
Long-term Debt	$ 1,486			$ 1,486
Stated interest rate (as a percent)	3.625%	3.625%	3.625%	3.625%	3.625%	3.625%
5.85% Debentures due 2038
Debt Instrument [Line Items]
Effective interest rate	5.85%	5.85%	5.85%	5.85%	5.85%	5.85%
Long-term Debt	$ 696			$ 696
Stated interest rate (as a percent)	5.85%	5.85%	5.85%	5.85%	5.85%	5.85%
3.400% Notes due 2038
Debt Instrument [Line Items]
Effective interest rate	3.42%	3.42%	3.42%	3.42%	3.42%	3.42%
Long-term Debt	$ 990			$ 990
Stated interest rate (as a percent)	3.40%	3.40%	3.40%	3.40%	3.40%	3.40%
4.50% Debentures due 2040
Debt Instrument [Line Items]
Effective interest rate	4.63%	4.63%	4.63%	4.63%	4.63%	4.63%
Long-term Debt	$ 538			$ 538
Stated interest rate (as a percent)	4.50%	4.50%	4.50%	4.50%	4.50%	4.50%
4.85% Notes due 2041
Debt Instrument [Line Items]
Effective interest rate	4.89%	4.89%	4.89%	4.89%	4.89%	4.89%
Long-term Debt	$ 297			$ 296
Stated interest rate (as a percent)	4.85%	4.85%	4.85%	4.85%	4.85%	4.85%
4.50% Notes due 2043
Debt Instrument [Line Items]
Effective interest rate	4.52%	4.52%	4.52%	4.52%	4.52%	4.52%
Long-term Debt	$ 495			$ 495
Stated interest rate (as a percent)	4.50%	4.50%	4.50%	4.50%	4.50%	4.50%
3.70% Notes due 2046
Debt Instrument [Line Items]
Effective interest rate	3.74%	3.74%	3.74%	3.74%	3.74%	3.74%
Long-term Debt	$ 1,972			$ 1,971
Stated interest rate (as a percent)	3.70%	3.70%	3.70%	3.70%	3.70%	3.70%
3.75% Notes due 2047
Debt Instrument [Line Items]
Effective interest rate	3.76%	3.76%	3.76%	3.76%	3.76%	3.76%
Long-term Debt	$ 991			$ 990
Stated interest rate (as a percent)	3.75%	3.75%	3.75%	3.75%	3.75%	3.75%
3.500% Notes due 2048
Debt Instrument [Line Items]
Effective interest rate	3.52%	3.52%	3.52%	3.52%	3.52%	3.52%
Long-term Debt	$ 742			$ 742
Stated interest rate (as a percent)	3.50%	3.50%	3.50%	3.50%	3.50%	3.50%
Other
Debt Instrument [Line Items]
Effective interest rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-term Debt	$ 24			$ 75

Borrowings - Narrative (Details

Borrowings - Narrative (Details) - USD ($) $ in Billions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017
Debt Disclosure [Abstract]
Excess of fair value over carrying value of debt	$ 0.3	$ 2
Line of Credit Facility, Initiation Date	Sep. 13, 2018
Borrowing capacity under credit facility	$ 10
Line of Credit Facility, Expiration Date	Sep. 12, 2019
Short-term borrowings and the current portion of long-term debt	$ 2.8	3.9
Borrowed under the commercial paper program		2.3
Current portion of long term debt	$ 2.6	$ 1.5

Borrowings - Aggregate Maturiti

Borrowings - Aggregate Maturities of Long Term Obligations (Details) $ in Millions	Dec. 30, 2018USD ($)
Aggregate maturities of long-term obligations
2,019	$ 2,636
2,020	1,098
2,021	1,796
2,022	2,134
2,023	1,553
After 2,023	$ 21,103

Income Taxes - Provision for I

Income Taxes - Provision for Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Income Tax Disclosure [Abstract]
Increase in effective tax rate (as a percent)		73.30%	(77.60%)	9.00%
Currently payable:
U.S. taxes			$ 1,081	$ 11,969	$ 1,896
U.S. taxes on international operations			203	126	49
International taxes			2,434	1,872	1,659
Total currently payable			3,718	13,967	3,604
Deferred:
U.S. taxes			(148)	(1,956)	294
U.S. taxes on international operations			1,358
International taxes			(2,226)	4,362	(635)
Total deferred	$ 1,900		(1,016)	2,406	(341)
Provision for taxes on income			$ 2,702	$ 16,373	$ 3,263

Income Taxes - Comparison of I

Income Taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 31, 2017	Oct. 01, 2017	Jul. 02, 2017	Apr. 02, 2017	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract
U.S.									$ 5,575	$ 4,865	$ 7,457
International									12,424	12,808	12,346
Earnings before provision for taxes on income	$ 3,122	$ 4,423	$ 4,973	$ 5,481	$ 2,560	$ 4,790	$ 4,748	$ 5,575	$ 17,999	$ 17,673	$ 19,803
Tax Rates:
U.S. statutory rate									21.00%	35.00%	35.00%
International operations (1)									(3.70%)	(12.80%)	(17.20%)
Research and orphan drug tax credits									(1.00%)	(0.40%)	(0.40%)
U.S. state and local									0.80%	0.60%	(0.10%)
U.S. manufacturing deduction									(0.00%)	(0.80%)	(0.60%)
U.S. tax on international income (2)									1.40%	0.70%	1.30%
Tax benefits on share-based compensation									(1.50%)	(2.10%)	(1.80%)
U.S. tax benefit on asset/business disposals									0.50%	(0.80%)	0.00%
All other									(0.60%)	(0.10%)	0.30%
TCJA and related impacts (3)									(1.90%)	73.30%	0.00%
Effective tax rate									15.00%	92.60%	16.50%
Increase in effective tax rate (as a percent)					73.30%				(77.60%)	9.00%
Foreign Tax Authority
Tax Rates:
Increase in effective tax rate (as a percent)									11.00%
State and Local Jurisdiction
Tax Rates:
Increase in effective tax rate (as a percent)									0.60%
Administration of the Treasury, Belgium
Tax Rates:
Increase in effective tax rate (as a percent)									3.40%

Income Taxes - Temporary Diffe

Income Taxes - Temporary Differences and Carryforwards (Details) - USD ($) $ in Millions	Dec. 30, 2018	Dec. 31, 2017
Components of Deferred Tax Assets and Liabilities [Abstract]
Deferred Tax Assets, Employee related obligations	$ 2,398	$ 2,259
Deferred Tax Assets, Stock based compensation	639	507
Deferred Tax Assets, Property, Plant and Equipment	1,784
Deferred Tax Assets, International R&D capitalized for tax	1,282	1,307
Deferred Tax Assets, Reserves & liabilities	1,647	1,718
Deferred Tax Assets, Income reported for tax purposes	1,104	1,316
Deferred Tax Assets, Net operating loss carryforward international	786	762
Deferred Tax Assets, Undistributed Foreign Earnings	693	1,101
Deferred Tax Liabilities, Non-deductible intangibles	(5,967)	(6,506)
Deferred Tax Liabilities, Undistributed Foreign Earnings	(2,240)	(4,457)
Deferred Tax Liability, Global Intangible Low-Taxed Income	(2,971)
Deferred Tax Assets, Miscellaneous international	603	755
Deferred Tax Assets Other Domestic	469	177
Deferred Tax Assets, Total deferred income taxes	11,405	9,902
Deferred Tax Liabilities, Depreciation		(9)
Deferred Tax Liabilities, Miscellaneous international	(93)	(194)
Deferred Tax Liabilities, Total deferred income taxes	$ (11,271)	$ (11,166)

Income Taxes - Summary of Acti

Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Summary of unrecognized tax benefits
Beginning of year	$ 3,151	$ 3,041	$ 3,080
Increases related to current year tax positions	242	332	348
Increases related to prior period tax positions	145	232	11
Decreases related to prior period tax positions	(137)	(416)	(338)
Settlements	(40)	(2)	(37)
Lapse of statute of limitations	(35)	(36)	(23)
End of year	$ 3,326	3,151	$ 3,041
Unrecognized tax benefits decrease from TCJA		$ 347

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017	Jan. 01, 2018	Jan. 03, 2016
Tax Credit Carryforward [Line Items]
U.S. statutory rate			21.00%	35.00%	35.00%
TCJA, provisional liability	$ 8,200		$ 8,200
Provisional tax cost		$ 13,000	200
Provisional toll tax charge		10,100
Deferred tax liability foreign taxes	2,240	4,457	$ 2,240	$ 4,457
Deferred tax asset offset		1,100		1,100
Remeasurement of deferred tax assets and liabilities		600
GILTI, deferred tax cost	1,400
GILTI, deferred tax liability		$ 1,600		$ 1,600
Increase (decrease) in effective tax rate (as a percent)		73.30%	(77.60%)	9.00%
Deferred tax liability, repatriation of foreign earnings	2,800		$ 2,800
Deferred tax asset, foreign tax credits	900		900
Net deferred tax benefit	1,900		(1,016)	$ 2,406	$ (341)
Deferred tax assets, net	2,000		$ 2,000
Effective income tax rate reconciliation, deduction			1.70%
Effective income tax rate reconciliation, TCJA			1.90%	(73.30%)	(0.00%)
Effective income tax rate reconciliation, GILTI			1.60%
Effective income tax rate reconciliation, stock-based compensation			1.50%	2.00%
Effective income tax rate reconciliation, divestiture of business			0.80%
Increase in effective tax rate from prior period (as a percent)			76.10%
Unrecognized tax benefits	3,326	$ 3,151	$ 3,326	$ 3,151	$ 3,041		$ 3,080
Unrecognized tax benefits, interest on income tax expense			53	60	$ 7
Unrecognized tax benefits, interest on income taxes accrued	503	436	$ 503	436
State and Local Jurisdiction
Tax Credit Carryforward [Line Items]
Deferred tax liability foreign taxes		$ 100		$ 100
Increase (decrease) in effective tax rate (as a percent)			0.60%
Retained Earnings
Tax Credit Carryforward [Line Items]
GILTI, deferred tax liability	$ 1,700		$ 1,700			$ 1,700
Administration of the Treasury, Belgium
Tax Credit Carryforward [Line Items]
Increase (decrease) in effective tax rate (as a percent)			3.40%

Employee Related Obligations -

Employee Related Obligations - Employee Related Obligations (Details) - USD ($) $ in Millions	Dec. 30, 2018	Dec. 31, 2017
Employee-related Liabilities [Abstract]
Pension benefits	$ 5,327	$ 5,343
Postretirement benefits	2,283	2,331
Postemployment benefits	2,330	2,250
Deferred compensation	410	475
Total employee obligations	10,350	10,399
Less current benefits payable	399	325
Employee related obligations — non-current	$ 9,951	$ 10,074

Employee Related Obligations _2

Employee Related Obligations - Narrative (Details) - USD ($) $ in Millions	Dec. 30, 2018	Dec. 31, 2017
Compensation Related Costs [Abstract]
Prepaid employee related obligations	$ 475	$ 526

Pensions and Other Benefit Pl_3

Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Retirement Plans
Components of net periodic benefit cost
Service cost	$ 1,283	$ 1,080	$ 949
Interest cost	996	927	927
Expected return on plan assets	(2,212)	(2,041)	(1,962)
Amortization of prior service cost (credit)	3	2	1
Recognized actuarial losses	852	609	496
Curtailments and settlements	1	17	11
Net periodic benefit cost	923	594	422
Other Benefit Plans
Components of net periodic benefit cost
Service cost	269	247	224
Interest cost	148	159	158
Expected return on plan assets	(7)	(6)	(6)
Amortization of prior service cost (credit)	(31)	(30)	(34)
Recognized actuarial losses	123	138	135
Curtailments and settlements	0	0	0
Net periodic benefit cost	$ 502	$ 508	$ 477

Pensions and Other Benefit Pl_4

Pensions and Other Benefit Plans - Amounts Expected to be Recognized in Net Periodic Benefit Cost (Details) $ in Millions	Dec. 30, 2018USD ($)
Pension and Other Postretirement Benefit Plans, Amounts that Will be Amortized from Accumulated Other Comprehensive Income (Loss) in Next Fiscal Year [Abstract]
Amortization of net transition obligation	$ 0
Amortization of net actuarial losses	656
Amortization of prior service credit	$ 27

Pensions and Other Benefit Pl_5

Pensions and Other Benefit Plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Retirement Plans
Net Periodic Benefit Cost
Service cost discount rate	3.20%	3.59%	3.98%
Interest cost discount rate	3.60%	3.98%	4.24%
Rate of increase in compensation levels	3.98%	4.01%	4.02%
Expected long-term rate of return on plan assets	8.46%	8.43%	8.55%
Benefit Obligation
Discount rate	3.76%	3.30%	3.78%
Rate of increase in compensation levels	3.97%	3.99%	4.02%
Other Benefit Plans
Net Periodic Benefit Cost
Service cost discount rate	3.85%	4.63%	4.77%
Interest cost discount rate	3.62%	3.94%	4.10%
Rate of increase in compensation levels	4.29%	4.31%	4.32%
Benefit Obligation
Discount rate	4.40%	3.78%	4.42%
Rate of increase in compensation levels	4.29%	4.30%	4.29%

Pensions and Other Benefit Pl_6

Pensions and Other Benefit Plans - Assumed Health Care Cost Trend Rates (Details)	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017
Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]
Health care cost trend rate assumed for next year	6.12%	6.33%
Rate to which the cost trend rate is assumed to decline (ultimate trend)	4.55%	4.55%
Year the rate reaches the ultimate trend rate	2,038	2,038

Pensions and Other Benefit Pl_7

Pensions and Other Benefit Plans - Effect of One Percentage Point Change in Assumed Health Care Cost Trend Rates (Details) $ in Millions	12 Months Ended
	Dec. 30, 2018USD ($)
Effect of one percentage point change in assumed health care cost trend rates
Effect of one percentage point increase on total interest and service cost	$ 28
Effect of one percentage point decrease on total interest and service cost	(22)
Effect of one percentage point increase on post-retirement benefit obligation	340
Effect of one percentage point decrease on post-retirement benefit obligation	$ (280)

Pensions and Other Benefit Pl_8

Pensions and Other Benefit Plans - Schedule of Net Funded Status (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Amounts Recognized in the Company’s Balance Sheet consist of the following:
Non-current assets	$ 475	$ 526
Current liabilities	(399)	(325)
Non-current liabilities	(9,951)	(10,074)
Retirement Plans
Change in Benefit Obligation
Projected benefit obligation - beginning of year	33,221	28,116
Service cost	1,283	1,080	$ 949
Interest cost	996	927	927
Plan participant contributions	66	60
Amendments	26	(7)
Actuarial (gains) losses	(2,326)	2,996
Divestitures & acquisitions	(29)	201
Curtailments, settlements & restructuring	(21)	(35)
Benefits paid from plan	(1,018)	(1,050)
Effect of exchange rates	(528)	933
Projected benefit obligation - end of year	31,670	33,221	28,116
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Plan assets at fair value — beginning of year	28,404	23,633
Actual return on plan assets	(1,269)	4,274
Company contributions	1,140	664
Plan participant contributions	66	60
Settlements	(13)	(32)
Divestitures & acquisitions	(17)	173
Benefits paid from plan assets	(1,018)	(1,050)
Effect of exchange rates	(475)	682
Plan assets at fair value - End of year	26,818	28,404	23,633
Funded status - end of year	(4,852)	(4,817)
Amounts Recognized in the Company’s Balance Sheet consist of the following:
Non-current assets	475	526
Current liabilities	(98)	(92)
Non-current liabilities	(5,229)	(5,251)
Total recognized in the consolidated balance sheet — end of year	(4,852)	(4,817)
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]
Net actuarial loss	8,323	8,140
Prior service cost (credit)	2	(25)
Unrecognized net transition obligation	0	0
Total before tax effects	8,325	8,115
Accumulated Benefit Obligation	28,533	29,793
Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]
Net periodic benefit cost	923	594	422
Net actuarial (gain) loss	1,153	740
Amortization of net actuarial loss	(852)	(609)
Prior service cost (credit)	26	(7)
Amortization of prior service (cost) credit	(3)	(2)
Effect of exchange rates	(114)	256
Total loss/(income) recognized in other comprehensive income, before tax	210	378
Total recognized in net periodic benefit cost and other comprehensive income	1,133	972
Other Benefit Plans
Change in Benefit Obligation
Projected benefit obligation - beginning of year	4,582	4,605
Service cost	269	247	224
Interest cost	148	159	158
Plan participant contributions	0	0
Amendments	0	(17)
Actuarial (gains) losses	(119)	(166)
Divestitures & acquisitions	0	88
Curtailments, settlements & restructuring	0	2
Benefits paid from plan	(383)	(351)
Effect of exchange rates	(17)	15
Projected benefit obligation - end of year	4,480	4,582	4,605
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Plan assets at fair value — beginning of year	281	75
Actual return on plan assets	0	12
Company contributions	282	545
Plan participant contributions	0	0
Settlements	0	0
Divestitures & acquisitions	0	0
Benefits paid from plan assets	(383)	(351)
Effect of exchange rates	0	0
Plan assets at fair value - End of year	180	281	75
Funded status - end of year	(4,300)	(4,301)
Amounts Recognized in the Company’s Balance Sheet consist of the following:
Non-current assets	0	0
Current liabilities	(281)	(228)
Non-current liabilities	(4,019)	(4,073)
Total recognized in the consolidated balance sheet — end of year	(4,300)	(4,301)
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]
Net actuarial loss	1,263	1,500
Prior service cost (credit)	(106)	(137)
Unrecognized net transition obligation	0	0
Total before tax effects	1,157	1,363
Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]
Net periodic benefit cost	502	508	$ 477
Net actuarial (gain) loss	(111)	(169)
Amortization of net actuarial loss	(123)	(138)
Prior service cost (credit)	0	(17)
Amortization of prior service (cost) credit	31	30
Effect of exchange rates	(3)	3
Total loss/(income) recognized in other comprehensive income, before tax	(206)	(291)
Total recognized in net periodic benefit cost and other comprehensive income	$ 296	$ 217

Pensions and Other Benefit Pl_9

Pensions and Other Benefit Plans - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Defined Benefit Plan Disclosure [Line Items]
Percentage of corridor of greater of market value of assets	10.00%
Accumulated benefit obligation unfunded plans	$ 7,500	$ 3,800
Projected benefit obligation, unfunded plans	8,800	4,600
Plan Assets	4,300	700
Fair value of company's common stock directly held in plan assets	$ 876	$ 938
Percentage of company's common stock to plan asset	3.30%	3.30%
Retirement Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	$ 26,818	$ 28,404	$ 23,633
Other Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	180	281	$ 75
U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	679
International Plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	461
Commingled funds | Level 2 | Other Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	72	81
Short-term Investments | Level 2 | Other Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	$ 108	$ 200
Minimum | Retirement Plans
Defined Benefit Plan Disclosure [Line Items]
Retirement plan benefits Employee compensation Period	3 years
Maximum | Retirement Plans
Defined Benefit Plan Disclosure [Line Items]
Retirement plan benefits Employee compensation Period	5 years

Pensions and Other Benefit P_10

Pensions and Other Benefit Plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details) - USD ($) $ in Millions	Dec. 30, 2018	Dec. 31, 2017
Qualified Plans | U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	$ 17,725	$ 18,681
Projected Benefit Obligation	18,609	19,652
Accumulated Benefit Obligation	16,851	17,654
Projected Benefit Obligation	(884)	(971)
Accumulated Benefit Obligation	874	1,027
Non-Qualified Plans | U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Projected Benefit Obligation	2,176	2,257
Accumulated Benefit Obligation	1,793	1,849
Projected Benefit Obligation	(2,176)	(2,257)
Accumulated Benefit Obligation	(1,793)	(1,849)
Funded Plans | International Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	9,093	9,723
Projected Benefit Obligation	10,467	10,863
Accumulated Benefit Obligation	9,510	9,893
Projected Benefit Obligation	(1,374)	(1,140)
Accumulated Benefit Obligation	(417)	(170)
Unfunded Plans | International Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Projected Benefit Obligation	418	449
Accumulated Benefit Obligation	379	397
Projected Benefit Obligation	(418)	(449)
Accumulated Benefit Obligation	$ (379)	$ (397)

Pensions and Other Benefit P_11

Pensions and Other Benefit Plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details) $ in Millions	Dec. 30, 2018USD ($)
Retirement plans
Defined Benefit Plan Disclosure [Line Items]
2,019	$ 1,062
2,020	1,104
2,021	1,182
2,022	1,257
2,023	1,332
2024-2028	7,679
Other benefit plans
Defined Benefit Plan Disclosure [Line Items]
2,019	375
2,020	397
2,021	411
2,022	428
2,023	413
2024-2028	$ 2,273

Pensions and Other Benefit P_12

Pensions and Other Benefit Plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details) $ in Millions	Dec. 30, 2018USD ($)
Retirement Benefits [Abstract]
2,019	$ 92
2,020	95
2,021	101
2,022	108
2,023	115
2024-2028	$ 697

Pensions and Other Benefit P_13

Pensions and Other Benefit Plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)	Dec. 30, 2018	Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Percent of Plan Assets	100.00%	100.00%
Target Allocation	100.00%
Equity securities
Defined Benefit Plan Disclosure [Line Items]
Percent of Plan Assets	71.00%	76.00%
Target Allocation	70.00%
Debt securities
Defined Benefit Plan Disclosure [Line Items]
Percent of Plan Assets	29.00%	24.00%
Target Allocation	30.00%

Pensions and Other Benefit P_14

Pensions and Other Benefit Plans - Schedule of Defined Benefit Plans Disclosures (Details) - Retirement plans - USD ($) $ in Millions	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	$ 26,818	$ 28,404	$ 23,633
Fair Value, Measurements, Recurring
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	26,818	28,404
Investments Measured at Net Asset Value	5,502	6,436
Fair Value, Measurements, Recurring | Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	11,420	14,277
Fair Value, Measurements, Recurring | Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	9,570	7,435
Fair Value, Measurements, Recurring | Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	326	256
Fair Value, Measurements, Recurring | Short-term investment funds
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	651	856
Fair Value, Measurements, Recurring | Short-term investment funds | Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	122	429
Fair Value, Measurements, Recurring | Short-term investment funds | Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	529	427
Fair Value, Measurements, Recurring | Short-term investment funds | Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring | Government and agency securities
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	3,595	3,094
Fair Value, Measurements, Recurring | Government and agency securities | Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring | Government and agency securities | Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	3,595	3,094
Fair Value, Measurements, Recurring | Government and agency securities | Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring | Debt instruments
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	3,105	2,013
Fair Value, Measurements, Recurring | Debt instruments | Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring | Debt instruments | Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	3,105	2,013
Fair Value, Measurements, Recurring | Debt instruments | Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	11,302	13,848
Fair Value, Measurements, Recurring | Equity securities | Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	11,298	13,848
Fair Value, Measurements, Recurring | Equity securities | Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	4	0
Fair Value, Measurements, Recurring | Equity securities | Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring | Commingled funds
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	7,638	7,995
Investments Measured at Net Asset Value	5,201	6,158
Fair Value, Measurements, Recurring | Commingled funds | Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring | Commingled funds | Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	2,304	1,780
Fair Value, Measurements, Recurring | Commingled funds | Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	133	57
Fair Value, Measurements, Recurring | Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	193	199
Investments Measured at Net Asset Value	0	0
Fair Value, Measurements, Recurring | Insurance contracts | Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring | Insurance contracts | Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring | Insurance contracts | Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	193	199
Fair Value, Measurements, Recurring | Other assets
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	334	399
Investments Measured at Net Asset Value	301	278
Fair Value, Measurements, Recurring | Other assets | Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring | Other assets | Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	33	121
Fair Value, Measurements, Recurring | Other assets | Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	$ 0	$ 0

Savings Plan - Narrative (Deta

Savings Plan - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Savings Plan [Abstract]
Matching contributions	$ 242	$ 214	$ 191

Capital and Treasury Stock - Ch

Capital and Treasury Stock - Changes in Treasury Stock (Details) - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Changes in Treasury Stock Shares Outstanding [Roll Forward]
Treasury Stock, Balance, Shares	437,318	413,332	364,681
Employee compensation and stock option plans, Shares	(22,082)	(25,508)	(30,839)
Treasury Stock, Ending Balance, Shares	457,519	437,318	413,332
Changes in treasury stock
Treasury Stock, Balance	$ 31,554	$ 28,352	$ 22,684
Employee compensation and stock option plans related to treasury stock	(3,060)	(3,156)	(3,311)
Repurchase of common stock, Amounts	5,868	6,358	8,979
Treasury Stock, Ending Balance	$ 34,362	$ 31,554	$ 28,352
Treasury Stock
Changes in Treasury Stock Shares Outstanding [Roll Forward]
Repurchase of common stock, Shares	42,283	49,494	79,490
Changes in treasury stock
Repurchase of common stock, Amounts	$ 5,868	$ 6,358	$ 8,979

Capital and Treasury Stock - Na

Capital and Treasury Stock - Narrative (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017	Dec. 17, 2018	Oct. 13, 2015
Equity, Class of Treasury Stock [Line Items]
Common stock, shares issued (in shares)	3,119,843	3,119,843	3,119,843
Cash dividends paid (in dollars per share)	$ 3.54	$ 3.32	$ 3.15
Payments for Repurchase of Common Stock	$ 5,868	$ 6,358	$ 8,979
December 17, 2018 Share Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount				$ 5,000
Payments for Repurchase of Common Stock	$ 900
October 13, 2015 Share Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount					$ 10,000

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance		$ 60,160	$ 70,418	$ 71,150
Net change		(1,791)	1,702	(1,736)
Cumulative adjustment	[1]	(486)
Ending Balance		59,752	60,160	70,418
Foreign Currency Translation
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance		(7,351)	(9,047)	(8,435)
Net change		(1,518)	1,696	(612)
Ending Balance		(8,869)	(7,351)	(9,047)
Gain/(Loss) On Securities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance		232	411	604
Net change		0	(179)	(193)
Cumulative adjustment		(232)
Ending Balance		0	232	411
Employee Benefit Plans
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance		(6,150)	(5,980)	(5,298)
Net change		(8)	(170)	(682)
Ending Balance		(6,158)	(6,150)	(5,980)
Gain/ (Loss) On Derivatives & Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance		70	(285)	(36)
Net change		(265)	355	(249)
Ending Balance		(195)	70	(285)
Accumulated Other Comprehensive Income
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance		(13,199)	(14,901)	(13,165)
Net change		(1,791)	1,702	(1,736)
Cumulative adjustment	[1]	(232)
Ending Balance		$ (15,222)	$ (13,199)	$ (14,901)
[1]	(1) See Note 1 to Consolidated Financial Statements for additional details on the effect of cumulative adjustments to retained earnings.

International Currency Transl_2

International Currency Translation - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Foreign Currency Translation [Abstract]
Foreign currency transaction gain (loss), before tax	$ (265)	$ (216)	$ (289)

Earnings Per Share - Reconcilia

Earnings Per Share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details) - $ / shares shares in Millions	3 Months Ended								12 Months Ended
	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 31, 2017	Oct. 01, 2017	Jul. 02, 2017	Apr. 02, 2017	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Reconciliation of basic net earnings per share to diluted net earnings per share
Basic net earnings per share (in dollars per share)	$ 1.14	$ 1.47	$ 1.47	$ 1.63	$ (3.99)	$ 1.40	$ 1.42	$ 1.63	$ 5.70	$ 0.48	$ 6.04
Average shares outstanding — basic (in shares)									2,681.5	2,692	2,737.3
Potential shares exercisable under stock option plans (in shares)									139	139.7	142.4
Less: shares repurchased under treasury stock method (in shares)									(92.5)	(87.3)	(92.1)
Convertible debt shares (in shares)									0.7	0.9	1.3
Average shares outstanding - diluted (in shares)									2,728.7	2,745.3	2,788.9
Diluted net earnings per share (in dollars per share)	$ 1.12	$ 1.44	$ 1.45	$ 1.60	$ (3.99)	$ 1.37	$ 1.40	$ 1.61	$ 5.61	$ 0.47	$ 5.93

Earnings Per Share - Narrative

Earnings Per Share - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Earnings Per Share [Abstract]
Interest expense convertible debt	$ 1	$ 1	$ 2

Rental Expense and Lease Comm_3

Rental Expense and Lease Commitments - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Leases, Operating [Abstract]
Rentals under operating leases	$ 332	$ 372	$ 330

Rental Expense and Lease Comm_4

Rental Expense and Lease Commitments - Schedule of Minimum Rental Payments Under Operating Leases (Details) $ in Millions	Dec. 30, 2018USD ($)
Minimum rental payments under operating leases
2,019	$ 223
2,020	188
2,021	154
2,022	116
2,023	76
After 2,023	139
Total	$ 896

Common Stock, Stock Option Pl_3

Common Stock, Stock Option Plans and Stock Compensation Agreements - Narrative (Details) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 30, 2018USD ($)StockBasedCompensationPlans$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Jan. 01, 2017USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock-based compensation plans | StockBasedCompensationPlans	2
Compensation cost charged for Long term incentive plan	$ 978	$ 962	$ 878
Total income tax benefit recognized	192	275	256
Excess tax benefits			353
Total compensation cost not yet recognized for option	$ 827	$ 798	$ 749
Weighted average period for total compensation cost not yet recognized	1 year 8 months 23 days	1 year 9 months 4 days	1 year 1 month 2 days
Average fair value of option granted (in dollars per share) | $ / shares	$ 17.98	$ 13.38	$ 10.01
Total intrinsic value of options exercised	$ 1,028	$ 1,060	$ 980
Stock options outstanding (in shares) | shares	109,652	111,306	113,455
Stock option average life	6 years 2 months 12 days	6 years 3 months 18 days	6 years 2 months 12 days
Stock options exercisable | shares		52,421	50,414
Stock options average price | $ / shares		$ 73.61	$ 65.77
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options expiration period	10 years
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average fair value of RSU's and PSU's granted | $ / shares	$ 119.67	$ 107.69	$ 92.45
Fair Value of RSU or PSU units settled	$ 613.7	$ 596.5	$ 587.7
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Average fair value of RSU's and PSU's granted | $ / shares	$ 120.64	$ 114.13	$ 105.30
Fair Value of RSU or PSU units settled	$ 128.8	$ 132.5	$ 127.7
Minimum | Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	6 months
Minimum | Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	6 months
Minimum | Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	6 months
Vesting percentage	0.00%
Maximum | Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Maximum | Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Maximum | Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Vesting percentage	200.00%
2012 Long-Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance under long-term incentive plan | shares	650,000
Shares available for future grants under long-term incentive plan | shares	351,000

Common Stock, Stock Option Pl_4

Common Stock, Stock Option Plans and Stock Compensation Agreements - Schedule Valuation Assumptions (Details)	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Weighted average assumptions of fair value of options
Risk-free rate	2.77%	2.25%	1.51%
Expected volatility	15.77%	15.30%	15.76%
Expected life (in years)	7 years	7 years	7 years
Expected dividend yield	2.70%	2.90%	3.10%

Common Stock, Stock Option Pl_5

Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017	Jan. 03, 2016
Outstanding Shares
Options outstanding beginning of period	111,306	113,455	116,517
Options granted	17,115	19,287	22,491
Options exercised	(16,228)	(18,975)	(22,547)
Options canceled/forfeited	(2,541)	(2,461)	(3,006)
Options outstanding end of period	109,652	111,306	113,455
Weighted Average Exercise Price
Options exercise price beginning of period	$ 90.48	$ 83.16	$ 76.41
Options granted, average exercise price (in dollars per share)	129.51	115.67	101.87
Options exercised, average exercise price (in dollars per share)	75.44	70.87	65.66
Options canceled/forfeited, average exercise price (in dollars per share)	112.90	101.40	92.83
Options exercise price end of period	$ 98.29	$ 90.48	$ 83.16
Aggregate intrinsic value	$ 3,214	$ 5,480	$ 3,636	$ 3,065

Common Stock, Stock Option Pl_6

Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Options Outstanding (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Stock options outstanding and exercisable
Outstanding number of Options (in shares)	109,652	111,306	113,455
Outstanding, Average Life	6 years 2 months 12 days	6 years 3 months 18 days	6 years 2 months 12 days
Outstanding Average Exercise Price (in dollars per share)	$ 98.29
Exercisable number of Options (in shares)	54,862
Exercisable, Average Exercise Price (in dollars per share)	$ 82.03
$52.13-$65.62
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	52.13
Price Range, Maximum (in dollars per share)	$ 65.62
Outstanding number of Options (in shares)	13,466
Outstanding, Average Life	1 year 9 months 18 days
Outstanding Average Exercise Price (in dollars per share)	$ 62.67
Exercisable number of Options (in shares)	13,466
Exercisable, Average Exercise Price (in dollars per share)	$ 62.67
$66.07-$72.54
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	66.07
Price Range, Maximum (in dollars per share)	$ 72.54
Outstanding number of Options (in shares)	12,710
Outstanding, Average Life	4 years
Outstanding Average Exercise Price (in dollars per share)	$ 72.53
Exercisable number of Options (in shares)	12,710
Exercisable, Average Exercise Price (in dollars per share)	$ 72.53
$90.44-$100.48
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	90.44
Price Range, Maximum (in dollars per share)	$ 100.48
Outstanding number of Options (in shares)	29,162
Outstanding, Average Life	5 years 7 months 6 days
Outstanding Average Exercise Price (in dollars per share)	$ 95.34
Exercisable number of Options (in shares)	28,537
Exercisable, Average Exercise Price (in dollars per share)	$ 95.23
$101.87-$115.67
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	101.87
Price Range, Maximum (in dollars per share)	$ 115.67
Outstanding number of Options (in shares)	37,877
Outstanding, Average Life	7 years 7 months 6 days
Outstanding Average Exercise Price (in dollars per share)	$ 108.33
Exercisable number of Options (in shares)	111
Exercisable, Average Exercise Price (in dollars per share)	$ 108.04
$115.68-$129.51
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	115.68
Price Range, Maximum (in dollars per share)	$ 129.51
Outstanding number of Options (in shares)	16,437
Outstanding, Average Life	9 years 1 month 6 days
Outstanding Average Exercise Price (in dollars per share)	$ 129.51
Exercisable number of Options (in shares)	38
Exercisable, Average Exercise Price (in dollars per share)	$ 129.51

Common Stock, Stock Option Pl_7

Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Restricted Share Units (Details) shares in Thousands	12 Months Ended
	Dec. 30, 2018shares
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Shares, Beginning balance	2,625
Shares, granted	1,142
Shares, issued	(1,151)
Shares, canceled/forfeited/adjusted	(122)
Shares, Ending balance	2,494
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Shares, Beginning balance	20,161
Shares, granted	6,074
Shares, issued	(6,684)
Shares, canceled/forfieted	(1,091)
Shares, Ending balance	18,460

Segments of Business and Geog_3

Segments of Business and Geographic Areas - Sales by Segment of Business (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 31, 2017	Oct. 01, 2017	Jul. 02, 2017	Apr. 02, 2017	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Segment Reporting Information [Line Items]
Sales to Customers	$ 20,394	$ 20,348	$ 20,830	$ 20,009	$ 20,195	$ 19,650	$ 18,839	$ 17,766	$ 81,581	$ 76,450	$ 71,890
Percentage Change In Sales By Segment Of Business									6.70%	6.30%
Consumer
Segment Reporting Information [Line Items]
Sales to Customers	3,536	3,415	3,504	3,398	3,540	3,356	3,478	3,228	$ 13,853	$ 13,602	13,307
Percentage Change In Sales By Segment Of Business									1.80%	2.20%
Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers	$ 10,190	$ 10,346	$ 10,354	$ 9,844	$ 9,681	$ 9,695	$ 8,635	$ 8,245	$ 40,734	$ 36,256	33,464
Percentage Change In Sales By Segment Of Business									12.40%	8.30%
Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 13,120	$ 12,244	11,968
Percentage Change In Sales By Segment Of Business									7.20%	2.30%
Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers									$ 3,304	$ 3,154	3,208
Percentage Change In Sales By Segment Of Business									4.80%	(1.70%)
Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 6,077	$ 5,986	6,085
Percentage Change In Sales By Segment Of Business									1.50%	(1.60%)
Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 9,844	$ 7,258	5,807
Percentage Change In Sales By Segment Of Business									35.60%	25.00%
Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,573	$ 1,327	0
Percentage Change In Sales By Segment Of Business									93.90%
Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 5,816	$ 6,287	6,396
Percentage Change In Sales By Segment Of Business									(7.50%)	(1.70%)
Medical Devices
Segment Reporting Information [Line Items]
Sales to Customers									$ 26,994	$ 26,592	25,119
Percentage Change In Sales By Segment Of Business									1.50%	5.90%
Medical Devices | Diabetes Care
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,009	$ 1,615	1,789
Percentage Change In Sales By Segment Of Business									(37.50%)	(9.70%)
Medical Devices | Diagnostics
Segment Reporting Information [Line Items]
Sales to Customers									$ 0	$ 1	66
Medical Devices | Interventional Solutions
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,646	$ 2,296	2,055
Percentage Change In Sales By Segment Of Business									15.20%	11.70%
Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 8,885	$ 9,058	9,128
Percentage Change In Sales By Segment Of Business									(1.90%)	(0.80%)
Medical Devices | Surgery
Segment Reporting Information [Line Items]
Sales to Customers									$ 9,901	$ 9,559	9,296
Percentage Change In Sales By Segment Of Business									3.60%	2.80%
Medical Devices | Vision
Segment Reporting Information [Line Items]
Sales to Customers									$ 4,553	$ 4,063	2,785
Percentage Change In Sales By Segment Of Business									12.10%	45.90%
Baby Care | Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,858	$ 1,916	2,001
Percentage Change In Sales By Segment Of Business									(3.00%)	(4.20%)
Beauty | Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 4,382	$ 4,200	3,897
Percentage Change In Sales By Segment Of Business									4.30%	7.80%
Oral Care | Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,555	$ 1,531	1,568
Percentage Change In Sales By Segment Of Business									1.60%	(2.40%)
OTC | Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 4,334	$ 4,126	3,977
Percentage Change In Sales By Segment Of Business									5.00%	3.70%
Women's Health | Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,049	$ 1,050	1,067
Percentage Change In Sales By Segment Of Business									(0.10%)	(1.60%)
Wound Care and Other | Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 675	$ 779	797
Percentage Change In Sales By Segment Of Business									(13.40%)	(2.30%)
Remicade | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 5,326	$ 6,315	6,966
Percentage Change In Sales By Segment Of Business									(15.70%)	(9.30%)
Simponi/Simponi Aria | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,084	$ 1,833	1,745
Percentage Change In Sales By Segment Of Business									13.70%	5.00%
Stelara | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 5,156	$ 4,011	3,232
Percentage Change In Sales By Segment Of Business									28.50%	24.10%
Tremfaya | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 544	$ 63	0
Other Immunology | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 10	$ 22	25
Percentage Change In Sales By Segment Of Business									(54.50%)	(12.00%)
EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers									$ 816	$ 714	573
Percentage Change In Sales By Segment Of Business									14.30%	24.60%
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,955	$ 1,821	1,851
Percentage Change In Sales By Segment Of Business									7.40%	(1.60%)
Other Infectious Diseases | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers									$ 533	$ 619	784
Percentage Change In Sales By Segment Of Business									(13.90%)	(21.00%)
CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 663	$ 791	863
Percentage Change In Sales By Segment Of Business									(16.20%)	(8.30%)
INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,928	$ 2,569	2,214
Percentage Change In Sales By Segment Of Business									14.00%	16.00%
RISPERDAL CONSTA | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 737	$ 805	893
Percentage Change In Sales By Segment Of Business									(8.40%)	(9.90%)
OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,749	$ 1,821	2,115
Percentage Change In Sales By Segment Of Business									(4.00%)	(13.90%)
DARZALEX | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,025	$ 1,242	572
Percentage Change In Sales By Segment Of Business									63.00%
IMBRUVICA | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,615	$ 1,893	1,251
Percentage Change In Sales By Segment Of Business									38.10%	51.30%
VELCADE | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,116	$ 1,114	1,224
Percentage Change In Sales By Segment Of Business									0.20%	(9.00%)
ZYTIGA | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 3,498	$ 2,505	2,260
Percentage Change In Sales By Segment Of Business									39.60%	10.80%
Other Oncology | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 590	$ 504	500
Percentage Change In Sales By Segment Of Business									17.10%	0.80%
OPSUMIT | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,215	$ 573	0
TRACLEER | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 546	403	0
Percentage Change In Sales By Segment Of Business									35.50%
UPTRAVI | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 663	263	0
Other | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 149	88	0
Percentage Change In Sales By Segment Of Business									69.30%
Other | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,470	$ 1,704	1,596
Percentage Change In Sales By Segment Of Business									(13.70%)	6.80%
Xarelto | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,477	$ 2,500	2,288
Percentage Change In Sales By Segment Of Business									(0.90%)	9.30%
INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 881	$ 1,111	1,407
Percentage Change In Sales By Segment Of Business									(20.70%)	(21.00%)
PROCRIT/EPREX | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 988	$ 972	1,105
Percentage Change In Sales By Segment Of Business									1.60%	(12.00%)
HIPS | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,418	$ 1,394	1,361
Percentage Change In Sales By Segment Of Business									1.70%	2.40%
KNEES | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,502	$ 1,523	1,524
Percentage Change In Sales By Segment Of Business									(1.40%)	(0.10%)
TRAUMA | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,699	$ 2,616	2,569
Percentage Change In Sales By Segment Of Business									3.20%	1.80%
SPINE & OTHER | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 3,266	$ 3,525	3,674
Percentage Change In Sales By Segment Of Business									(7.30%)	(4.10%)
ADVANCED | Medical Devices | Surgery
Segment Reporting Information [Line Items]
Sales to Customers									$ 4,002	$ 3,756	3,517
Percentage Change In Sales By Segment Of Business									6.50%	6.80%
GENERAL | Medical Devices | Surgery
Segment Reporting Information [Line Items]
Sales to Customers									$ 4,557	$ 4,463	4,362
Percentage Change In Sales By Segment Of Business									2.10%	2.30%
SPECIALTY | Medical Devices | Surgery
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,342	$ 1,340	1,417
Percentage Change In Sales By Segment Of Business									0.10%	(5.40%)
CONTACT LENSES/OTHER | Medical Devices | Vision
Segment Reporting Information [Line Items]
Sales to Customers									$ 3,302	$ 3,036	2,785
Percentage Change In Sales By Segment Of Business									8.80%	9.00%
SURGICAL | Medical Devices | Vision
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,251	$ 1,027	0
Percentage Change In Sales By Segment Of Business									21.80%
UNITED STATES
Segment Reporting Information [Line Items]
Sales to Customers									$ 41,884	$ 39,863	37,811
Percentage Change In Sales By Segment Of Business									5.10%	5.40%
UNITED STATES | Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 5,761	$ 5,565	5,420
Percentage Change In Sales By Segment Of Business									3.50%	2.70%
UNITED STATES | Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers									$ 23,286	$ 21,474	20,125
Percentage Change In Sales By Segment Of Business									8.40%	6.70%
UNITED STATES | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 9,073	$ 8,871	8,846
Percentage Change In Sales By Segment Of Business									2.30%	0.30%
UNITED STATES | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,378	$ 1,358	1,461
Percentage Change In Sales By Segment Of Business									1.50%	(7.00%)
UNITED STATES | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,574	$ 2,630	2,628
Percentage Change In Sales By Segment Of Business									(2.10%)	0.10%
UNITED STATES | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 4,331	$ 3,098	2,335
Percentage Change In Sales By Segment Of Business									39.80%	32.70%
UNITED STATES | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,651	$ 773	0
UNITED STATES | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 4,279	$ 4,744	4,855
Percentage Change In Sales By Segment Of Business									(9.80%)	(2.30%)
UNITED STATES | Medical Devices
Segment Reporting Information [Line Items]
Sales to Customers									$ 12,837	$ 12,824	12,266
Percentage Change In Sales By Segment Of Business									0.10%	4.50%
UNITED STATES | Medical Devices | Diabetes Care
Segment Reporting Information [Line Items]
Sales to Customers									$ 371	$ 612	739
Percentage Change In Sales By Segment Of Business									(39.40%)	(17.20%)
UNITED STATES | Medical Devices | Diagnostics
Segment Reporting Information [Line Items]
Sales to Customers									$ 0	$ 0	0
UNITED STATES | Medical Devices | Interventional Solutions
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,283	$ 1,148	1,031
Percentage Change In Sales By Segment Of Business									11.80%	11.30%
UNITED STATES | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 5,281	$ 5,404	5,438
Percentage Change In Sales By Segment Of Business									(2.30%)	(0.60%)
UNITED STATES | Medical Devices | Surgery
Segment Reporting Information [Line Items]
Sales to Customers									$ 4,125	$ 4,085	4,026
Percentage Change In Sales By Segment Of Business									1.00%	1.50%
UNITED STATES | Medical Devices | Vision
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,777	$ 1,575	1,032
Percentage Change In Sales By Segment Of Business									12.80%	52.60%
UNITED STATES | Baby Care | Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 422	$ 449	488
Percentage Change In Sales By Segment Of Business									(6.00%)	(8.00%)
UNITED STATES | Beauty | Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,403	$ 2,335	2,135
Percentage Change In Sales By Segment Of Business									2.90%	9.40%
UNITED STATES | Oral Care | Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 637	$ 616	648
Percentage Change In Sales By Segment Of Business									3.40%	(4.90%)
UNITED STATES | OTC | Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,850	$ 1,716	1,675
Percentage Change In Sales By Segment Of Business									7.80%	2.40%
UNITED STATES | Women's Health | Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 13	$ 12	19
Percentage Change In Sales By Segment Of Business									8.30%	(36.80%)
UNITED STATES | Wound Care and Other | Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 436	$ 437	455
Percentage Change In Sales By Segment Of Business									(0.20%)	(4.00%)
UNITED STATES | Remicade | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 3,664	$ 4,525	4,842
Percentage Change In Sales By Segment Of Business									(19.00%)	(6.50%)
UNITED STATES | Simponi/Simponi Aria | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,051	$ 954	959
Percentage Change In Sales By Segment Of Business									10.20%	(0.50%)
UNITED STATES | Stelara | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 3,469	$ 2,767	2,263
Percentage Change In Sales By Segment Of Business									25.40%	22.30%
UNITED STATES | Tremfaya | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 453	$ 62	0
UNITED STATES | Other Immunology | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 0	$ 0	0
Percentage Change In Sales By Segment Of Business									0.00%	0.00%
UNITED STATES | EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers									$ 58	$ 58	52
Percentage Change In Sales By Segment Of Business									0.00%	11.50%
UNITED STATES | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,169	$ 1,109	1,143
Percentage Change In Sales By Segment Of Business									5.40%	(3.00%)
UNITED STATES | Other Infectious Diseases | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers									$ 151	$ 191	266
Percentage Change In Sales By Segment Of Business									(20.90%)	(28.20%)
UNITED STATES | CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 229	$ 384	468
Percentage Change In Sales By Segment Of Business									(40.40%)	(17.90%)
UNITED STATES | INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,791	$ 1,590	1,343
Percentage Change In Sales By Segment Of Business									12.60%	18.40%
UNITED STATES | RISPERDAL CONSTA | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 315	$ 360	381
Percentage Change In Sales By Segment Of Business									(12.50%)	(5.50%)
UNITED STATES | OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 239	$ 296	436
Percentage Change In Sales By Segment Of Business									(19.30%)	(32.10%)
UNITED STATES | DARZALEX | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,203	$ 884	471
Percentage Change In Sales By Segment Of Business									36.10%	87.70%
UNITED STATES | IMBRUVICA | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,129	$ 841	613
Percentage Change In Sales By Segment Of Business									34.20%	37.20%
UNITED STATES | VELCADE | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 0	$ 0	0
Percentage Change In Sales By Segment Of Business									0.00%	0.00%
UNITED STATES | ZYTIGA | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,771	$ 1,228	1,089
Percentage Change In Sales By Segment Of Business									44.20%	12.80%
UNITED STATES | Other Oncology | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 228	$ 145	162
Percentage Change In Sales By Segment Of Business									57.20%	(10.50%)
UNITED STATES | OPSUMIT | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 700	$ 320	0
UNITED STATES | TRACLEER | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 268	161	0
Percentage Change In Sales By Segment Of Business									66.50%
UNITED STATES | UPTRAVI | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 598	238	0
UNITED STATES | Other | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 85	54	0
Percentage Change In Sales By Segment Of Business									57.40%
UNITED STATES | Other | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 417	$ 625	527
Percentage Change In Sales By Segment Of Business									(33.30%)	18.60%
UNITED STATES | Xarelto | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,477	$ 2,500	2,288
Percentage Change In Sales By Segment Of Business									(0.90%)	9.30%
UNITED STATES | INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 711	$ 944	1,273
Percentage Change In Sales By Segment Of Business									(24.70%)	(25.80%)
UNITED STATES | PROCRIT/EPREX | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 674	$ 675	767
Percentage Change In Sales By Segment Of Business									(0.10%)	(12.00%)
UNITED STATES | HIPS | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 841	$ 827	798
Percentage Change In Sales By Segment Of Business									1.70%	3.60%
UNITED STATES | KNEES | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 911	$ 948	943
Percentage Change In Sales By Segment Of Business									(3.90%)	0.50%
UNITED STATES | TRAUMA | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,599	$ 1,576	1,545
Percentage Change In Sales By Segment Of Business									1.50%	2.00%
UNITED STATES | SPINE & OTHER | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,930	$ 2,053	2,152
Percentage Change In Sales By Segment Of Business									(6.00%)	(4.60%)
UNITED STATES | ADVANCED | Medical Devices | Surgery
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,657	$ 1,620	1,524
Percentage Change In Sales By Segment Of Business									2.30%	6.30%
UNITED STATES | GENERAL | Medical Devices | Surgery
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,751	$ 1,728	1,669
Percentage Change In Sales By Segment Of Business									1.30%	3.50%
UNITED STATES | SPECIALTY | Medical Devices | Surgery
Segment Reporting Information [Line Items]
Sales to Customers									$ 717	$ 737	833
Percentage Change In Sales By Segment Of Business									(2.70%)	(11.50%)
UNITED STATES | CONTACT LENSES/OTHER | Medical Devices | Vision
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,237	$ 1,122	1,032
Percentage Change In Sales By Segment Of Business									10.20%	8.70%
UNITED STATES | SURGICAL | Medical Devices | Vision
Segment Reporting Information [Line Items]
Sales to Customers									$ 540	$ 453	0
Percentage Change In Sales By Segment Of Business									19.20%
Non-US
Segment Reporting Information [Line Items]
Sales to Customers									$ 39,697	$ 36,587	34,079
Percentage Change In Sales By Segment Of Business									8.50%	7.40%
Non-US | Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 8,092	$ 8,037	7,887
Percentage Change In Sales By Segment Of Business									0.70%	1.90%
Non-US | Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers									$ 17,448	$ 14,782	13,339
Percentage Change In Sales By Segment Of Business									18.00%	10.80%
Non-US | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 4,047	$ 3,373	3,122
Percentage Change In Sales By Segment Of Business									20.00%	8.00%
Non-US | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,926	$ 1,796	1,747
Percentage Change In Sales By Segment Of Business									7.20%	2.80%
Non-US | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 3,503	$ 3,356	3,457
Percentage Change In Sales By Segment Of Business									4.40%	(2.90%)
Non-US | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 5,513	$ 4,160	3,472
Percentage Change In Sales By Segment Of Business									32.50%	19.80%
Non-US | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 922	$ 554	0
Percentage Change In Sales By Segment Of Business									66.40%
Non-US | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,537	$ 1,543	1,541
Percentage Change In Sales By Segment Of Business									(0.40%)	0.10%
Non-US | Medical Devices
Segment Reporting Information [Line Items]
Sales to Customers									$ 14,157	$ 13,768	12,853
Percentage Change In Sales By Segment Of Business									2.80%	7.10%
Non-US | Medical Devices | Diabetes Care
Segment Reporting Information [Line Items]
Sales to Customers									$ 638	$ 1,003	1,050
Percentage Change In Sales By Segment Of Business									(36.40%)	(4.50%)
Non-US | Medical Devices | Diagnostics
Segment Reporting Information [Line Items]
Sales to Customers									$ 0	$ 1	66
Non-US | Medical Devices | Interventional Solutions
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,363	$ 1,148	1,024
Percentage Change In Sales By Segment Of Business									18.70%	12.10%
Non-US | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 3,604	$ 3,654	3,690
Percentage Change In Sales By Segment Of Business									(1.40%)	(1.00%)
Non-US | Medical Devices | Surgery
Segment Reporting Information [Line Items]
Sales to Customers									$ 5,776	$ 5,474	5,270
Percentage Change In Sales By Segment Of Business									5.50%	3.90%
Non-US | Medical Devices | Vision
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,776	$ 2,488	1,753
Percentage Change In Sales By Segment Of Business									11.60%	41.90%
Non-US | Baby Care | Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,436	$ 1,467	1,513
Percentage Change In Sales By Segment Of Business									(2.10%)	(3.00%)
Non-US | Beauty | Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,979	$ 1,865	1,762
Percentage Change In Sales By Segment Of Business									6.10%	5.80%
Non-US | Oral Care | Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 918	$ 915	920
Percentage Change In Sales By Segment Of Business									0.30%	(0.50%)
Non-US | OTC | Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,484	$ 2,410	2,302
Percentage Change In Sales By Segment Of Business									3.10%	4.70%
Non-US | Women's Health | Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,036	$ 1,038	1,048
Percentage Change In Sales By Segment Of Business									(0.20%)	(1.00%)
Non-US | Wound Care and Other | Consumer
Segment Reporting Information [Line Items]
Sales to Customers									$ 239	$ 342	342
Percentage Change In Sales By Segment Of Business									(30.10%)	0.00%
Non-US | Remicade | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,226	$ 1,227	1,342
Percentage Change In Sales By Segment Of Business									(0.10%)	(8.60%)
Non-US | Simponi/Simponi Aria | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,033	$ 879	786
Percentage Change In Sales By Segment Of Business									17.50%	11.80%
Non-US | Stelara | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,687	$ 1,244	969
Percentage Change In Sales By Segment Of Business									35.60%	28.40%
Non-US | Tremfaya | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 91	$ 1	0
Non-US | Other Immunology | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 10	$ 22	25
Percentage Change In Sales By Segment Of Business									(54.50%)	(12.00%)
Non-US | EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers									$ 758	$ 656	521
Percentage Change In Sales By Segment Of Business									15.50%	25.90%
Non-US | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers									$ 786	$ 712	708
Percentage Change In Sales By Segment Of Business									10.40%	0.60%
Non-US | Other Infectious Diseases | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers									$ 382	$ 428	518
Percentage Change In Sales By Segment Of Business									(10.70%)	(17.40%)
Non-US | CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 434	$ 407	395
Percentage Change In Sales By Segment Of Business									6.60%	3.00%
Non-US | INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,137	$ 979	871
Percentage Change In Sales By Segment Of Business									16.10%	12.40%
Non-US | RISPERDAL CONSTA | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 422	$ 445	512
Percentage Change In Sales By Segment Of Business									(5.20%)	(13.10%)
Non-US | OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,510	$ 1,525	1,679
Percentage Change In Sales By Segment Of Business									(1.00%)	(9.20%)
Non-US | DARZALEX | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 822	$ 358	101
Non-US | IMBRUVICA | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,486	$ 1,052	638
Percentage Change In Sales By Segment Of Business									41.30%	64.90%
Non-US | VELCADE | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,116	$ 1,114	1,224
Percentage Change In Sales By Segment Of Business									0.20%	(9.00%)
Non-US | ZYTIGA | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,727	$ 1,277	1,171
Percentage Change In Sales By Segment Of Business									35.20%	9.10%
Non-US | Other Oncology | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers									$ 362	$ 359	338
Percentage Change In Sales By Segment Of Business									0.80%	6.20%
Non-US | OPSUMIT | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 515	$ 253	0
Non-US | TRACLEER | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 278	242	0
Percentage Change In Sales By Segment Of Business									14.90%
Non-US | UPTRAVI | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 65	25	0
Non-US | Other | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers									$ 64	34	0
Percentage Change In Sales By Segment Of Business									88.20%
Non-US | Other | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,053	$ 1,079	1,069
Percentage Change In Sales By Segment Of Business									(2.40%)	0.90%
Non-US | Xarelto | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 0	$ 0	0
Percentage Change In Sales By Segment Of Business									0.00%	0.00%
Non-US | INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 170	$ 167	134
Percentage Change In Sales By Segment Of Business									1.80%	24.60%
Non-US | PROCRIT/EPREX | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers									$ 314	$ 297	338
Percentage Change In Sales By Segment Of Business									5.70%	(12.10%)
Non-US | HIPS | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 577	$ 567	563
Percentage Change In Sales By Segment Of Business									1.80%	0.70%
Non-US | KNEES | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 591	$ 575	581
Percentage Change In Sales By Segment Of Business									2.80%	(1.00%)
Non-US | TRAUMA | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,100	$ 1,040	1,024
Percentage Change In Sales By Segment Of Business									5.80%	1.60%
Non-US | SPINE & OTHER | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers									$ 1,336	$ 1,472	1,522
Percentage Change In Sales By Segment Of Business									(9.20%)	(3.30%)
Non-US | ADVANCED | Medical Devices | Surgery
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,345	$ 2,136	1,993
Percentage Change In Sales By Segment Of Business									9.80%	7.20%
Non-US | GENERAL | Medical Devices | Surgery
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,806	$ 2,735	2,693
Percentage Change In Sales By Segment Of Business									2.60%	1.60%
Non-US | SPECIALTY | Medical Devices | Surgery
Segment Reporting Information [Line Items]
Sales to Customers									$ 625	$ 603	584
Percentage Change In Sales By Segment Of Business									3.60%	3.30%
Non-US | CONTACT LENSES/OTHER | Medical Devices | Vision
Segment Reporting Information [Line Items]
Sales to Customers									$ 2,065	$ 1,914	1,753
Percentage Change In Sales By Segment Of Business									7.90%	9.20%
Non-US | SURGICAL | Medical Devices | Vision
Segment Reporting Information [Line Items]
Sales to Customers									$ 711	$ 574	0
Percentage Change In Sales By Segment Of Business									23.90%
UNITED STATES Exports | Remicade | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers									$ 436	$ 563	$ 782
Percentage Change In Sales By Segment Of Business									(22.60%)	(28.00%)

Segments of Business and Geog_4

Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 31, 2017	Oct. 01, 2017	Jul. 02, 2017	Apr. 02, 2017	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Segment Reporting Information [Line Items]
Sales to Customers	$ 20,394	$ 20,348	$ 20,830	$ 20,009	$ 20,195	$ 19,650	$ 18,839	$ 17,766	$ 81,581	$ 76,450	$ 71,890
Earnings before provision for taxes on income	3,122	4,423	4,973	5,481	2,560	4,790	4,748	5,575	17,999	17,673	19,803
Identifiable Assets	152,954				157,303				152,954	157,303
Additions to Property, Plant & Equipment									3,670	3,279	3,226
Depreciation and Amortization									6,929	5,642	3,754
United States
Segment Reporting Information [Line Items]
Sales to Customers									41,884	39,863	37,811
Non-US
Segment Reporting Information [Line Items]
Sales to Customers									39,697	36,587	34,079
Consumer
Segment Reporting Information [Line Items]
Sales to Customers	3,536	3,415	3,504	3,398	3,540	3,356	3,478	3,228	13,853	13,602	13,307
Consumer | United States
Segment Reporting Information [Line Items]
Sales to Customers									5,761	5,565	5,420
Consumer | Non-US
Segment Reporting Information [Line Items]
Sales to Customers									8,092	8,037	7,887
Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers	10,190	$ 10,346	$ 10,354	$ 9,844	9,681	$ 9,695	$ 8,635	$ 8,245	40,734	36,256	33,464
Pharmaceutical | United States
Segment Reporting Information [Line Items]
Sales to Customers									23,286	21,474	20,125
Pharmaceutical | Non-US
Segment Reporting Information [Line Items]
Sales to Customers									17,448	14,782	13,339
Medical Devices
Segment Reporting Information [Line Items]
Sales to Customers									26,994	26,592	25,119
Medical Devices | United States
Segment Reporting Information [Line Items]
Sales to Customers									12,837	12,824	12,266
Medical Devices | Non-US
Segment Reporting Information [Line Items]
Sales to Customers									14,157	13,768	12,853
Operating Segments
Segment Reporting Information [Line Items]
Identifiable Assets	128,767				129,893				128,767	129,893
Additions to Property, Plant & Equipment									3,293	2,987	2,885
Depreciation and Amortization									6,593	5,306	3,422
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Less: Expense not allocated to segments									1,286	1,326	1,043
Corporate, Non-Segment | General Corporate
Segment Reporting Information [Line Items]
Identifiable Assets	24,187				27,410				24,187	27,410
Additions to Property, Plant & Equipment									377	292	341
Depreciation and Amortization									336	336	332
Operating Segments
Segment Reporting Information [Line Items]
Sales to Customers									81,581	76,450	71,890
Earnings before provision for taxes on income									19,285	18,999	20,846
Operating Segments | United States
Segment Reporting Information [Line Items]
Sales to Customers									41,884	39,863	37,811
Operating Segments | Consumer
Segment Reporting Information [Line Items]
Earnings before provision for taxes on income									2,320	2,524	2,441
Identifiable Assets	25,877				25,030				25,877	25,030
Additions to Property, Plant & Equipment									438	485	486
Depreciation and Amortization									688	674	608
Operating Segments | Pharmaceutical
Segment Reporting Information [Line Items]
Earnings before provision for taxes on income									12,568	11,083	12,827
Identifiable Assets	56,636				59,450				56,636	59,450
Additions to Property, Plant & Equipment									1,012	936	927
Depreciation and Amortization									3,802	2,416	886
Operating Segments | Medical Devices
Segment Reporting Information [Line Items]
Earnings before provision for taxes on income									4,397	5,392	5,578
Identifiable Assets	$ 46,254				$ 45,413				46,254	45,413
Additions to Property, Plant & Equipment									1,843	1,566	1,472
Depreciation and Amortization									2,103	2,216	1,928
Immunology | Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers									13,120	12,244	11,968
Immunology | Pharmaceutical | United States
Segment Reporting Information [Line Items]
Sales to Customers									9,073	8,871	8,846
Immunology | Pharmaceutical | Non-US
Segment Reporting Information [Line Items]
Sales to Customers									4,047	3,373	3,122
Immunology | Tremfaya | Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers									544	63	0
Immunology | Tremfaya | Pharmaceutical | United States
Segment Reporting Information [Line Items]
Sales to Customers									453	62	0
Immunology | Tremfaya | Pharmaceutical | Non-US
Segment Reporting Information [Line Items]
Sales to Customers									$ 91	$ 1	$ 0

Segments of Business and Geog_5

Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 30, 2018USD ($)	Sep. 30, 2018USD ($)	Jul. 01, 2018USD ($)	Apr. 01, 2018USD ($)	Dec. 31, 2017USD ($)	Oct. 01, 2017USD ($)	Jul. 02, 2017USD ($)	Apr. 02, 2017USD ($)	Dec. 30, 2018USD ($)Segment	Dec. 31, 2017USD ($)Segment	Jan. 01, 2017USD ($)Segment
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	$ 20,394	$ 20,348	$ 20,830	$ 20,009	$ 20,195	$ 19,650	$ 18,839	$ 17,766	$ 81,581	$ 76,450	$ 71,890
Identifiable Assets	152,954				157,303				152,954	157,303
Gain (Loss) on Disposition of Assets									$ 1,200	$ 1,300	$ 600
Number of segments | Segment									3	3	3
Acquisition related costs					217
Restructuring charges	227		176						$ 251	$ 309	$ 491
After Tax Restructuring Charge	190	162	152	81	237	136	101	121
Asset write-downs									1,258	795	283
In-process research and development		1,126			408				1,126	408	29
Litigation expense	1,288		703		645	118	493
Gain from divestiture									1,217	1,307	563
Medical Devices
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers									26,994	26,592	25,119
Restructuring charges		190		107	284	187	128	161	462	114	700
Asset write-downs							182			200
Litigation expense									1,700	1,100	800
Restructuring Charge, Net of Accrual Adjustment									600	800
Gain from divestiture										700
Consumer
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	3,536	3,415	3,504	3,398	3,540	3,356	3,478	3,228	13,853	13,602	13,307
Litigation expense									300
Gain from divestiture										500
Pharmaceutical
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers	10,190	10,346	$ 10,354	9,844	9,681	9,695	8,635	8,245	40,734	36,256	33,464
Unrealized loss on securities									200
In-process research and development										400
Litigation expense										100
Positive adjustment											$ 500
Property, Plant and Equipment
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	17,035				17,005				17,035	17,005
Other Intangible Assets
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	78,064				85,134				78,064	85,134
Alios Biopharma Inc and XO1 Limited | Pharmaceutical
Revenues from External Customers and Long-Lived Assets [Line Items]
In-process research and development									1,100
XO1
Revenues from External Customers and Long-Lived Assets [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability		$ (184)							(200)
Actelion
Revenues from External Customers and Long-Lived Assets [Line Items]
Acquisition related costs				$ 96		$ 367	$ 213		200	800
Actelion | Pharmaceutical
Revenues from External Customers and Long-Lived Assets [Line Items]
Acquisition related costs									200	800
AMO
Revenues from External Customers and Long-Lived Assets [Line Items]
Acquisition related costs								$ 38
AMO | Medical Devices
Revenues from External Customers and Long-Lived Assets [Line Items]
Acquisition related costs									100	100
Sales Revenue, Net
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk (as a percent)											13.50%
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers									41,884	39,863	$ 37,811
United States | Medical Devices
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers									12,837	12,824	12,266
United States | Consumer
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers									5,761	5,565	5,420
United States | Pharmaceutical
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers									23,286	21,474	20,125
Corporate, Non-Segment
Revenues from External Customers and Long-Lived Assets [Line Items]
Other Non Long Lived Assets	57,855				55,164				57,855	55,164
Corporate, Non-Segment | General Corporate
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	1,064				1,143				1,064	1,143
Identifiable Assets	24,187				27,410				24,187	27,410
Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers									81,581	76,450	71,890
Long-Lived Assets	94,035				100,996				94,035	100,996
Operating Segments | Medical Devices
Revenues from External Customers and Long-Lived Assets [Line Items]
Identifiable Assets	46,254				45,413				46,254	45,413
Operating Segments | Consumer
Revenues from External Customers and Long-Lived Assets [Line Items]
Identifiable Assets	25,877				25,030				25,877	25,030
Operating Segments | Pharmaceutical
Revenues from External Customers and Long-Lived Assets [Line Items]
Identifiable Assets	56,636				59,450				56,636	59,450
Operating Segments | NIZORAL | Consumer
Revenues from External Customers and Long-Lived Assets [Line Items]
Gain (Loss) on Disposition of Assets									300
Operating Segments | PANCREASE | Pharmaceutical
Revenues from External Customers and Long-Lived Assets [Line Items]
Gain (Loss) on Disposition of Assets									200
Operating Segments | LifeScan | Medical Devices
Revenues from External Customers and Long-Lived Assets [Line Items]
Gain (Loss) on Disposition of Assets									500
Operating Segments | United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers									41,884	39,863	37,811
Long-Lived Assets	37,117				38,556				37,117	38,556
Operating Segments | Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers									18,753	17,126	15,770
Long-Lived Assets	51,433				56,677				51,433	56,677
Operating Segments | Western Hemisphere excluding U.S.
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers									6,113	6,041	5,734
Long-Lived Assets	2,752				2,990				2,752	2,990
Operating Segments | Asia-Pacific, Africa
Revenues from External Customers and Long-Lived Assets [Line Items]
Sales to Customers									14,831	13,420	$ 12,575
Long-Lived Assets	$ 2,733				$ 2,773				$ 2,733	$ 2,773
Wholesaler 1 | Sales Revenue, Net
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk (as a percent)									14.00%	14.00%
Wholesaler 2 | Sales Revenue, Net
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk (as a percent)									11.00%	10.00%	10.70%
Wholesaler 3 | Sales Revenue, Net
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk (as a percent)									11.00%

Selected Quarterly Financial _3

Selected Quarterly Financial Data (unaudited) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 31, 2017	Oct. 01, 2017	Jul. 02, 2017	Apr. 02, 2017	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Summary of Selected Quarterly Financial Data (unaudited)
Sales to customers	$ 20,394	$ 20,348	$ 20,830	$ 20,009	$ 20,195	$ 19,650	$ 18,839	$ 17,766	$ 81,581	$ 76,450	$ 71,890
Gross profit	13,433	13,759	13,903	13,395	12,936	12,725	12,993	12,357	54,490	51,011	50,101
Earnings before provision for taxes on income	3,122	4,423	4,973	5,481	2,560	4,790	4,748	5,575	17,999	17,673	19,803
Net earnings	$ 3,042	$ 3,934	$ 3,954	$ 4,367	$ (10,713)	$ 3,764	$ 3,827	$ 4,422	$ 15,297	$ 1,300	$ 16,540
Basic net earnings per share (in dollars per share)	$ 1.14	$ 1.47	$ 1.47	$ 1.63	$ (3.99)	$ 1.40	$ 1.42	$ 1.63	$ 5.70	$ 0.48	$ 6.04
Diluted net earnings per share (in dollars per share)	$ 1.12	$ 1.44	$ 1.45	$ 1.60	$ (3.99)	$ 1.37	$ 1.40	$ 1.61	$ 5.61	$ 0.47	$ 5.93
Restructuring charge, after tax	$ 190	$ 162	$ 152	$ 81	$ 237	$ 136	$ 101	$ 121
Restructuring charges	227		176						$ 251	$ 309	$ 491
Litigation income (expense) net after-tax	(1,113)		(609)		(506)	(97)	(352)
Litigation expense	1,288		703		645	118	493
Acquisition related costs after tax					313
Acquisition related costs					217
In-process research and development, after tax		859			266
In-process research and development		1,126			408				1,126	408	29
Asset impairment benefit					116
asset impairment charge after-tax							125
Asset Impairment Charges									1,258	795	283
Provisional charge	(137)	(265)			13,600
Medical Devices
Summary of Selected Quarterly Financial Data (unaudited)
Sales to customers									26,994	26,592	25,119
Restructuring charges		190		107	284	187	128	161	462	114	700
Litigation expense									1,700	1,100	800
Asset Impairment Charges							182			200
Consumer
Summary of Selected Quarterly Financial Data (unaudited)
Sales to customers	3,536	3,415	3,504	3,398	3,540	3,356	3,478	3,228	13,853	13,602	13,307
Litigation expense									300
Pharmaceutical
Summary of Selected Quarterly Financial Data (unaudited)
Sales to customers	10,190	10,346	10,354	9,844	9,681	9,695	8,635	8,245	40,734	36,256	$ 33,464
Litigation expense										100
In-process research and development										400
Med Devices
Summary of Selected Quarterly Financial Data (unaudited)
Sales to customers	$ 6,668	6,587	$ 6,972	6,767	$ 6,974	6,599	6,726	6,293
XO1
Summary of Selected Quarterly Financial Data (unaudited)
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability		$ (184)							(200)
AMO
Summary of Selected Quarterly Financial Data (unaudited)
Acquisition related costs after tax								251
Acquisition related costs								$ 38
AMO | Medical Devices
Summary of Selected Quarterly Financial Data (unaudited)
Acquisition related costs									100	100
Actelion
Summary of Selected Quarterly Financial Data (unaudited)
Acquisition related costs after tax				92		255	199
Acquisition related costs				$ 96		$ 367	$ 213		200	800
Actelion | Pharmaceutical
Summary of Selected Quarterly Financial Data (unaudited)
Acquisition related costs									$ 200	$ 800

Business Combinations and Div_3

Business Combinations and Divestitures - Narrative (Details) ¥ / shares in Units, $ / shares in Units, ¥ in Billions

Feb. 13, 2019USD ($)

Oct. 23, 2018USD ($)

Oct. 23, 2018JPY (¥)

Jun. 16, 2017USD ($)$ / shares

Jul. 01, 2018USD ($)

Apr. 01, 2018USD ($)

Dec. 31, 2017USD ($)

Oct. 01, 2017USD ($)

Jul. 02, 2017USD ($)

Apr. 02, 2017USD ($)

Oct. 01, 2017USD ($)

Dec. 30, 2018USD ($)

Dec. 31, 2017USD ($)

Jan. 01, 2017USD ($)

Dec. 30, 2012USD ($)

Jan. 17, 2019¥ / shares

Business Acquisition [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

$ 10,000,000,000

Goodwill

$ 31,906,000,000

30,453,000,000

$ 31,906,000,000

$ 22,805,000,000

Acquisition payments

899,000,000

35,151,000,000

4,509,000,000

Acquisition related costs

217,000,000

Liabilities assumed

148,000,000

1,786,000,000

77,000,000

Indefinite lived intangible assets

11,283,000,000

9,190,000,000

11,283,000,000

Purchase price

899,000,000

35,151,000,000

4,509,000,000

Asset write-downs

1,258,000,000

795,000,000

283,000,000

Gain on divestitures, pre-tax

1,200,000,000

1,300,000,000

600,000,000

Ci:z Holdings Co. Ltd.

Business Acquisition [Line Items]

Business Combination, Consideration Transferred

$ 2,100,000,000

¥ 230

Foreign Currency Exchange Rate, Translation

109.06

109.06

2017 Acquisitions

Business Acquisition [Line Items]

Purchase price over fair value of assets acquired

34,400,000,000

34,400,000,000

2016 Acquisitions

Business Acquisition [Line Items]

Purchase price over fair value of assets acquired

$ 4,100,000,000

Vogue International LLC

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

22 years

Actelion

Business Acquisition [Line Items]

Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory

$ 642,000,000

Goodwill, Subsequent Recognition of Deferred Tax Asset

$ 200,000,000

Business Combination, Initial Accounting Incomplete, Adjustment, Current Liabilities

$ 400,000,000

Goodwill

6,161,000,000

Acquisition payments

29,600,000,000

Acquisition price (in dollars per share) | $ / shares

$ 280

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

9 years

Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual

1,400,000,000

Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual

(1,400,000,000)

Acquisition related costs

$ 96,000,000

$ 367,000,000

$ 213,000,000

$ 200,000,000

800,000,000

Idorsia

Business Acquisition [Line Items]

Business Acquisition, Percentage of Voting Interests Acquired

9.90%

9.00%

Convertible Note, Equity Interest, Percentage

22.10%

20.80%

AMO

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

14 years 4 months 24 days

Acquisition related costs

$ 38,000,000

Synthes, Inc

Business Acquisition [Line Items]

Purchase price

$ 20,200,000,000

In Process Research and Development | Actelion

Business Acquisition [Line Items]

Fair Value Inputs, Discount Rate

9.00%

Purchased in-process research and development

Business Acquisition [Line Items]

Indefinite lived intangible assets

4,201,000,000

$ 2,253,000,000

4,201,000,000

Medical Devices

Business Acquisition [Line Items]

Goodwill

13,922,000,000

12,720,000,000

13,922,000,000

$ 11,702,000,000

Asset write-downs

$ 182,000,000

200,000,000

Medical Devices | AMO

Business Acquisition [Line Items]

Goodwill

1,700,000,000

1,700,000,000

1,700,000,000

Acquisition payments

$ 4,300,000,000

Finite-lived Intangible Assets Acquired

2,300,000,000

Acquisition related costs

100,000,000

100,000,000

Consumer

Business Acquisition [Line Items]

Goodwill

8,875,000,000

8,670,000,000

8,875,000,000

8,263,000,000

Consumer | Vogue International LLC

Business Acquisition [Line Items]

Acquisition payments

3,300,000,000

Finite-lived Intangible Assets Acquired

2,300,000,000

Business Acquisition, Goodwill, Expected Tax Deductible Amount

$ 1,100,000,000

Maximum | Actelion

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

10 years

Minimum | Actelion

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

4 years

Intellectual Property | Actelion

Business Acquisition [Line Items]

Finite-lived Intangible Assets Acquired

$ 24,230,000,000

Intellectual Property | Valchlor

Business Acquisition [Line Items]

Finite-lived Intangible Assets Acquired

$ 400,000,000

In Process Research and Development | 2018 Acquisitions

Business Acquisition [Line Items]

Purchase price over fair value of assets acquired

1,000,000,000

In Process Research and Development | 2017 Acquisitions

Business Acquisition [Line Items]

Purchase price over fair value of assets acquired

$ 1,100,000,000

$ 1,100,000,000

Trademarks | Vogue International LLC

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

22 years

Trademarks | Maximum | Vogue International LLC

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

22 years

Trademarks | Minimum | Vogue International LLC

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

10 years

Line of Credit | Idorsia

Business Acquisition [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

250,000,000

Convertible Debt | Idorsia

Business Acquisition [Line Items]

Long-term Debt

$ 500,000,000

$ 500,000,000

Debt Instrument, Term

10 years

Debt Instrument, Redemption, Period One | Convertible Debt | Idorsia

Business Acquisition [Line Items]

Debt Instrument, Restrictive Covenants, Shareholder Ownership Threshold, Percent

20.00%

Convertible Note, Equity Interest, Percentage

16.00%

R&D Expense

Business Acquisition [Line Items]

Concentration risk (as a percent)

5.00%

Discontinued Operations, Held-for-sale or Disposed of by Sale | LifeScan

Business Acquisition [Line Items]

Disposal Group, Including Discontinued Operation, Consideration

$ 2,100,000,000

Discontinued Operations, Held-for-sale or Disposed of by Sale | AdvancedSterilizationProducts

Business Acquisition [Line Items]

Disposal Group, Including Discontinued Operation, Consideration

2,700,000,000

Disposal Group, Including Discontinued Operation, Inventory

200,000,000

Disposal Group, Including Discontinued Operation, Property, Plant and Equipment

100,000,000

Disposal Group, Including Discontinued Operation, Goodwill

300,000,000

Disposal Group, Including Discontinued Operation, Receivables Retained

100,000,000

Disposal Group, Including Discontinued Operation, Inventory, Current

200,000,000

Discontinued Operations, Held-for-sale or Disposed of by Sale | Supply Chain

Business Acquisition [Line Items]

Disposal Group, Including Discontinued Operation, Property, Plant and Equipment

100,000,000

Disposal Group, Including Discontinued Operation, Inventory, Current

$ 300,000,000

Subsequent Event | Ci:z Holdings Co. Ltd.

Business Acquisition [Line Items]

Business Acquisition, Percentage of Voting Interests Acquired

89.00%

Acquisition price (in dollars per share) | ¥ / shares

¥ 5,900

Subsequent Event | Actelion

Business Acquisition [Line Items]

Acquisition payments

$ 3,400,000,000

Contingent consideration

$ 2,350,000,000

Business Combinations and Div_4

Business Combinations and Divestitures - Schedule of Preliminary Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Business Acquisition [Line Items]
Goodwill	$ 30,453	$ 31,906	$ 22,805
Actelion
Business Acquisition [Line Items]
Cash & Cash equivalents	469
Inventory1	759
Accounts Receivable	485
Other current assets	93
Property, plant and equipment	104
Goodwill	6,161
Intangible assets	25,010
Deferred Taxes	99
Other non-current assets	19
Total Assets Acquired	33,199
Current liabilities	956
Deferred Taxes	1,776
Other non-current liabilities	413
Total Liabilities Assumed	3,145
Net Assets Acquired	$ 30,054

Business Combinations and Div_5

Business Combinations and Divestitures - Purchase Price Allocation of Identifiable Intangible Assets (Details) - Actelion $ in Millions	Jun. 16, 2017USD ($)
Business Acquisition [Line Items]
Finite-lived and Indefinite-lived Intangible Assets Acquired	$ 25,010
In Process Research and Development
Business Acquisition [Line Items]
Indefinite-lived Intangible Assets Acquired	780
Intellectual Property
Business Acquisition [Line Items]
Finite-lived Intangible Assets Acquired	$ 24,230

Business Combinations and Div_6

Business Combinations and Divestitures - Schedule of Pro Forma Results (Details) - Actelion - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017
Business Acquisition [Line Items]
Net Sales	$ 77,681	$ 74,339
Net Earnings	$ 1,509	$ 13,916
Diluted Net Earnings per Common Share	$ 0.55	$ 4.99

Legal Proceedings (Details)

Legal Proceedings (Details) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 30, 2018USD ($)claimantpatient	Sep. 30, 2018USD ($)	Jul. 01, 2018USD ($)	Apr. 01, 2018USD ($)	Dec. 31, 2017USD ($)claim	Oct. 01, 2017USD ($)	Jul. 02, 2017USD ($)	Apr. 02, 2017USD ($)	Dec. 30, 2018USD ($)claimantpatient	Oct. 31, 2017claim	Dec. 28, 2014claim
Loss Contingencies [Line Items]
Restructuring charge, after tax | $	$ 190	$ 162	$ 152	$ 81	$ 237	$ 136	$ 101	$ 121
Litigation expense | $	$ 1,288		$ 703		$ 645	$ 118	$ 493
Xarelto
Loss Contingencies [Line Items]
Number of plaintiffs	25,600								25,600
ASR
Loss Contingencies [Line Items]
Number of plaintiffs	1,800								1,800
Pinnacle Acetabular Cup System
Loss Contingencies [Line Items]
Number of plaintiffs	10,500								10,500
Risperdal
Loss Contingencies [Line Items]
Number of plaintiffs	13,400								13,400
Pelvic Meshes
Loss Contingencies [Line Items]
Number of plaintiffs	34,800								34,800
Invokana
Loss Contingencies [Line Items]
Number of plaintiffs	1,050								1,050
Physiomesh
Loss Contingencies [Line Items]
Number of plaintiffs	2,100								2,100
Talc
Loss Contingencies [Line Items]
Number of plaintiffs	13,000								13,000
Pending Litigation
Loss Contingencies [Line Items]
Pending claims | claim					1,400					66	1,600
DePuy ASR U.S. | Settled Litigation
Loss Contingencies [Line Items]
Number of patients in settlement | patient	10,000								10,000
Baby Powder | Judicial Ruling | Damages from Product Defects
Loss Contingencies [Line Items]
Loss Contingency, Damages Sought, Value | $									$ 4,700

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 30, 2018USD ($)	Sep. 30, 2018USD ($)	Jul. 01, 2018USD ($)	Apr. 01, 2018USD ($)	Dec. 31, 2017USD ($)	Oct. 01, 2017USD ($)	Jul. 02, 2017USD ($)	Apr. 02, 2017USD ($)	Dec. 30, 2018USD ($)Employee	Dec. 31, 2017USD ($)	Jan. 01, 2017USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 227		$ 176						$ 251	$ 309	$ 491
Number of positions eliminated and receiving severance payments | Employee									2,375
Medical Devices
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 190		$ 107	$ 284	$ 187	$ 128	$ 161	$ 462	114	$ 700
Restructuring costs incurred since announced	2,500								2,500
Medical Devices | Cost of products sold
Restructuring Cost and Reserve [Line Items]
Restructuring charges									46
Medical Devices | Other Income Expense Net
Restructuring Cost and Reserve [Line Items]
Restructuring charges									227
Medical Devices | Severance
Restructuring Cost and Reserve [Line Items]
Restructuring charges										$ 151
Supply Chain
Restructuring Cost and Reserve [Line Items]
Restructuring charges									238
Supply Chain | Cost of products sold
Restructuring Cost and Reserve [Line Items]
Restructuring charges									59
Supply Chain | Other Income Expense Net
Restructuring Cost and Reserve [Line Items]
Restructuring charges									117
Supply Chain | Minimum
Restructuring Cost and Reserve [Line Items]
Pre-tax restructuring charges	1,900								1,900
Restructuring and Related Cost, Expected Future Savings	600								$ 600
Supply Chain | Minimum | Medical Devices
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Duration of Restructuring Plan									4 years
Supply Chain | Maximum
Restructuring Cost and Reserve [Line Items]
Pre-tax restructuring charges	2,300								$ 2,300
Restructuring and Related Cost, Expected Future Savings	$ 800								$ 800
Supply Chain | Maximum | Medical Devices
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Duration of Restructuring Plan									5 years
Medical Devices
Restructuring Cost and Reserve [Line Items]
Restructuring charges									$ 700
Medical Devices | Severance
Restructuring Cost and Reserve [Line Items]
Restructuring charges									$ 0

Restructuring - Summary of Seve

Restructuring - Summary of Severance Charges and Associated Spending (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 30, 2018	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Dec. 31, 2017	Oct. 01, 2017	Jul. 02, 2017	Apr. 02, 2017	Dec. 30, 2018	Dec. 31, 2017	Jan. 01, 2017
Restructuring Reserve [Roll Forward]
Restructuring charges	$ (227)		$ (176)						$ (251)	$ (309)	$ (491)
Medical Devices
Restructuring Reserve [Roll Forward]
Reserve balance beginning				$ 267				$ 381	267	381	501
Activity during the period											(120)
Restructuring charges		$ (190)		(107)	$ (284)	$ (187)	$ (128)	(161)	(462)	(114)	(700)
Reserve balance ending	242				267				242	267	381
Medical Devices | Severance
Restructuring Reserve [Roll Forward]
Reserve balance beginning				229				380	229	380	484
Activity during the period											(104)
Restructuring charges										(151)
Reserve balance ending	194				229				194	229	380
Medical Devices | Asset Write-offs
Restructuring Reserve [Roll Forward]
Reserve balance beginning				0				0	0	0	0
Activity during the period											0
Restructuring charges										0
Reserve balance ending	0				0				0	0	0
Medical Devices | Other
Restructuring Reserve [Roll Forward]
Reserve balance beginning				$ 38				$ 1	38	1	17
Activity during the period											(16)
Restructuring charges										(37)
Reserve balance ending	$ 48				$ 38				48	$ 38	$ 1
Medical Devices
Restructuring Reserve [Roll Forward]
Restructuring charges									(700)
Cash payments									(593)
Settled non cash									(132)
Medical Devices | Severance
Restructuring Reserve [Roll Forward]
Restructuring charges									0
Cash payments									(35)
Settled non cash									0
Medical Devices | Asset Write-offs
Restructuring Reserve [Roll Forward]
Restructuring charges									(132)
Cash payments									0
Settled non cash									(132)
Medical Devices | Other
Restructuring Reserve [Roll Forward]
Restructuring charges									(568)
Cash payments									(558)
Settled non cash									$ 0